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ABSTRACT 
Liquid chromatography mass spectrometry (LC-MS) is a powerful analytical tool 
for multi-analyte quantification. This method can be combined with microdialysis 
sampling to study small molecules and neuropeptides within discrete brain regions. This 
thesis focuses on the development of targeted LC-MS assays to analyze dialysate samples 
collected from awake animals to correlate neurochemical dynamics with behavior. 
Previous LC-MS assays used benzoyl chloride derivatization to enable 
quantification of 17 neurotransmitters and metabolites in dialysate samples. In this work, 
derivatization conditions were modified to improve sensitivity up to 25-fold and reduce 
complexity of the procedure. The assay was also expanded to 70 compounds including 
amino acids, polyamines (e.g., putrescine, spermidine, spermine), compounds from 
catecholamine biosynthesis pathways (e.g., tyrosine and tryptophan metabolic pathways), 
and trace amines (e.g., tyramine, octopamine, synephrine). Besides measurements in 
dialysate, the method was able to analyze plasma and cerebrospinal fluid samples. This 
work improves the utility of benzoyl chloride, which labels multiple important functional 
groups, for widely targeted metabolomics methods.  
Neuropeptides constitute the largest group of neurotransmitters in the central 
nervous system. Neuropeptide signaling is involved in many physiological functions but 
detection in vivo is challenging due to low picomolar concentrations. Targeted capillary 
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LC-MS methods were developed for neurotensin, oxytocin, dynorphin, and enkephalins. 
The assays utilize desalting and preconcentration on a single analytical column to achieve 
low picomolar limits of detection. Detection was improved by optimizing all facets of 
neuropeptide handling from sampling to detection with capillary LC-MS.  
These techniques were applied to examine several aspects of neuronal function. 
Specific neuronal circuits were defined, confirmed, and targeted by combining these 
analytical tools with pharmacogenetic and optogenetic methods. Novel 
pathophysiological changes to opioid neuropeptide (dynorphin and enkephalins) 
dynamics were elucidated in a rat model of Parkinson’s disease, and a potential 
neuropeptide-based treatment was established to reduce the abnormal dyskinetic 
movements associated with chronic dopamine replacement therapies in Parkinson’s 
Disease. These new multiplexed approaches will advance our understanding of the 
complex processes underlying neuronal function at the molecular and circuit levels, as 
well as provides an improved set of experimental tools to better understand lingering 
questions in the field of neuroscience.  
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CHAPTER 1: INTRODUCTION 
Submitted, in part, as a book chapter in Advances in Real-Time Neuroscience, Volume 2.  
Editorial contributions from co-authors Dr. Samuel S. Pappas and Dr. Robert T. Kennedy. 
 
The extracellular space of the brain contains chemicals involved in 
neurotransmitter signaling, metabolism, and communication with the periphery. 
Microdialysis sampling of this environment enables measurement of endogenous 
neurochemicals and exogenous (e.g., drugs) chemicals in vivo. Such measurements 
provide valuable insights into the neurochemical substrates in relation to behavior, 
diseases, and drug effects. 
Microdialysis is a simple and robust technique to collect multiple extracellular 
analytes within discrete brain regions (Figure 1-1). Microdialysis probes utilize inlet and 
outlet capillaries ensheathed in a semipermeable membrane. When used in the brain, a 
perfusion media such as ringer solution or artificial cerebral spinal fluid, similar in ionic 
composition to the surrounding extracellular environment, is passed through the 
semipermeable probe membrane. This membrane excludes proteins and enzymes above a 
given molecular weight cut-off (MWCO). By filtering these large molecules from the 
collected perfusate, it decreases the complexity of the sample and decreases the rate of 
enzymatic degradation. Neurochemicals that are below the MWCO diffuse across the 
membrane from higher to lower concentration regions. Fractions are collected and 
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analyzed, preserving temporal information which can be correlated to behavior or stimuli. 
Extracellular neurochemicals in the collected dialysate can then be measured using a 
number of different analytical methods. 
 
Figure 1-1 Microdialysis probes utilize inlet and outlet capillaries ensheathed by a semi-permeable 
membrane allowing for sampling of surrounding tissue. Compounds below the MWCO (blue spheres) of 
the membrane diffuse in and out of the probe based on concentration gradients. The semi-permeable 
membrane excludes large molecules (purple octagons) such as proteins and enzymes.  
Depending on the method, multiple neurotransmitters and metabolites may be 
measured within each fraction to provide a comprehensive view of the neurochemical 
environment. Multi-analyte measurements are invaluable for understanding the 
interactions of neurotransmitter systems, discovering unexpected chemical changes or 
associations between neurotransmitters, and discerning how multiple neurotransmitters 
coordinate to drive behavior and other physiological functions. For example, glucose, 
lactate, pyruvate, glutamate, and the protein tau were monitored in patients with 
traumatic brain injury to examine potential biomarkers of injury severity1. This study 
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demonstrated that the protein tau could be used to assess damage severity, whereas other 
metabolic markers were less reliable.  
Microdialysis sampling provides a relatively unbiased sample of the low 
molecular weight compounds present in brain extracellular space, but comprehensive 
analytical techniques for monitoring a wide range of neurotransmitters and their 
metabolites have been lacking. As a result, most attempts to broadly measure many 
neurochemicals have used multiple analytical techniques on collected fractions.  
Liquid chromatography (LC) is the mostly widely used method for measuring 
neurochemicals in dialysate, but different detection modes are required depending on the 
analyte. LC with electrochemical detection (ECD) is commonly employed to detect 
electroactive compounds such as dopamine, norepinephrine, serotonin, and some 
metabolites2, 3. LC-ECD is also used to measure acetylcholine (ACh), which is not 
electroactive, but may be monitored indirectly via the formation of electrochemically 
detectable hydrogen peroxide from a reaction with acetylcholinesterase and choline 
oxidase4, 5. LC effluent may also be exposed to enzymes via post-column addition or 
immobilized enzyme reactors6-8. These assays typically utilize phosphate buffer at pH 8 
as mobile phase, a compromise between column stability and optimized enzyme reaction 
conditions. Because of this mobile phase pH requirement, ACh and choline are measured 
in separate assays from other electroactive compounds.  
LC with fluorescence detection is commonly used for detecting amino acid 
neurotransmitters in dialysate. Most amino acids do not naturally fluoresce, so pre-
column derivatization is employed to add a fluorescent tag using commercially available 
kits or reagents such as OPA (ortho-phthaladehyde)9, 10, NDA (naphthalene-2,3-
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dicarboxyaldehyde)11-13, or FITC (fluorescein isothiocyanate)14-16. Derivatization also 
allows LC-ECD for amino acids as well. For example, precolumn derivatization of 
amines with OPA and a thiol such as β-mercaptoethanol or tert-butyl thiol (t-BuSH) 
forms products that are both fluorescent17 and easily oxidized, permitting the use of either 
fluorescent or ECD18, 19. LC-ECD with sample derivatization by OPA and t-BuSH detects 
neuroactive amino acids in the picomolar range18, 20. Capillary LC-ECD allows for 
preconcentration prior to detection, while optimized gradient and buffer conditions 
enable detection of multiple amino acids and catecholamines in dialysate and brain 
homogenate in a single run21. However, this method has not been often used to measure 
amines and amino acids simultaneously.  
Capillary electrophoresis-laser induced fluorescence (CE-LIF) has also been used 
to measure multiple neurotransmitters in a single assay22-24. Derivatization with NDA11-13, 
FITC14, 15 or carboxyfluorescein succinimidyl ester16, 25 has been used to measure 
neurotransmitters such as dopamine, norepinephrine, glutamate, and aspartate. In some 
cases, the high-speed of CE-LIF allows on-line measurements on the seconds time scale. 
However, in general it has been possible to optimize conditions for only a sub-set of 
neurotransmitters and metabolites. Thus, despite the power of separation techniques, the 
complexity of dialysate samples has made it difficult to measure large numbers of 
neurotransmitters and metabolites in a single assay. Instead, multiple assays are 
performed, requiring split samples and added time, or multiple animals. For example, 
previous dialysis monitoring of dynorphin B, dopamine, and 4-amino butyric acid 
(GABA) required a single sample to be split into three and analyzed with 
radioimmunoassay, ECD, and ECD with OPA and t-BuSh derivatization, respectively26. 
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Another study employed several assays to monitor multiple analytes: glutamate, aspartate 
and GABA with precolumn derivatization and fluorimetric detection, the monoamines 
dopamine and serotonin and their metabolites 3,4-dihydroxyphenylacetic acid (DOPAC), 
homovanillic acid (HVA), and 5-hydroxyindole-3-acetic acid (5HIAA) with LC-ECD, 
and pyruvate and lactate with LC-ultra violet detection27.  
A single assay measuring multiple neurochemical classes and their metabolites 
would remove the technical limitations that arise from the use of multiple assays. LC-
mass spectrometry (MS) is well suited for measuring many components in complex 
samples because of its high resolution, selectivity, and sensitivity. Indeed, several LC-MS 
methods have been developed to allow measurements of multiple neurotransmitters and 
metabolites from dialysate samples28-34. Although MS can potentially detect 
neurotransmitters directly without a dedicated separation step35, LC separation helps to 
pre-concentrate and remove salt and other interferences present in the dialysate that result 
in ionization suppression and reduced efficiency of droplet formation, which limit the 
number of ions reaching the detector, during electrospray ionization (ESI)36. The added 
resolving power and specificity of MS allow selective detection even if the 
neurochemicals are not fully resolved by LC. In tandem MS (MS/MS), a specific mass-
to-charge ratio is isolated and fragmented by the addition of energy through an energetic 
collision with an inert gas to form unique fragments, or product ions. In multiple reaction 
monitoring, a second stage of MS then detects the selected product ion(s) of analytes of 
interest based on a selected fragmentation pathway. MS/MS decreases noise levels, 
thereby improving signal-to-noise ratios, which improves the limit of detection (LOD). 
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The combined use of LC and MS/MS provides high selectivity by utilizing retention 
time, mass to charge ratio, and characteristic fragmentation patterns. 
Detection of small molecules in dialysate 
A key to using LC-MS is that the mobile phase conditions must be compatible 
with ESI, i.e., mobile phases that contain low concentrations of salts and are preferably 
volatile. The most common form of LC, reversed phase LC (RPLC), generally has mobile 
phases that are compatible with ESI. However, most classical neurotransmitters are polar 
and poorly retained by RPLC, where retention is by hydrophobic or lipophilic 
interactions. Ion-pairing agents such as long-chain sulfonic acids can be used to enhance 
retention of polar neurochemicals on RPLC columns, e.g., with ECD; however, these 
agents are generally considered to be harmful to mass spectrometers and therefore this is 
not a desirable approach for LC-MS assays. Detection on RPLC columns has been used 
to detect monoamines and amino acids ranging from 0.7-30 nM for dopamine, 
norepinephrine, serotonin, GABA, glutamate, and lysine30, 37.  
A second option for separation of the polar compounds is hydrophilic interaction 
liquid chromatography (HILIC). HILIC columns utilize a polar stationary phase, similar 
to normal-phase LC, with a mobile phase containing water and a high percent of organic 
solvent such as acetonitrile38. Retention of analytes is based on the partitioning between 
mobile phase and a water-enriched layer on the hydrophilic stationary phase39-41. This 
method is advantageous because it retains polar compounds using mobile phases that are 
compatible with ESI-MS. As a result, it has become popular for metabolomics assays of 
polar metabolites. Several studies have reported detection of multiple neurochemicals by 
HILIC-ESI-MS33, 42-44. However, the detection limits achieved by HILIC-ESI-MS for 
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many of the neurotransmitters is modest and less than satisfactory for many dialysis 
samples. For example, detection of proline, glutamate, aspartate, and glycine in a single 
assay reported detection limits of 3-8 μM for standards on HILIC45. Others have reported 
low to moderate detection limits of dopamine, serotonin, GABA, and glutamate ranging 
from 0.3-190 nM concentrations33, 44 by HILIC-MS/MS.  
A third method for LC-MS of neurotransmitters is to derivatize them for RPLC. 
Although LC-MS can be used to detect molecules without derivatization, several benefits 
arise from these labeling techniques. Labels enhance retention on reversed phase 
columns, enabling use of columns that are more efficient, stable, and widely available 
than HILIC. Also, poor retention on reversed phase columns results in spectral 
interference and ionization suppression from salt and early eluting polar compounds. 
Labels can also enhance the ionization of molecules by improving droplet formation in 
ESI, and therefore increase sensitivity. Furthermore, if the reagent can be obtained in a 
stable isotope-labeled form, it is possible to make internal standards for all of the 
derivatized analytes. The addition of an internal standard improves quantification by 
accounting for variability of ionization due to the sample and drift in the MS response.  
 
Derivatization techniques with LC-MS for small molecules in dialysate 
Several reagents are suitable for enhancing neurotransmitter analysis by RPLC-
MS. Primary and secondary amine-containing analytes can be labeled with formaldehyde 
by a dimethylation reaction46. Diethylation can label primary amines30 via reductive 
amination chemistry. These reagents require 10 and 25 min incubation times, 
respectively. Primary and secondary amines can also be derivatized at elevated 
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temperatures with 7-fluoro-4-nitrobenzoxadiazole (NBD-F) prior to LC-MS47, 48. Amine 
derivatization with (5-N-succinimidoxy-5-oxopentyl)triphenylphosphonium bromide 
(SPTPP) has also been reported. This reaction requires 10 min at elevated temperatures49, 
50. N-α-Boc-L-tryptophan hydroxysuccinimide ester only labels primary amines but is 
completed in 5 min at neutral pH and room temperature51. Derivatization of carboxylic 
acids with custom synthesized p-dimethylaminophenacyl bromide is achieved with 60 
min incubation requiring quenching with tripheylacetic acid, which is resolved with 
RPLC52. Propyl chloroformate derivatization reacts with both amines and carboxylic acid 
groups, but is tedious since it requires solvent evaporation prior to derivatization37. 
Dansyl chloride is a useful derivatization technique employed with LC-MS to label 
primary amines, secondary amines, and phenolic hydroxyls53, 54. Dansyl chloride 
derivatization is typically performed at high pH and elevated temperatures, which 
requires 20 min for the reaction, and produces light sensitive samples31, 54. 
In this work we explore benzoyl chloride (BzCl) based on previous studies by 
Song et al.31. BzCl reacts with primary and secondary amines, phenols, and ribose-
hydroxyl groups (Figure 1-2), allowing it to be used for a wide range of 
neurochemicals31. This reactivity is similar to dansyl chloride, but contrasts with many 
other reagents that are limited to labeling amines. BzCl labeling has several other 
advantages relative to other derivatization techniques that make it attractive. BzCl is a 
liquid that can be easily added to a sample. The reaction is rapid at room temperature, 
with samples typically requiring < 1 min sample preparation prior to analysis. Unlike 
dansyl chloride, derivatized samples are not light sensitive and are stable at room 
temperature overnight (with stability for up to 6 months when frozen at -80 °C). 
 9 
Benzoylated compounds fragment easily in the mass spectrometer, generating high yield 
of fragment ions, thereby allowing for sensitive detection. Furthermore, heavy isotope 
13C6-BzCl is commercially available at a relatively low cost, which allows for preparation 
of heavy isotope labeled internal standards for all labeled compounds of interest and 
improves quantitative analysis. 
 
 
Figure 1-2 Reaction scheme of benzoyl chloride derivatization of primary and secondary amines, and 
phenols. 
In the initial report of this method for LC-MS of neurochemicals, BzCl was used 
to label 16 analytes in microliter volumes of dialysate samples31, 55. This method detected 
the neurotransmitters ACh, adenosine, dopamine, norepinephrine, serotonin, histamine, 
glutamate, glycine, aspartate, GABA, serine, and taurine and the metabolites DOPAC, 3-
methoxytyramine (3-MT), HVA, normetanephrine, and 5HIAA. ACh was not labeled, 
but was sufficiently ionized to yield sensitive detection in the same assay. Importantly, 
the assay not only labeled the amine neurotransmitters (catecholamines, indoleamines, 
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and amino acids) but adenosine and many metabolites as well. All of these compounds 
were separated in an 8 min gradient (Figure 1-3). Commercially available 13C6-BzCl was 
used to generate isotope internal standards, which improved quantification and relative 
standard deviation for repeated sample injections. The LOD for monoamine 
neurotransmitters and metabolites ranged from 0.03 – 11 nM, amino acids from 2- 250 
nM, 0.5 nM for ACh, 2 nM for histamine, and 25 nM for adenosine in 5 μL samples31.  
 
Figure 1-3 Reconstructed ion chromatogram for 17 analytes detected using benzoyl chloride derivatization. 
 
To demonstrate that BzCl derivatization was viable for in vivo sampling, a dual 
probe microdialysis experiment of the mesolimbic pathway, i.e., the ventral tegmental 
area (VTA) and the nucleus accumbens (NAc), was conducted. Neurotransmitter changes 
were monitored locally in the VTA and distally in the NAc during a local VTA perfusion 
of the GABA receptor antagonist bicuculline (Figure 1-4)31. As expected, NAc dopamine 
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and metabolite DOPAC increased and GABA decreased as a result of bicuculline in the 
VTA; but bicuculline also resulted in unanticipated increases in serotonin, 
norepinephrine, glutamate, ACh, and histamine release. Locally in the VTA, bicuculline 
resulted in enhanced dendritic dopamine, DOPAC, serotonin, norepinephrine, ACh, 
adenosine, and glycine, showing the complexity of neuromodulation.  
 
 
Figure 1-4 Dual probe microdialysis of the mesolimbic pathway (VTA and NAc). Neurotransmitters were 
monitored locally in the VTA and distally in the NAc during bicuculline (50 μM) perfusion in the VTA. 
The heat map shows color blocks correlating to changes in neurochemicals expressed as percent baseline. 
Times in the heat map are referenced to infusion of bicuculline. *p < 0.05, **p < 0.01, and ***p < 0.001 
compared to basal level in respective brain region. Reprinted with permission from Song et al., 2012a. 
Copyright 2012 American Chemical Society. 
 
While the report demonstrated a significant improvement over previous 
techniques with the simultaneous monitoring of 17 neurochemicals in a single fraction, 
this only covers a small proportion of potential neurochemical targets. One aim of this 
thesis is to further expand this method to monitor precursors and metabolites to study 
biosynthesis pathways (e.g., tyrosine and tryptophan metabolic pathways) in different 
sample matrixes beyond dialysate.  
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Detection of neuropeptides in dialysate 
Neuropeptides are the largest class of neuromessengers in the central nervous 
system and act as neurotransmitters, neuromodulators, and hormones56. Monitoring 
neuropeptides by microdialysis is difficult because they are present at low picomolar 
extracellular concentrations. At these low levels, neuropeptides have traditionally been 
detected using immunoassays57-60, which have low concentration LODs but require larger 
sample volumes and lack sequence specificity. 
 Capillary LC-MS (with column inner diameters of 25-100 µm) is an attractive 
alternative to immunoassays as it allows microliter samples to be preconcentrated into 
nanoliter volumes15, 61-73. The use of smaller bore columns also results in lower mobile 
phase consumption and better sensitivity due to increased ionization efficiency at low 
flow rates (nL/min) when coupled with ESI-MS/MS. This analytical method enables the 
detection of multiple analytes with sequence specificity and attomole LOD 
(corresponding to low picomolar concentration in microliter samples). Capillary LC-
MS/MS has been used to detect endogenous neurotensin61, leu-enkephalin (LE) and met-
enkephalin (ME) surges during eating74, dynorphin67, 73, β-endorphin67, angiotensin IV66, 
oxytocin68, and orexins A and B75. 
 
Neuropeptide processing 
Neuropeptides are produced from precursor proteins, which are cleaved by 
various peptidases as well as convertases and undergo posttranslational modification to 
form bioactive peptides76-78. Protease-mediated prepropeptide processing into functional 
neuropeptides likely occurs during axonal transport of the propeptide in dense core 
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vesicles79. It is important to understand the degradation of bioactive fragments when 
using a targeted LC-MS assay, since these pathways may be compromised in disease 
states. Targeted approaches ignore other potential fragments derived from the same 
precursor protein, possibly missing important aspects of the neurobiology. While there 
are hundreds of neuropeptides that signal in the brain, the work in this thesis targets 
neurotensin, oxytocin, and the opioid peptides dynorphin, LE and ME.  
Neurotensin is a tridecapeptide derived from a polypeptide encoded by the gene 
preproneurotensin/neuromedin N, which also encodes for neuromedin N80 (Figure 1-5). 
Neurotensin neurons are found throughout the brain, and have been implicated in the 
control of feeding and regulation of the mesolimbic dopaminergic system70, 80. 
Oxytocin is a 9 amino acid polypeptide with wide ranging actions throughout the 
nervous system and periphery. Oxytocin is commonly studied for its role in maternity, 
affiliative behaviors and pair bonding81. The gene prepro-oxytocin/neurophysin 1 
encodes for the propeptide precursor, which cleaves into oxytocin and neurophysin 
(Figure 1-5). 
Opioid peptides are produced by the processing of four distinct genes: 
preproopiomelanocortin, preproenkephalin, preprodynorphin (also referred to as 
preproenkephalinB), and prepronociceptin/orphanin FQ82, 83. Proopiomelanocortin 
encodes for opioid peptide β-endorphin, and non-opioid peptides adrenocorticotropic 
hormone, α-melanocyte-stimulating hormone, and β-lipotropic pituitary hormone82. 
Pronociceptin/orphanin FQ encodes for a single copy of nociception, nocistatin, and 
orphanin FQ283, 84. 
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Both prodynorphin and proenkephalin are inactive precursors that require 
protease processing to produce biologically functional peptides85, 86 (Figure 1-5). 
Prodynorphin products include neoendorphin, dynorphin A, dynorphin B, and bridge 
peptide domain sequences86. Proenkephalin contains four copies of ME, two extended 
copies of ME, and one copy of LE87, 88. While prodynorphin contains five LE sequences, 
prodynorphin products (i.e. dynorphin A and dynorphin B) rarely co-localize with LE due 
to the lack of cleavage of the dibasic Arg-Arg sequence85, 86, 89. Proenkephalin is the 
primary source of LE, even though it contains only one copy of the LE sequence, which 
is confirmed by LE immunoreactivity colocalized with ME86. 
The extent of pro-hormone processing depends on the available endoproteases in 
a given cell type and brain region. Disruption of peptide metabolism has been implicated 
in depression, anxiety, addiction, and diseases such as Parkinson’s disease90-93. 
Traditional methods of peptide detection, such as immunoassays, often cannot discern 
between fragments due to lack of specificity, highlighting the advantage of untargeted 
LC-MSn assays or targeted assays if the fragments can be predicted.  
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Figure 1-5 Graphical representation of precursor polypeptides with their respective peptide fragments. 
Fragments can be processed further to form smaller peptides. Not drawn to scale.  
 
Capillary LC-MS of neuropeptides in dialysate 
Several variations of capillary LC-MS have been employed to detect endogenous 
neuropeptides in dialysate. Table 1-1 lists various capillary LC-MS setups researchers 
have used to measure neuropeptides from dialysate or similar matrix. To achieve rapid 
preconcentration and desalting online prior to MS detection, a trap column with a wider 
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i.d. than the small bore analytical column can be used with high flow rates (μL/min), 
followed by back flushing the sample onto an analytical column and elution with lower 
flow rates (nL/min)66, 69. Dialysate samples can also be preconcentrated and desalted on a 
single analytical column to reduce dead volume61, 63. Ideally, samples would be quickly 
desalted and preconcentrated using higher flow rates. However, this can be challenging if 
a single column and pump are employed as the pump equilibration time would be ~20 
min before using lower flow rates for elution. Conversely, if an LC pump desalted and 
preconcentrated a 5 μL sample at 100 nL/min, samples would take 50 min to load onto a 
column, which reduces sample throughput. 
With our current capillary LC-MS setup, microliter samples are injected onto a 
single reverse phase capillary column for trapping and elution. We use 50 μm i.d. 
capillary columns packed in-house with C18 particle slurry suspended in acetone and 
water70, 73. The columns are connected by a Teflon union to a disposable emitter tip, 
allowing for column re-use if the tip is clogged. This setup typically allows for more than 
80 injections per column. Analytes are stacked at the head of the packed bed and the 
sample is desalted and preconcentrated at high flow rates (μL/min) using a low elution 
strength solvent. A second LC pump is used to deliver an elution gradient, which allows 
for separation of multiple analytes at a slower flow rate (nL/min), and is more amenable 
to ESI. A six-port valve enables quick switching from high-to-low flow rates without 
waiting for pump equilibration.  
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Table 1-1 Instruments and column configurations used in capillary LC-MS to analyze neuropeptides. 
Mass Spectrometer LC Instruments Trap Column Analytical Column Injection  Volume Peptide Reference 
Ion 
Trap 
LTQ-XL  
(ThermoFisher) 
Haskel high-pressure 
pump (Haskel Inc.) 
MicroPro  
(Eldex Laboratories) 
n/a 
25 μm i.d. × 4 cm,  
5 μm C18  
(Altima, Alltech) 
5 μL 
Dynorphin 
Enkephalins 
Endorphins 
67 
  n/a 
25 μm i.d. × 10 cm,  
5 μm C18  
(Altima, Alltech) 
5 μL Enkephalins 94 
  n/a 
50 μm i.d. × 4 cm,  
5 μm C18  
(Altima, Alltech) 
5 μL 
Arg-
Vasopressin 
Oxytocin  
68 
  n/a 
50 μm i.d. × 3 cm,  
5 um C18  
(Altima, Alltech) 
7.5 μL Dynorphin Enkephalins  
74 
ISCO 100D 
(Teledyne Isco) 
Agilent 1100 
(Agilent) 
n/a 
75 μm i.d. × 4 cm,  
5 μm C18  
(Altima, Alltech) 
8 μL 
Dynorphin 
Enkephalins 
Endorphins 
Neurotensin 
Orexins 
75 
  n/a 
50 μm i.d. × 3.5 cm,  
5 μm C18  
(Altima, Alltech) 
5 μL Neurotensin 70 
Ultimate 3000  
(Dionex) 
200 μm i.d. ×  
5 mm, 
monolith  
(PS-DVB,  
LC Packings) 
100 μm i.d. × 5 cm, 
monolith  
(PepSwift, PS-DVB,  
LC Packings) 
Not 
specified 
Untargeted 
proteins and 
peptides 
95 
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Mass Spectrometer LC Instruments Trap Column Analytical Column 
Injection  
Volume Peptide Reference 
IonTrap 
LCQ Deca XP 
Plus (Thermo 
Fisher) 
ISCO 100D 
(Teledyne 
Isco) Waters 
626 pump 
(Waters)  
n/a 
75 μm i.d. × 3.6 cm,  
10 μm C18  
(Altima, Alltech) 
5 μL DynorphinEnkephalins 73 
Haskel DSFH-
151  
(Haskel Inc.) 
ISCO 100D 
(Teledyne 
Isco) 
n/a 
25 μm i.d. × 2 cm,  
5 μm C18  
(Altima, Alltech) 
1.8 μL Enkephalins 65 
Haskel high-
pressure pump 
(Haskel Inc.) 
MicroPro 
(Eldex 
Laboratories) 
n/a 
25 μm i.d. ×2 cm,  
5 μm C18  
(Altima, Alltech) 
2.5 μL Enkephalins 96 
HCTultra  
(Bruker 
Daltonics) 
CapLC 
(Micromass) n/a 
300 μm i.d. × 15cm,  
3 μm C18 
(Acclaim PepMap100, 
Dionex) 
1 μL 
Angiotensin 
Bradykinins  
Neurotensin 
97 
Orbitrap Orbitrap  (ThermoFisher) 
Ultimate 3000  
(Dionex) 
300 μm i.d. ×  
5 mm,  
5 μm C18  
(Pepmap™, 
LC Packings) 
75 μm i.d. ×15 cm  
C18  
(Gemini C18, 
Phenomenex)  
Not 
specified 
Untargeted 
proteins and peptides 
95 
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Mass Spectrometer LC Instruments Trap Column Analytical Column Injection  Volume Peptide Reference 
Q-TOF 
Q-TOF  
(Micromass-
Waters) 
nanoACQUITY 
UPLC (Waters) n/a 
75 μm i.d. ×10 cm,  
3 μm C18  
(Magic, Michrom) 
Not 
specified 
(Crab) 
Bradykinin  
Somatostatin 
Substance P 
98 
Waters capillary LC 
system 
300 μm i.d × 
1 mm,  
5 μm C18  
(Pepmap™, 
LC Packings) 
75 μm i.d. ×15 cm,  
3 μm C18  
(Microsil nano C18, 
Microtech Scientific) 
1 - 3 μL 
(Crab) 
Allatotatins 
Orcokinins 
Tachykinin  
62 
JASCO n/a 
75 μm i.d. × 3 cm,  
10 μm C18  
(ODS-AQ 120A S-10, 
YMC Co.) 
10 μL Dynorphin 91 
Q-TOF Ultima  
(Waters) 
Ultimate 3000 
(Dionex) 
300 μm i.d. ×  
5 mm,  
5 μm C18  
(Pepmap™, 
LC Packings) 
75 μm i.d. ×15 cm  
C18  
(LC Packings)  
Not 
specified 
Untargeted 
proteins and 
peptides 
95 
Q-TOF hybrid 
Quadrupole  
(Micromass) 
Ultimate (Dionex) 
500 μm i.d. 
×15 mm, 
strong cation 
exchange  
(Bio-SCX, LC 
Packings) 
C18 (μ-guard 
MGU-30, LC 
Packings) 
100 μm i.d. × 10 cm,  
3 μm C18  
(Atlantis, Waters) 
20 μL 
(Caenorhabditis 
elegans)  
Untargeted, 
peptides  
99 
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Mass Spectrometer LC Instruments Trap Column Analytical Column Injection  Volume Peptide Reference 
QQQ 
Quattro Premier  
(Micromass-Waters) 
nanoACQUITY 
UPLC (Waters) 
180 μm i.d. × 
20 mm,  
5 μm C18  
(Symmetry® 
C18, Waters)  
100 μm i.d. ×10 cm,  
1.7 μm C18  
(ACQUITY UPLC® 
BEH 130, Waters) 
5 μL Neuromedin Neurotensin 
69 
Ultimate™ 
quaternary  
(LC Packings, 
Dionex) 
300 μm i.d. ×  
5 mm,  
5 μm C18  
(Pepmap™, 
LC Packings) 
75 μm i.d. ×15 cm,  
3 μm C18  
(Pepmap™,  
LC Packings)  
10 μL 
Angiotensin 
Enkephalins 
Neurotensin 
66 
Xevo TQ-S  
(Waters) 
nanoACQUITY 
UPLC (Waters) 
180 μm i.d. × 
20 mm,  
5 μm C18  
(Symmetry® 
C18, Waters)  
100 μm i.d. ×10 cm,  
1.7 μm C18  
(ACQUITY UPLC® 
BEH 130, Waters) 
5 μL Neuromedin Neurotensin 
69 
Finnigan TSQ700  
(Finnigan) 
Not specified n/a 
50 μm i.d. ×2 cm,  
10 μm C18  
(YMC Co.) 
10 μL Enkephalin Neurotensin 
63 
Not specified n/a 
50 μm i.d. × 10 cm,  
10 μm C18  
(YMC Co.) 
10 μL Neurotensin 61 
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Improving the repeatability of neuropeptide measurement in dialysate samples 
Capillary LC-MS provides exquisite sensitivity, peptide sequence specificity, and 
potential for multiple peptide monitoring. However, low recovery from the probes and 
surfaces of the analytical system can prevent realization of neuropeptide detection.  
Several methods have been applied to improve relative recovery, including using probes 
with high MWCO membranes, push-pull microdialysis100, 101, and affinity-enhanced 
microdialysis98, 102-104. Our recent studies using AN69 membrane demonstrate that 
membrane surface modification can dramatically alter recovery. AN69 is a copolymer of 
acrylonitrile and sodium methallylsulfonate, with an 80 kDa MWCO105. While the 
MWCO of AN69 is large, the copolymer composition of the membrane yields a negative 
charge due to embedded sulfonate groups, which may cause electrostatic interactions 
with peptides that have an overall positive charge (e.g., dynorphin A1-17, mouse β-
endorphin, and orexin B). Treatment of the dialysis membrane with polyethylenimine 
neutralized these negative charges and improved in vitro probe recovery 1.2 to 80 fold for 
a series of neuropeptides with a net positive charge75.  
Beyond recovery through the dialysis probe, sample loss due to adsorption during 
transport from the probe to the LC column can reduce detectability and reproducibility as 
well as increase carryover75, 106. Several studies show that addition of organic solvents 
such as ethanol107, methanol108, dimethylsulfonate72, or acetonitrile75, 106 to samples 
improves reproducibility and reduces carryover of peptides by reducing adsorption in LC 
lines during injection.  
Polyethylenimine treatment of AN69 dialyzing membranes improves sample 
recovery and the addition of acetonitrile to samples and reduces sample loss due to 
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adsorption; these changes dramatically increased the detectability of some neuropeptides 
in vivo75. However, these techniques were only applied to a small number of 
neuropeptides in a preliminary study with potassium stimulation, and are yet to be fully 
tested with pharmacologic manipulations or behavioral applications. 
 
Applications of LC-MS for dialysate analysis: Neurochemical monitoring during 
selective neuronal stimulation 
While microdialysis is a powerful technique, it has been previously limited to 
examining the effects of drugs on neurotransmitter release, and to better understand 
processes underlying behavioral changes, such as feeding, pain, and drug self-
administration109. However, advancements in molecular biology and transgenic 
techniques have provided novel ways to selectively activate or inhibit specific neuronal 
populations in vivo with external stimuli. The ability to modulate activity of neurons on 
command provides researchers with precise tools to parse out the underlying functions of 
neuronal circuits. Techniques for selective stimulation include optogenetics and designer 
receptors exclusively activated by designer drugs (DREADDs)110, 111. Work in this thesis 
combines both of these powerful selective stimulation techniques with microdialysis 
samples and analytical techniques to elucidate specific neuronal contributions to behavior 
and disease (see Chapters 3 and 4).  
Optogenetics utilizes engineered ion channels and pumps (e.g., channel 
rhodopsin-2 and halorhodopsin) that are activated by light to selectively activate or 
silence neuronal activity in vivo111. Activation of channel rhodopsin-2 and halorhopsin in 
vivo is obtained via pulsed laser light through a fiber optic implanted near neurons 
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expressing these receptors. The temporal and spatial precision of optogenetic techniques 
allows for near instantaneous modulation of neuronal firing112. For example, optogenetics 
has been used to study the roles of specific neuronal populations in both normal 
physiological functions (e.g., basal ganglia-mediated control of motor output113), and 
disorders such as obsessive-compulsive disorder and drug seeking114, 115.  
Another technique for selective stimulation is DREADDs. DREADDs utilize 
modified G protein-coupled receptors (e.g., altered muscarinic receptors) that are 
activated by systemic administration of otherwise biologically inert compounds such as 
clozapine-N-oxide (CNO)110, 116. Selective expression of these receptors on neurons of 
interest allows for specific activation or inhibition of specific neuronal subsets. 
DREADDs works on longer time scales (minutes to hours) than optogenetics, in part due 
to the systemic route of CNO administration. However, activation and inhibition of 
neurons utilizing DREADDs technology is less invasive than optogenetics because 
receptor activation can be achieved through a systemic injection and without implantation 
of a fiber optic in the brain. DREADDs has been used to demonstrate that orexin and 
GABAergic neurons modulate sleep-wake cycles, and that D2-expressing striatal medium 
spiny neurons modulate cocaine self-administration in mice117, 118.  
These powerful techniques are often combined with behavioral, pharmacological, 
and ex vivo studies to further evaluate the physiological circuits and disease states under 
examination. However, while these studies allow selective stimulation, the actual 
neurotransmitter dynamics that result from such treatments typically have been inferred 
without direct measurements. Direct in vivo measurements of neurochemical dynamics 
with these selective stimulation techniques in awake, behaving animals have been 
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scarce70, 119-122. In vivo neurochemical monitoring is imperative to understand the 
relationship between neuronal activation and neurochemistry123. Selective modulation of 
discrete neuronal populations can potentially alter many different neurochemicals such as 
monoamines, amino acids, and neuropeptides. Local and distal measurements relative to 
the site of activation provide important information to help elucidate the role of 
neurochemical signaling in circuits. For example, extracellular glutamate and dopamine 
were measured in the NAc shell after optogenetic stimulation of glutamatergic terminals 
in the infralimbic cortex, showing a connection between these two regions124.  
In vivo neurochemical monitoring has been coupled with optogenetic stimulation 
to investigate catecholamines using carbon fiber electrodes with fast scan cyclic 
voltammetry125, and microdialysis with LC-ECD126, 127. While these reports show 
neurochemical changes correlating with optical stimulation, the detection assays 
monitored single analytes, precluding the discovery of other related neurochemical 
alterations. Optogenetics coupled to MS has not yet been reported. The multi-analyte 
capabilities of LC-MS would provide a more comprehensive understanding of the 
multifaceted dynamic changes with optogenetic stimulations. Furthermore, the power of a 
comprehensive analysis of both neuropeptides and small molecules would establish the 
roles of different neural systems in behavior. 
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Dissertation overview 
Improvements in monitoring small molecules and neuropeptides will yield new 
frontier and discoveries in neuroscience. As described in Chapter 2, derivatization 
conditions were modified to improve sensitivity and to expand a BzCl small molecule 
assay to detect other metabolites including amino acids, polyamines (e.g. putrescine, 
spermidine, spermine), compounds from catecholamine biosynthesis pathways (e.g. 
tyrosine and tryptophan metabolic pathways), and trace amines (e.g., tyramine, 
octopamine, synephrine). The assay was also used to analyze dialysate, plasma, and CSF 
samples. Thus, this method is easily employed for a wide range of samples and 
essentially can be used for any classical neurotransmitter or metabolite.  
Chapters 3 and 4 focus on using complementary techniques to interrogate small 
molecule and neuropeptide dynamics with pharmacogenetic techniques to provide a more 
in-depth understanding of neurochemical interactions in multiple brain circuits. In 
Chapter 3, designer receptors exclusively activated by designer drugs were used in mice 
to investigate how a population of neurotensin neurons originating in the lateral 
hypothalamic area modulate the mesolimbic dopamine system (dopamine neurons in the 
ventral tegmental area that project to the nucleus accumbens). In Chapter 4, optogenetic 
techniques and analytical assays monitoring small molecules and opioid peptides were 
used to create a neurochemical profile within discrete sub-regions of the nucleus 
accumbens. 
Chapters 5 and 6 describe the use of these small molecule and neuropeptide 
monitoring techniques, which were applied to elucidate pathophysiological changes in 
and a potential symptomatic treatment of a rat model of Parkinson’s disease. 
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Advancements in spatial and temporal resolution combined with improvements in 
analytical methods will improve the sensitivity and selectivity for detecting multiple 
analytes in a single assay. Chapter 7 summarizes the findings in this thesis, and proposes 
potential future directions for the continuation of this work. These multiplexed 
approaches will advance our understanding of the complex processes underlying neuronal 
function at the molecular and circuit levels and will provide an improved set of 
experimental tools to enable better understanding of outstanding questions in 
neuroscience. 
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CHAPTER 2: BENZOYL CHLORIDE DERIVATIAZATION WITH LIQUID 
CHROMATOGRAPHY MASS SPECTROMETRY FOR TARGETED 
METABOLOMICS OF NEUROCHEMICALS IN BIOLOGICAL SAMPLES 
Reproduced in part from Wong, Malec et al. Journal of Chromatography A 2016, 1446, 78 - 90.  
Copyright 2016 Elsevier. Equal authorship was awarded to Wong and Malec. Specific contributions from 
Wong to this work included optimization of derivatization reagents, selection of compounds assayed, 
gradient optimization, and applications in rat dialysate and human cerebrospinal fluid.  
Introduction 
Metabolomics is a valuable approach for studying physiological mechanisms and 
identifying biomarkers. Both untargeted and targeted assays, also called metabolite 
profiling, are used in such studies. Targeted assays measuring a limited number of 
metabolites allow focus on important known compounds or pathways and offer better 
quantification, but they provide lower metabolome coverage compared to untargeted 
methods. Targeted assays that measure relatively large numbers of compounds (i.e., over 
50) help mitigate the disadvantage of limited metabolome coverage. Gas 
chromatography-mass spectrometry (MS) and high performance liquid chromatography 
(HPLC)-MS are well-suited platforms for developing such widely targeted assays. 
Several methods for measuring over 100 known metabolites in a single assay using these 
techniques have been reported 129-134. These widely targeted assays are powerful, but they 
rarely use more than a few internal standards, and for HPLC often make use of ion-
pairing reagents131, 134 or multiple LC pumps132, 133 to account for the wide polarity range 
of the metabolites. Here we report a targeted method for 70 neurochemicals that uses 
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HPLC-MS/MS with benzoyl chloride (BzCl) as a derivatizing agent and avoids these 
limitations. 
HPLC- tandem mass spectrometry (MS/MS) using a triple quadrupole mass 
spectrometer is well established as a sensitive, quantitative, and selective technique for 
metabolite profiling135, 136. Although compounds can be detected by MS/MS without 
labeling, the use of BzCl provides numerous advantages with only minor drawbacks. In 
particular, addition of a phenyl group to the polar analytes increases retention on reversed 
phase columns, which aids resolution and decreases ion suppression. Many compounds 
are detected with greater sensitivity after labeling, e.g. 1,000-fold increases in sensitivity 
have been reported for BzCl labeling31. The labeling step allows rapid creation of stable-
isotope labeled internal standards by using 13C-BzCl for labeling standards, thereby 
improving quantification for every analyte. BzCl is widely applicable because it 
derivatizes primary and secondary amines, phenols, thiols, and some alcohols (e.g., 
ribose hydroxyls and glucose). Indeed, it has previously been used with MS or ultraviolet 
absorption detection for monitoring neurochemicals in dialysate31, 34, plasma34, and 
human cerebrospinal fluid (CSF)137. It has also been used for other amine138, 139 and 
alcohol140, 141 containing compounds. These previous assays targeted a relatively narrow 
group of compounds.  
Although we focus on BzCl, other reagents such as dansyl chloride may provide 
similar utility for metabolomics51, 53, 54, 142. We favor BzCl because it reacts faster 
(seconds at room temperature compared to 20 min at elevated temperature), has a wider 
pH range for reaction, is less prone to photodegradation, and is commercially available in 
13C-labeled form. Additionally benzoylated products are stable for a week at room 
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temperature31, and standards and internal standards are stable for six months at -80°C 
(data not shown). 
The 70 compound assay described here targets neurochemicals. Neurons 
specialize in storing and transmitting information using neurotransmitters and 
neuromodulators. Low molecular weight polar compounds represent an important class 
of neurotransmitters including acetylcholine, adenosine, catecholamines, indoleamines, 
amino acids, trace amines, and dipeptides. A variety of other compounds, such as energy 
metabolites, antioxidants, and polyamines that affect neuronal function or have been 
linked to neurological disease are also included in the assay (a complete list of the 
compounds included in the assay and their functions is in Table 2-1). This assay focuses 
on these compounds and their precursors and degradation products, as their measurement 
can provide insights into neuronal function to better understand the neurochemical 
changes in brain diseases. Although this is not a comprehensive assay for all 
neurochemicals, it demonstrates the wide applicability of BzCl derivatization. The 
method is an improvement over previous neurochemical assays which were limited to 
even smaller subsets of neurochemicals28, 29, 32-34, 44, 45, 143, including our previously 
described 17 compound method based on similar technology31.  
This report demonstrates the utility of BzCl with HPLC-MS for targeted 
metabolomics on several sample types including tissue, serum, CSF, and microdialysate. 
Tissue samples are used to characterize concentrations at fixed time points and are best 
used for determining the overall production and metabolism of neurochemicals. We 
demonstrate the assay for Drosophila melanogaster tissue and hemolymph, an important 
neurochemical model system. Serum and CSF assays are useful for biomarker studies and 
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assessment of overall physiological state. Microdialysis samples the brain extracellular 
space and enables the measurement of released neurochemicals over time, making it 
valuable for correlating neurochemical dynamics to behavior, monitoring drug effects, 
and assessing the effect of disease states on neurochemical concentrations. However, the 
low samples volumes of microdialysate in our studies (typically 1 µL) make analysis 
challenging. 
Although BzCl labeling with HPLC-MS/MS has been used for neurochemicals 
before, the current work increases the number of analyzed compounds by 4-fold, 
streamlines reagent addition, and improves labeling conditions to give better sensitivity 
and reproducibility for some compounds. Finally, the assay is shown to be useful for a 
wider range of sample types.  
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Table 2-1 Relevance of 70 compounds assayed and reported literature concentrations.  
Abbreviation Analyte Relevance Reference 
DOMA 3,4-Dihydroxymandelic acid Minor NE metabolite 144 
DOPAC 3,4-Dihydroxyphenylacetic acid DA metabolite 31 
LDOPA 3,4-Dihydroxyphenylalanine DA precursor 145 
DOPEG 3,4-Dihydroxyphenylglycol NE Metabolite 146 
3HAA 3-Hydroxyanthranilic acid Kyn metabolite 147 
3HK 3-Hydroxykynurenine Neurotoxic Kyn metabolite 148 
MOPEG 3-Methoxy-4-hydroxyphenylglycol NE Metabolite 149 
3MT 3-Methoxytyramine DA metabolite 31 
GABA 4-Aminobutyric acid Neurotransmitter 31 
5HIAA 5-Hydroxyindoleacetic acid 5HT metabolite 31 
5HTP 5-Hydroxytryptophan Trp metabolite; 5HT precursor 150 
5HTOL 5-Hydroxytryptophol 5HT metabolite; Marker of alcohol consumption 151 
ACh Acetylcholine Neurotransmitter 31 
Ado Adenosine Nucleoside; Neurotransmitter 31 
Agm Agmatine Polyamine; Potential neurotransmitter 152 
Ala Alanine Amino acid 153 
Ans Anserine Dipeptide antioxidant 154 
Arg Arginine Amino acid; Polyamine Precursor 155 
Asn Asparagine Amino acid 156 
Asp Aspartate Neuroactive amino acid 31 
BAla β-Alanine Neuroactive isomer of Ala 157 
Carn Carnosine Dipeptide antioxidant 154 
Ch Choline Precursor to ACh 158 
Cit Citrulline Intermediate in urea cycle 159 
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Abbreviation Analyte Relevance Reference 
CA Cysteic acid Cys metabolite; Tau precursor 160 
Cys Cysteine Neuroactive amino acid 161 
DA Dopamine Neurotransmitter 31 
E Epinephrine Neurotransmitter; NE metabolite 162 
ETA Ethanolamine Widely distributed amine 163 
Glc Glucose Primary source of energy 164 
Glu Glutamate Neuroactive amino acid 31 
Gln Glutamine Neuroactive amino acid 153 
GSH Glutathione Tripeptide antioxidant 161 
Gly Glycine Neuroactive amino acid 31 
Hist Histamine Neurotransmitter 31 
His Histidine Amino acid; Hist Precursor 165 
HCA Homocysteic acid Potential neurotransitter; Can induce seizures 166 
HCY Homocysteine Met metabolite; Potential neurotransmitter 167 
HSer Homoserine Nonproteinogenic amino acid 168 
HVA Homovanillic acid DA metabolite 31 
HTau Hypotaurine Potential antioxidant 169 
KA Kynurenic acid Neuroprotective Kyn metabolite 170 
Kyn Kynurenine Trp metabolite 148 
Kyo Kyotorphin Dipeptide; Role in pain regulation 171 
Leu Leucine Amino acid 172 
Lys Lysine Amino acid 172 
Met Methionine Amino acid 172 
NAP N-Acetylputrescine Polyamine 173 
NAS N-Acetylserotonin 5HT metabolite; Melatonin precursor 174  
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Abbreviation Analyte Relevance Reference 
NE Norepinephrine Neurotransmitter; DA metabolite 31 
NM Normetanephrine NE Metabolite 31 
OA Octopamine Trace amine; TyrA metabolite 175 
Orn Ornithine Intermediate in urea cycle 172 
PhEt Phenethylamine Trace amine; Phe metabolite 176 
Phe Phenylalanine Amino acid; Precursor to catecholamines 177 
Pro Proline Amino acid 154 
Put Putrescine Polyamine 172 
Ser Serine Neuroactive amino acid 31 
5HT Serotonin Neurotransmitter 31 
Spd Spermidine Polyamine 178 
Spm Spermine Polyamine 178 
Syn Synephrine OA metabolite 179 
Tau Taurine Neurotransmitter 31 
Thr Threonine Amino acid 172 
TrpA Tryptamine Trace amine; Trp metabolite 176 
Trp Tryptophan 5HT precursor; Kyn precursor 177 
TyrA Tyramine Trace amine 176 
Tyr Tyrosine Amino acid; Precursor to catecholamines 177 
Val Valine Amino acid 172 
VMA Vanillylmandelic acid NE Metabolite 180 
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Experimental 
Chemicals and reagents 
All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless 
otherwise noted. Water, methanol, and acetonitrile for mobile phases are Burdick & 
Jackson HPLC grade purchased from VWR (Radnor, PA). Stock solutions of 500 mM 
Glc; 10 mM DOMA, DOPAC (Acros Organics, Geel, Belgium), MOPEG, GABA, 
5HIAA, 5HTP, Agm, Ala, Ans, Arg, Asn, Asp, βAla, Carn, Cit, CA, Cys, DA, E, ETA, 
Glu, Gln, GSH, Gly, Hist, His, HCA, HCY, HSer, HVA (Tocris, Bristol, UK), HTau, 
Kyo (MP Biomedicals, Santa Ana, CA), Leu, Lys, Met, NAP, NAS, NE, NM, OA, Orn 
(Acros Organics, Geel, Belgium), PhEt (MP Biomedicals, Santa Ana, CA), Pro, Put, Ser, 
5HT, Spd, Spm, Syn, Tau, Thr, Val, and VMA; 5 mM ACh, 5HTOL (Cayman Chemical, 
Ann Arbor, MI), Ado, Kyn, LDOPA, Phe, and Trp; 2.5 mM 3HK; 2 mM Tyr; 1 mM 
DOPEG, 3HAA, 3MT, KA, and TyrA; 0.25 mM TrpA; and 20 mM isotopically labeled 
d4-ACh and d4-Ch (C/D/N isotopes, Pointe-Claire, Canada); were made in HPLC water 
and kept at -80 °C. A standard mixture was diluted from stocks with artificial 
cerebrospinal fluid (aCSF) consisting of 145 mM NaCl, 2.68 mM KCl, 1.4 mM CaCl2, 
1.0 mM MgSO4, 1.55 mM Na2HPO4, and 0.45 mM NaH2PO4 adjusted pH to 7.4 with 
NaOH. Calibration curves were made using standards at 0.1, 0.5, 1, 5, 10, 25, 50 μM for 
Glc; 10, 50, 100, 500, 1000, 250, 5000 nM for 3HK, Asn, Asp, CA, GSH, Gly, HTau, 
Ser, and Tau; 1, 5, 10, 50, 100, 250, 500 nM for Ch, 3HAA, MOPEG, 5HIAA, 5HTP, 
5HTOL, Ado, Agm, Ala, Ans, βAla, Carn, Cit, Cys, ETA, Glu, Gln, His, HCA, HCY, 
HSer, HVA, KA, Kyn, Met, NAP, Orn, Phe, Pro, Thr, Trp, Val, and VMA; 0.1, 0.5, 1, 5, 
10, 25, 50 nM for ACh, DOMA, DOPAC, DOPEG, 3MT, GABA, Arg, DA, E, Hist, 
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Kyo, LDOPA, Leu, Lys, NAS, NE, NM, OA, PhEt, Put, 5HT, Spd, Spm, Syn, TrpA, 
TyrA, and Tyr. An internal standard stock was prepared with 5 mM Glc; 500 μM 3HK, 
Asn, Asp, CA, GSH, Gly, HTau, Ser, and Tau; 50 μM 3HAA, MOPEG, 5HIAA, 5HTP, 
5HTOL, Ado, Agm, Ala, Ans, βAla, Carn, Cit, Cys, ETA, Glu, Gln, His, HCA, HCY, 
HSer, HVA, KA, Kyn, Met, NAP, Orn, Phe, Pro, Thr, Trp, Val, and VMA; 5 μM 
DOMA, DOPAC, DOPEG, 3MT, GABA, Arg, DA, E, Hist, Kyo, LDOPA, Leu, Lys, 
NAS, NE, NM, OA, PhEt, Put, 5HT, Spd, Spm, Syn, TrpA, TyrA, and Tyr; and 
derivatized with 13C6-BzCl using a similar procedure as 12C reagents. 
Calibration standard and internal standard stocks were frozen at -80 °C in aliquots 
to prevent multiple freeze/thaw cycles. A single internal standard stock aliquot was 
thawed the day of use, diluted 100-fold in 20% (v/v) acetonitrile containing 1% (v/v) 
sulfuric acid, and spiked with deuterated acetylcholine and choline (C/D/N isotopes, 
Pointe-Claire, Canada) to a final concentration of 20 nM. A fresh benzoyl chloride 
solution was made daily. 
 
Microdialysis in anesthetized rat 
Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-275 g 
were used for microdialysis collection. Rats were housed with access to food and water 
ad libitum in a temperature and humidity controlled room with 12 h light/dark cycles. All 
animals were treated as approved by the University Committee on Use and Care of 
Animals at the University of Michigan, the National Institute of Health Guidelines for the 
Care and Use of Laboratory Animals. All precautions were taken to prevent animal 
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discomfort through the course of the experiments. In addition, all animal experiments 
were conducted within the guidelines of Animal Research Reporting in vivo Experiments. 
A custom-made concentric microdialysis probe (4 mm dialyzing membrane), 
made using regenerated cellulose (Spectrum Laboratories, Inc., Rancho Dominguez, CA, 
USA) was implanted into the striatum. Rats were anesthetized with 1-4% isoflurane and 
placed into a stereotaxic frame (David Kopf, Tujunga, CA). A burr hole was placed 
above the striatum using the anterior-posterior +1.0 mm and lateral ±3.0 mm coordinates 
from bregma. The microdialysis probe was flushed with artificial CSF (aCSF) at a flow 
rate of 2 μL/min using a Fusion 400 syringe pump (Chemyx, Stafford, TX) as it was 
lowered 6.15 mm from top of skull. Once the probe was positioned, the probe was 
flushed at 2 μL/min for 30 min followed by 30 min at 1.0 μL/min prior to collection. Ten 
μL dialysate was derivatized using the modified method reported: 5 μL of 100 mM 
sodium carbonate, 5 μL BzCl (2% (v/v) in acetonitrile), and 5 μL internal standard 
mixture were added sequentially, with vortex mixing after each addition. At the 
completion of the experiment, animals were euthanized, brains were extracted and stored 
at 4 °C in 4% paraformaldehyde. Probe placement was confirmed with histology.  
 
Human CSF 
Pooled human CSF from healthy patients was obtained from the Batemen lab at 
Washington University School of Medicine, St. Louis, MO181. Samples were diluted 100-
fold in water, and a 10 μL aliquot was derivatized using 5 μL of 100 mM sodium 
carbonate, 5 μL BzCl (2% (v/v) in acetonitrile), and 5 μL internal standard mixture 
before LC-MS analysis.  
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Human serum 
Pooled human serum from the American Red Cross Detroit National Testing Lab 
was provided by the Michigan Regional Comprehensive Metabolomics Resource Core. 
To remove proteins, 20 µL of serum were diluted with 80 µL of ice-cold acetonitrile. The 
samples were vortexed briefly, then centrifuged for 10 min at 12,100 × g. 20 μL of the 
supernatant was derivatized by sequential addition of 10 μL of 100 mM sodium 
carbonate, 10 μL of BzCl (2% (v/v) in acetonitrile), and 10 μL of the internal standard 
mixture. Fifty μL of water were added to reduce the organic content of the samples. 
Calibration standards were prepared in aCSF, which is similar in composition to serum 
without proteins182. Five μL aliquots of the standards were diluted with 20 μL acetonitrile 
to match the sample composition, and then derivatized in the same manner as the serum 
supernatant. 
 
Fly tissue homogenate 
Homogenized Drosophila samples were provided by the Pletcher lab at the 
University of Michigan, Ann Arbor. Female flies were treated with 250 μM 5HTP for 
four days prior to harvesting. The flies were snap frozen in liquid nitrogen and vortexed 
to remove heads. The heads were homogenized in 4 μL of ice cold acetonitrile per head, 
and 20 μL ice-cold acetonitrile per body, using a pestle grinder. The homogenate was 
centrifuged at 18,000 × g for 5 min and the supernatant was removed and stored at -80 °C 
until derivatization. 20 μL of the supernatant was derivatized by sequential addition of 10 
μL of 100 mM sodium carbonate, 10 μL of BzCl (2% (v/v) in acetonitrile), and 10 μL of 
the internal standard mixture. Finally, 50 μL of water were added to reduce the organic 
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content of the samples. Calibration standards were prepared in aCSF. Five μL aliquots of 
the standards were diluted with 20 μL acetonitrile to match the sample composition, and 
then derivatized in the same manner as the tissue homogenate supernatant. 
 
Fly hemolymph 
Hemolymph from Drosophila was provided by the Dus lab at the University of 
Michigan. Flies were reared in standard cornmeal-glucose medium at 25 °C in a 12:12 
light/dark cycle. After eclosion groups of 100 w1118CS (w1118 backcrossed to CS for 10 
generations) males were placed in bottles and aged for 7-10 days until the time of 
hemolymph collection. Fresh food was provided every 2 days.  
Hemolymph collection was performed as previously described, with 
modifications to the sated condition183. w118CS males in groups of 100 were moved into 
bottles containing agar and fasted for 24 h. For the starved condition, males were 
collected directly from the starvation bottles; for the sated condition, males were moved 
to bottles containing 5% sucrose agar and red food dye for 1 h, and then gathered for 
hemolymph collection. To generate a sufficient sample volume, multiple collections of 
hemolymph each from 100 males were pooled together. Hemolymph was stored at -80 °C 
until derivatization. 
Twenty µL of hemolymph were diluted with 80 µL of ice-cold acetonitrile. The 
samples were vortexed, then centrifuged for 10 min at 12,100 × g. Twenty μL of the 
supernatant was derivatized by sequential addition of 10 μL of 100 mM sodium 
carbonate, 10 μL of BzCl (2% (v/v) in acetonitrile), and 10 μL of the internal standard 
mixture. Fifty μL of water were added. Calibration standards were prepared in aCSF. 
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Five μL aliquots of the standards were diluted with 20 μL acetonitrile to match the 
sample composition, and then derivatized in the same manner as the hemolymph 
supernatant. 
 
Protein precipitation method validation 
To validate the method and test recovery of the solvent precipitation, we spiked a 
mixture of isotopically labeled metabolites (500 nM 13C5-glutamate, 50 nM d6-GABA, 50 
nM d4-serotonin, and 50 nM 13C6-dopamine) into 50 µL of pooled human serum. The 
spiked serum was diluted with 200 µL ice cold acetonitrile, followed by centrifugation 
for 10 minutes at 12,100 × g. 20 µL of supernatant was derivatized by sequential addition 
of 10 µL of 100 mM sodium carbonate, 10 µL of BzCl (2% (v/v) in acetonitrile), and 10 
µL of the internal standard mixture. Three spiked serum samples were extracted and 
derivatized in parallel for triplicate analysis. Calibration standards were prepared in 
aCSF, and 5 μL aliquots of the standards were diluted with 20 μL acetonitrile to match 
the sample composition, and then derivatized in the same manner as the serum 
supernatant. 
 
Small molecule neurochemical analysis using QQQ MS/MS 
Derivatized samples were analyzed by LC-MS (as further described in the results 
section) using a Waters nanoAcquity UPLC (Milford, MA) coupled to an Agilent 6410 
(Santa Clara, CA) triple quadrupole mass spectrometer operating in dynamic multiple 
reaction monitoring (dMRM) mode. Five µL were injected onto an Acquity HSS T3 C18 
column (1 mm x 100 mm, 1.8 µm, 100 Å pore size) in partial loop injection mode. 
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Samples were analyzed in triplicate. Mobile phase A was 10 mM ammonium formate 
with 0.15% formic acid, and mobile phase B was acetonitrile. The flow rate was 100 
µL/min and the elution gradient was as follows: initial, 0% B; 0.01 min, 15% B; 0.5 min, 
17% B; 14 min, 55% B; 14.5 min, 70% B; 18 min, 100% B; 19 min, 100% B; 19.1 min, 
0% B; and 20 min, 0% B. An additional 10 min of column equilibration at 0% B were 
required to achieve reproducible chromatography. The required pressure over the 
gradient was from 2,500 - 8,000 psi. The autosampler was kept at ambient temperature 
and the column was kept at 27 °C. Electrospray ionization was used in positive mode at 4 
kV. The gas temperature was 350 °C, gas flow was 11 L/min, and the nebulizer was at 15 
psi. Automated peak integration was performed using Agilent MassHunter Workstation 
Quantitative Analysis for QQQ, version B.05.00; all peaks were visually inspected to 
ensure proper integration. 
 
Statistical analyses 
All statistical analyses were performed in Prism 7 (GraphPad, La Jolla, CA). For 
statistical analysis unpaired Student’s t test were applied. Differences were deemed 
significant if p < 0.05.   
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Results and Discussion 
BzCl labeling has been previously reported for the analysis of small molecule 
neurotransmitters, polyamines and steroids with HPLC-MS or ultraviolet-absorption 
detection31, 34, 184, 185. Here we identify new reaction conditions that improve sensitivity 
for LC-MS/MS for many of the neurochemicals tested and demonstrate the wide 
applicability of BzCl derivatization for low molecular weight metabolites in a variety of 
complex sample matrices. 
 
Effect of buffer and solvents on reaction conditions  
The initial report of using BzCl with HPLC-MS/MS for neurochemicals utilized 
four reagent addition steps31: 1) sodium tetraborate buffer (100 mM) to the sample to 
achieve basic pH conditions required for BzCl labeling; 2) 2% (v/v) BzCl in acetonitrile; 
3) internal standards diluted in dimethyl sulfoxide (DMSO) with 1% (v/v) formic acid, 4) 
d4-ACh in water to provide an internal standard for this neurotransmitter that does not 
react with BzCl. Tetraborate buffer was originally selected because it forms a reversible 
complex with catechol groups31, 186 to prevent oxidation under high pH conditions. Our 
present work first focused on modifying reaction conditions to improve sensitivity and 
reduce the number of steps. These initial studies used 17 neurochemicals as test analytes 
(Figure 2-1, Table 2-2). 
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Figure 2-1 Normalized effect of sodium borate versus sodium carbonate buffer on calibration slope for 
select analytes. Standards made using sodium borate buffer and sodium carbonate buffer were analyzed 
with LC-MS in triplicate. A 6-point calibration curve for all analytes of interest was made to determine the 
average calibration slope for each analyte (n = 3 for each concentration tested). For the calibrations, the 
high concentrations were 20 nM for ACh, 5HT, NE, NM, DA and 3MT; 200 nM for Hist, GABA, 5HIAA, 
HVA, and DOPAC; and 2 μM for Tau, Ser, Asp, Ado, Gly, and Glu; followed by serial dilution. Analyte to 
internal standard ratios were plotted against known concentrations and a linear trend line was applied to 
determine slope (A). Sodium carbonate slopes were normalized to sodium borate slopes. Significant 
improvements to Ado, Gly, Hist, NE, DA, and DOPAC occurred when using 100 mM sodium carbonate as 
the buffer. Slopes were decreased for 5HT, NM, 3MT, and HVA. Unpaired two-tailed Students t test 
statistics were performed (B). Data expressed as percent borate ± SD. *p < 0.05, n = 3. 
 
We found that sodium carbonate instead of borate buffer significantly improved 
sensitivity (i.e. slope of the calibration curve; Figure 2-1) for compounds containing a 
1,2 diol group, such as dopamine, norepinephrine, and DOPAC (Figure 2-2A). Use of 
100 mM carbonate buffer instead of 100 mM borate increased the slope of 
norepinephrine 221% (t(4) = 19.6, p < 0.0001), dopamine 170% (t(4) = 27.7, p < 0.0001), 
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and DOPAC 330% (t(4) = 39.5, p < 0.0001). The slope was increased 2550% for 
adenosine (t(4) = 52.0, p < 0.0001), which is also a diol. The slope increased slightly for 
two compounds without diols: glycine 103% (t(4) = 5.6, p < 0.01) and histamine 110% 
(t(4) = 5.4, p < 0.01). Although these compounds improved, the calibration slope was 
reduced 25% for serotonin (t(4) = 4.2, p < 0.05), 10% for normetanephrine (t(4) = 5.3, p < 
0.01), 20% for 3MT (t(4) = 7.7, p < 0.01), and 10% for HVA (t(4) = 2.9, p < 0.05). These 
small decreases in slope are a reasonable trade-off for the large gains for the diols. 
Improved catechol detection sensitivity may relate to how the buffers interact 
with 1,2 diol groups. Both borate and carbonate can be used as protecting groups for 1,2 
 
Figure 2-2 Chemical structures of neurochemicals enhanced by sodium carbonate buffer (A). Structures of 
neurochemical reduced with carbonate buffer (B). 
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diols187; however, cyclic borates are deprotected using dilute acid187, 188, while cyclic 
carbonates hydrolyze in water187, 189. The protection of the carbonate group is more 
readily reversed than borate due to the high aqueous content of the sample, allowing for 
greater access of the diols for BzCl. The reason for the decreases in sensitivity of some 
compounds is unclear, but several of the compounds with decreased slopes have an ortho 
configuration of an alcohol and methoxy group (Figure 2-2B). 
A potential problem with the BzCl assay is that organic solvent in the injected 
sample could cause poor peak shape for the most polar analytes, particularly 
acetylcholine (Figure 2-3). However, some organic solvent is needed to maintain 
solubility of the hydrophobic internal standards that are added to the sample. Replacing 
DMSO in the internal standard mixture with 20% (v/v) acetonitrile improved peak shape 
and signal intensity for acetylcholine, while retaining sufficient organic content to 
maintain solubility of hydrophobic compounds. The peak area for acetylcholine standards 
treated with internal standards in 20% (v/v) acetonitrile increased 5-fold relative to 
samples treated with internal standards in DMSO. This change in solvent reduces the 
final organic content of the samples, so band broadening is reduced for polar metabolites 
such as acetylcholine, as the sample composition is more closely matched in elution 
strength to the initial gradient conditions.  
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Figure 2-3 Replacement of DMSO with acetonitrile as solvent for internal standards improves the peak 
shape and area for early eluting metabolite ACh. Standards were derivatized with 2% BzCl (v/v in 
acetonitrile), 100 mM sodium carbonate, and an internal standard mixture diluted in either DMSO or 20% 
(v/v) acetonitrile. ACh ion chromatograms were extracted and normalized to the ACh peak in acetonitrile 
and overlaid. 
Substituting 1% (v/v) sulfuric acid for 1% (v/v) formic acid in the internal 
standard mixture improved signals of late eluting compounds by 237% for 
normetanephrine, 165% for DOPAC, 481% for serotonin, 476% for norepinephrine, 
440% for 3MT, and 468% for dopamine (Table 2-2). While the explanation for this 
increased signal is unclear, we hypothesize that it is due to the decreased formation of 
formate adducts late in the gradient. The production of undetectable formate adducts 
limits the production of detectable proton adducts. Formic acid is used in our mobile 
phase A, so early eluting compounds may still form formate adducts; whereas later 
eluting compounds have less likelihood of formate adducts due to the lack of formic acid 
in sample and mobile phase B.  
 46 
Table 2-2 Improvements in sensitivity using sulfuric acid compared to formic acid additive to reagent 
mixture. Standards were derivatized with sodium carbonate (100 mM), BzCl (2% (v/v) in acetonitrile), and 
an internal mixture that contained 20% (v/v) acetonitrile with 1% (v/v) formic acid or sulfuric acid.  
 
  Retention Time Concentration Formic Acid Sulfuric Acid Increase with 
Analyte (min) (nM) Peak Area Peak Area Sulfuric (%) 
ACh 1.2 50 9409 8219 87 
Tau 2.3 2000 17373 17723 102 
Hist 2.3 200 78624 81494 104 
Ser 2.6 5000 19108 20770 109 
Asp 2.8 200 1118 1324 118 
Gly 2.9 5000 4163 4695 113 
Glu 3.1 2000 19442 23809 122 
GABA 3.7 200 23076 30285 131 
Ado 4.6 200 8894 12443 140 
5HIAA 5.2 500 12758 16814 132 
HVA 5.3 500 54869 69455 127 
NM 5.5 20 13240 31391 237 
DOPAC 5.9 500 158474 261578 165 
5HT 5.9 20 2221 10703 482 
NE 6.0 20 5974 28457 476 
3MT 6.0 20 16229 71462 440 
DA 6.4 20 21510 100588 468  
 
To reduce the number of reagent addition steps and the dilution associated with 
derivatization, we added the d4-acetylcholine internal standard to the 13C-labeled internal 
standards and introduced all internal standards in one step. This modification had no 
effect on d4-acetylcholine or the 13C-labeled compounds. 
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Addition of new compounds  
To illustrate the potential for more comprehensive measurement of neurochemical 
pathways with this assay, 53 compounds were added to the original 17 compound assay 
(Table 2-1). The selected 70 compounds include 19 proteinogenic amino acids and 
intermediates in the metabolism of phenylalanine, tyrosine, tryptophan, and arginine. 
Phenylalanine and tyrosine are precursors to the catecholamines and several trace amines, 
so many metabolites in this pathway were added. These include several norepinephrine 
metabolites (e.g., VMA and MOPEG), as well as tyrosine derivatives such as tyramine 
and octopamine. Trace amines (tyramine, octopamine, tryptamine, and phenethylamine) 
play prominent roles in many invertebrate species190-194, and are present as metabolic by-
products in the mammalian central nervous system, where they may neuromodulate 
biogenic amine signaling176, 194. Serotonin is derived from tryptophan, so several 
intermediates in tryptophan metabolism were included (Figure 2-4). These include 
5HTP, the direct precursor to serotonin, as well as serotonin metabolite N-
acetylserotonin, which is particularly relevant in flies195, 196. Monoamine oxidase (MAO) 
activity is limited in flies, so metabolites produced via MAO (e.g., 5HIAA) are not 
typically observed. Instead, monoamines are preferentially metabolized by N-acetylation, 
producing compounds such as N-acetylserotonin195-197. Tryptophan is also the precursor 
to kynurenine and its metabolites, which may have both neuroprotective and neurotoxic 
properties198. 
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Figure 2-4 Tryptophan Metabolic Pathway. Abbreviations: aromatic amino acid decarboxylase (AADC), 
aralkylamine N-acetyltransferase (AANAT), aldehyde dehydrogenase (ALDH), aldehyde reductase 
(ALDR), indoleamine 2,3-dioxygenase (IDO), kynurenine aminotransferase (KAT), kynurenine 3-
monooxygenase (KMO), kynureninase (KYNU), monoamine oxidase (MAO), tryptophan 2,3-dioxygenase 
(TDO), and tryptophan hydroxylase (TPH). 
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Several intermediates in arginine metabolism were also included in the method. 
Arginine is involved in the urea cycle and nitric oxide production. Ornithine, another 
member of the urea cycle, serves as a precursor for many polyamines, ubiquitous small 
molecules with a broad array of functions199, whose dysfunction are associated with 
neurodegenerative disease200, 201. Thiol-containing dipeptide glutathione, and histidine-
containing dipeptides, carnosine and metabolite anserine, have antioxidative effects in the 
brain202-204, and decreased glutathione activity is associated with oxidative stress. 
Postmortem prefrontal-cortex tissue from human patients with psychiatric conditions 
such as bipolar, depression, and schizophrenia, show decreased levels of glutathione204. 
Carnosine may be neuroprotective by inhibiting the formation of β-amyloid 
polymerization and α-synuclein oligomerization203, toxic species in Alzheimer’s and 
Parkinson’s diseases. Glucose indicates neuronal energy expenditure, and alterations of 
normal glucose metabolism can lead to synaptic dysfunction, including glucose 
hypometabolism in Alzheimer’s disease and Parkinsonian patients with dementia205-208. 
All 70 analytes of interest and their internal standards are benzoylated, except 
acetylcholine and choline, and detected by MS/MS (Table 2-3 and Table 2-4). Analytes 
were labeled 1-4 times with BzCl depending on the functional groups. In all cases, only 
the fully labeled compounds were observed, indicating quantitative (i.e., complete 
labeling) reactions. As an example, dopamine is triply labeled; singly and doubly labeled 
dopamine were not detectable. Protonated benzoylation products (MW + 1) were 
observed for most compounds with ESI in positive mode. A protonated water loss was 
observed for octopamine, normetanephrine, and synephrine (MW – 18 + 1), and the 
ammonium adduct (MW + 18) was detected for VMA, MOPEG, 5HIAA, HVA. DOMA, 
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DOPEG, and DOPAC. A sodium adduct was observed for glucose (MW + 23). Other 
hexoses (e.g. fructose, mannose, and galactose) were resolved chromatographically or by 
MRM. For acetylcholine and choline, the unlabeled molecular ions were used for 
detection. 
 
Figure 2-5 Fragmentation patterns for select benzoyl labeled compounds. Analytes were detected by 
MS/MS under collision activated dissociation (CAD) conditions. While the benzoyl fragment of 105 m/z 
was the most abundant product ion for most analytes detected, unique fragments were chosen for detection 
to increase the selectivity of the assay for these compounds. 
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Table 2-3 Labeling patterns and MRM conditions of 70 targeted metabolites 
Analyte 
Precursor Product Fragmentor Collision Energy 
Retention 
Time Labeling MS 
(m/z) (m/z) (V) (V) (min) Pattern Species 
ACh 146 87 120 15 1.30 non [M]+ 
Ch 104 60 120 20 1.30 non [M]+ 
Bz-CA 274 105 120 10 2.31 mono [M + H]+ 
Bz-His 260 110 130 20 2.33 mono [M + H]+ 
Bz-Ans 345 105 130 30 2.40 mono [M + H]+ 
Bz-Carn 331 110 135 20 2.40 mono [M + H]+ 
Bz-HTau 214 105 120 20 2.48 mono [M + H]+ 
Bz-Tau 230 105 120 10 2.49 mono [M + H]+ 
Bz-Arg 279 105 135 30 2.58 mono [M + H]+ 
Bz-Hist 216 105 120 20 2.61 mono [M + H]+ 
Bz-Asn 237 105 120 20 2.62 mono [M + H]+ 
Bz-Ser 210 105 120 20 2.71 mono [M + H]+ 
Bz-Gln 251 105 120 20 2.72 mono [M + H]+ 
Bz-HSer 224 105 120 20 2.88 mono [M + H]+ 
Bz-Cit 280 105 120 20 2.91 mono [M + H]+ 
Bz-ETA 166 105 120 20 2.93 mono [M + H]+ 
Bz-Asp 238 105 120 10 2.98 mono [M + H]+ 
Bz-Agm 235 176 110 30 3.02 mono [M + H]+ 
Bz-Glc 307 185 130 20 3.10 mono [M + Na]+ 
Bz-Gly 180 105 120 10 3.10 mono [M + H]+ 
Bz-Glu 252 105 120 20 3.28 mono [M + H]+ 
Bz-BAla 194 105 120 20 3.53 mono [M + H]+ 
Bz-Ala 194 105 120 20 3.78 mono [M + H]+ 
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Analyte 
Precursor Product Fragmentor Collision Energy 
Retention 
Time Labeling MS 
(m/z) (m/z) (V) (V) (min) Pattern Species 
Bz-NAP 235 176 135 20 3.85 mono [M + H]+ 
Bz-GABA 208 105 120 10 3.99 mono [M + H]+ 
Bz-Pro 220 105 120 20 4.60 mono [M + H]+ 
Bz-Ado 372 136 120 30 6.28 mono [M + H]+ 
Bz-Val 222 105 120 30 6.63 mono [M + H]+ 
Bz-Met 254 105 120 15 6.73 mono [M + H]+ 
Bz-Orn 341 174 120 15 7.50 bi [M + H]+ 
Bz-GSH 516 105 120 15 8.28 bi [M + H]+ 
Bz-Lys 355 188 120 20 8.35 bi [M + H]+ 
Bz-Put 297 105 120 30 8.79 bi [M + H]+ 
Bz-Leu 236 105 120 30 9.30 mono [M + H]+ 
Bz-Phe 270 120 120 10 9.67 mono [M + H]+ 
Bz-Thr 224 105 140 20 9.67 mono [M + H]+ 
Bz-VMA 320 181 120 10 9.77 mono [M + NH4]+ 
Bz-Trp 309 159 120 10 9.96 mono [M + H]+ 
Bz-MOPEG 306 105 120 20 10.08 mono [M + NH4]+ 
Bz-Kyo 546 175 110 30 11.35 bi [M + H]+ 
Bz-Cys 330 105 120 20 11.64 bi [M + H]+ 
Bz-KA 294 105 120 30 11.78 mono [M + H]+ 
Bz-Spd 458 162 120 30 12.00 tri [M + H]+ 
Bz-PhEt 226 105 120 15 12.23 mono [M + H]+ 
Bz-TrpA 265 144 130 30 12.38 mono [M + H]+ 
Bz-NAS 323 264 120 15 12.39 mono [M + H]+ 
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Analyte 
Precursor Product Fragmentor Collision Energy 
Retention 
Time Labeling MS 
(m/z) (m/z) (V) (V) (min) Pattern Species 
Bz-5HIAA 313 146 120 15 12.60 mono [M + NH4]+ 
Bz-5HTOL 282 160 130 20 12.73 mono [M + H]+ 
Bz-HCY 344 105 120 20 13.00 bi [M + H]+ 
Bz-3HAA 362 240 120 10 13.07 bi [M + H]+ 
Bz-HCA 288 105 120 10 13.13 mono [M + H]+ 
Bz-HVA 304 105 120 15 13.13 mono [M + NH4]+ 
Bz-DOMA 410 105 130 20 13.35 bi [M + NH4]+ 
Bz-Kyn 417 122 120 10 13.35 bi [M + H]+ 
Bz-Spm 619.6 497 135 25 13.52 quad [M + H]+ 
Bz-DOPEG 396 105 120 20 13.59 bi [M + NH4]+ 
Bz-5HTP 429 279 120 15 13.82 bi [M + H]+ 
Bz-OA 344 105 140 20 13.84 bi [M - H2O + H]+ 
Bz-NM 374 105 140 15 13.88 bi [M - H2O + H]+ 
Bz-Tyr 390 105 120 30 14.12 bi [M + H]+ 
Bz-3HK 537 240 135 25 14.40 tri [M + H]+ 
Bz-Syn 358 105 140 20 14.43 bi [M - H2O + H]+ 
Bz-5HT 385 264 140 20 15.46 bi [M + H]+ 
Bz-DOPAC 394 105 140 20 15.49 bi [M + NH4]+ 
Bz-3MT 376 105 120 20 15.67 bi [M + H]+ 
Bz-LDOPA 510 105 120 25 15.67 tri [M + H]+ 
Bz-TyrA 346 105 135 25 15.73 bi [M + H]+ 
Bz-NE 482 105 140 30 15.77 tri [M + H]+ 
Bz-E 496 105 120 15 15.96 tri [M + H]+ 
Bz-DA 466 105 140 20 16.40 tri [M + H]+ 
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Table 2-4 Transitions for 13C6-BzCl labeled internal standard 
Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
d4-Ach 150 91 120 15 1.30 
d4-Ch 108 60 120 20 1.30 
13C6Bz-CA 280 111 120 10 2.31 
13C6Bz-His 266 110 130 20 2.33 
13C6Bz-Ans 351 111 130 30 2.40 
13C6Bz-Carn 337 110 135 20 2.40 
13C6Bz-HTau 220 111 120 20 2.48 
13C6Bz-Tau 236 111 120 10 2.49 
13C6Bz-Arg 285 111 135 30 2.58 
13C6Bz-Hist 222 111 120 20 2.61 
13C6Bz-Asn 243 111 120 20 2.62 
13C6Bz-Ser 216 111 120 20 2.71 
13C6Bz-Gln 257 111 120 20 2.72 
13C6Bz-HSer 230 111 120 20 2.88 
13C6Bz-Cit 286 111 120 20 2.91 
13C6Bz-ETA 172 111 120 20 2.93 
13C6Bz-Asp 244 111 120 10 2.98 
13C6Bz-Agm 241 182 110 30 3.02 
13C6Bz-Glc 313 185 130 20 3.10 
13C6Bz-Gly 186 111 120 10 3.10 
13C6Bz-Glu 258 111 120 20 3.28 
13C6Bz-BAla 200 111 120 20 3.53 
13C6Bz-Ala 200 111 120 20 3.78 
13C6Bz-NAP 241 182 135 20 3.85 
13C6Bz-GABA 214 111 120 10 3.99 
13C6Bz-Pro 226 111 120 20 4.60 
13C6Bz-Ado 378 136 120 30 6.28 
13C6Bz-Val 228 111 120 30 6.63 
13C6Bz-Met 260 111 120 15 6.73 
13C6Bz-Orn 353 180 120 15 7.50 
13C6Bz-GSH 528 111 120 15 8.28 
13C6Bz-Lys 367 194 120 20 8.35 
13C6Bz-Put 309 111 120 30 8.79 
13C6Bz-Leu 242 111 120 30 9.30 
13C6Bz-Phe 276 120 120 10 9.67 
13C6Bz-Thr 230 111 140 20 9.67 
 
 55 
Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
13C6Bz-VMA 326 181 120 10 9.77 
13C6Bz-Trp 315 159 120 10 9.96 
13C6Bz-MOPEG 312 111 120 20 10.08 
13C6Bz-Kyo 558 175 110 30 11.35 
13C6Bz-Cys 342 111 120 20 11.64 
13C6Bz-KA 300 111 120 30 11.78 
13C6Bz-Spd 476 168 120 30 12.00 
13C6Bz-PhEt 232 111 120 15 12.23 
13C6Bz-TrpA 271 144 130 30 12.38 
13C6Bz-NAS 329 270 120 15 12.39 
13C6Bz-5HIAA 319 146 120 15 12.60 
13C6Bz-5HTOL 288 160 130 20 12.73 
13C6Bz-HCY 356 111 120 20 13.00 
13C6Bz-3HAA 374 246 120 10 13.07 
13C6Bz-HCA 294 111 120 10 13.13 
13C6Bz-HVA 310 111 120 15 13.13 
13C6Bz-DOMA 422 111 130 20 13.35 
13C6Bz-Kyn 429 128 120 10 13.35 
13C6Bz-Spm 643.6 515.6 135 25 13.52 
13C6Bz-DOPEG 408 111 120 20 13.59 
13C6Bz-5HTP 441 285 120 15 13.82 
13C6Bz-OA 356 111 140 20 13.84 
13C6Bz-NM 386 111 140 15 13.88 
13C6Bz-Tyr 402 111 120 30 14.12 
13C6Bz-3HK 555 246 135 25 14.40 
13C6Bz-Syn 370 111 140 20 14.43 
13C6Bz-5HT 397 270 140 20 15.46 
13C6Bz-DOPAC 406 111 140 20 15.49 
13C6Bz-3MT 388 111 120 20 15.67 
13C6Bz-LDOPA 528 111 120 25 15.67 
13C6Bz-TyrA 358 111 135 25 15.73 
13C6Bz-NE 500 111 140 30 15.77 
13C6Bz-E 514 111 120 15 15.96 
13C6Bz-DA 484 111 140 20 16.40 
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Analytes were detected by MS/MS under collision activated dissociation (CAD) 
conditions. The fragmentation of each analyte was examined to determine the best 
product ion to use for quantification (Table 2-3 and Table 2-4). For benzoylated 
analytes, the benzoyl fragment of 105 m/z was usually the most abundant product ion, 
and used for dMRM. Unique fragments for acetylcholine, choline, histidine, carnosine, 
phenylalanine, kynurenine, adenosine, tryptamine, 5HIAA, tryptophan, 5HTOL, 
spermidine, ornithine, kyotorphin, agmatine, N-acetylputrescine, VMA, glucose, lysine, 
3HAA, 3HK, N-acetylserotonin, serotonin, 5HTP, and spermine were identified. These 
correspond to immonium ions for histidine, phenylalanine, and tryptophan, y ions for 
kyotorphin and carnosine, and the adenine moiety for adenosine. Several fragmentation 
patterns are shown in Figure 2-5. When possible, unique fragments were chosen for 
quantification to increase the selectivity of the assay for these compounds, reducing the 
likelihood of interferences from unknowns with similar precursor masses. The unique 
fragments have comparable or increased sensitivity relative to the 105 fragments for 
those compounds.  
After determining the MS/MS transitions, a gradient was developed to separate 
the analytes (Figure 2-6). The gradient was not designed to fully resolve all analytes but 
to spread the analytes out over the 20 min separation time and minimize the number of 
dMRMs at any given time. The gradient results show that even very polar compounds 
like dopamine can be well retained after benzoylation. Total analysis time for each 
sample is around 33 min including injection time, elution and column re-equilibration on 
the Waters nanoAcquity system. Higher throughput may be possible. In preliminary tests, 
the method was transferred to a higher flow rate HPLC with higher pressure limits  
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Figure 2-6 Reconstructed ion chromatogram of 70 compounds detected in 20 min. Extracted ion 
chromatograms for each compound at the highest concentration calibration standard run, were normalized 
to highest intensity and overlaid. 
and the separation time was reduced to 12 min, with a total analysis time of around 14 
min. Further reductions in the analysis time per sample can be achieved as LC pressure 
limits and MS scan rates continue to increase. 
The method yields good detection limits, linearity, reproducibility and low 
carryover for all detected compounds (Table 2-5). All detection limits were better than 
10 nM except for glutathione, alanine, citrulline, glycine, serine, and glucose209. While 
limits of detection (LOD) for these select compounds were higher than other reported 
compounds in the assay, these levels were below the observed concentrations in dialysate 
and CSF.   
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Table 2-5 Summary of limits of detection (LOD), carryover, relative standard deviation (n = 3), and R2 
value of a six-point calibration for aqueous standards. 
Analyte 
LoD Carryover RSD Fit 
Analyte 
LoD Carryover RSD Fit 
(nM) (%) (%) (R2) (nM) (%) (%) (R2) 
ACh 1 1 0.7 0.9996 Thr 5 0.3 1 0.9995 
Ch 3 0.2 1 0.9997 VMA 1 0.1 1 0.9999 
CA 4 0.02 2 1.0000 Trp 1 0.1 0.9 0.9997 
His 2 0.1 2 0.9996 MOPEG 0.7 0.08 0.6 0.9999 
Ans 0.4 0.03 2 0.9999 Kyo 0.2 0.2 2 0.9998 
Carn 0.8 0.04 2 0.9999 Cys 1 0.1 5 0.9971 
HTau 7 0.05 4 0.9977 KA 1 0.1 0.9 0.9997 
Tau 3 0.02 1 0.9998 Spd 0.09 0.1 0.5 0.9994 
Arg 1 0.5 3 0.9576 PhEt 0.08 0.09 2 0.9989 
Hist 0.09 0.04 3 0.9996 TrpA 0.1 0.09 3 0.9993 
Asn 2 0.1 2 0.9999 NAS 0.09 0.06 0.8 0.9997 
Ser 70 0.6 1 0.9976 5HIAA 0.7 0.08 0.8 0.9999 
Gln 4 0.2 3 0.9998 5HTOL 0.9 0.07 1 0.9997 
HSer 11 0.5 3 0.9994 HCY 0.9 0.08 1 0.9968 
Cit 20 2 2 0.9965 3HAA 1 0.1 0.9 0.9996 
ETA 6 0.4 2 0.9997 HCA 1 0.09 2 0.9998 
Asp 8 0.05 1 0.9999 HVA 0.6 0.07 0.4 1.0000 
Agm 1 0.03 4 0.9997 DOMA 0.3 0.2 3 0.9998 
Glc 160 0.06 6 0.9997 Kyn 1 0.1 3 0.9994 
Gly 30 0.09 7 0.9997 Spm 0.1 0.1 2 0.9984 
Glu 0.3 0.2 1 1.0000 DOPEG 0.1 0.1 1 0.9992 
BAla 5 0.09 1 1.0000 5HTP 2 0.2 3 0.9996 
Ala 20 2 2 0.9994 OA 0.2 0.2 1 0.9983 
NAP 0.5 0.05 1 0.9999 NM 0.08 0.09 2 0.9988 
GABA 0.5 0.4 2 0.9997 Tyr 4 2 3 0.9950 
Pro 5 0.5 0.4 0.9996 3HK 8 0.06 2 0.9941 
Ado 1 0.1 0.2 0.9956 Syn 0.2 0.2 0.1 0.9982 
Val 7 0.6 3 0.9998 5HT 0.4 0.4 1 0.9970 
Met 0.7 0.09 1 0.9998 DOPAC 0.2 0.2 2 0.9999 
Orn 7 0.4 0.2 0.9963 3MT 0.2 0.2 2 0.9987 
GSH 10 0.1 2 0.9999 LDOPA 1 0.9 2 0.9999 
Lys 4 2 0.7 0.9867 TyrA 0.2 0.3 1 0.9964 
Put 0.1 0.1 1 0.9999 NE 0.3 0.2 2 0.9970 
Leu 5 4 2 0.9894 E 0.3 0.2 1 0.9964 
Phe 3 0.2 0.8 0.9999 DA 0.3 0.3 3 0.9965 
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Application of 70 compound assay in various matrices  
To test the versatility of the assay, we analyzed several types of biological 
samples, including rat striatal dialysate, human CSF, human serum, and Drosophila 
tissue homogenate (Table 2-6, Table 2-7, Table 2-8). Fifty seven compounds were 
detected in dialysate samples, whereas 35 and 50 compounds were above the limits of 
detection in human CSF and serum samples, respectively. Drosophila heads and bodies 
were isolated and analyzed separately, with detection of 44 compounds in head and 42 
compounds in bodies. 54 compounds were detected in hemolymph from Drosophila. 
All commonly studied neurotransmitters (i.e., GABA, glutamate, and 
monoamines) were within expected ranges in rat striatal dialysate (Table 2-6). Several 
detectable compounds were not previously reported in rat dialysate or tissue homogenate 
studies, and include homoserine, a precursor to amino acids threonine and methionine; N-
acetylputrescine, a metabolite of polyamine putrescine; and DOMA, a norepinephrine 
metabolite. Polyamines putrescine, spermidine, and spermine were also detected in the 
dialysate sample. The norepinephrine and normetanephrine metabolites MOPEG, 
DOPEG, and DOMA (but not epinephrine or VMA) were detected in rat dialysate, 
demonstrating the potential for analysis of metabolic pathways.  
Analysis of human serum, derivatized after protein precipitation, revealed 
kyotorphin at 31 nM concentration. Kyotorphin is an endogenous analgesic dipeptide 
with potential neuroprotective properties. It has previously been found in rat brain tissue 
and human CSF samples210, 211. This is the first report of quantitative detection of 
kyotorphin in human serum. Kyotorphin is proposed to have indirect opioid-like actions 
by modulating enkephalin release212. Kyotorphin does not cross the blood brain barrier, 
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and is a candidate biomarker for neurodegenerative diseases such as Alzheimer’s 
disease210. While previous studies detected kyotorphin in CSF samples obtained from 
lumbar puncture, less invasive blood sample collection would be beneficial for patients, 
with subsequent detection as reported here. Interestingly, kyotorphin was not detected in 
our analysis of pooled human CSF from healthy patients, which did not undergo a protein 
precipitation step prior to analysis.  
Fly tissue homogenate contained detectable levels of tyramine and octopamine, 
which was expected as they are the fly analogs of epinephrine and norepinephrine, 
respectively. 5HTP pretreatment of the flies resulted in high levels of 5HTP in both 
bodies and heads. 5HTP metabolites serotonin and N-acetylserotonin were also elevated, 
though the effect was more pronounced in the bodies. Interestingly, 5HIAA was observed 
in both bodies and heads, despite the expected lack of MAO activity in flies, likely due to 
the excess of 5HTP197.  
Of the 54 compounds detected in fly hemolymph, 10 showed significant (p < 
0.05) changes between starved and sated states (Figure 2-7). These compounds were Ch 
(t(4) = 9.7, p < 0.0001); Ser (t(4) = 10.5, p < 0.0001), Cit (t(4) = 39.3, p < 0.0001), Pro 
(t(4) = 80.2, p < 0.0001), Orn (t(4) = 9.8, p < 0.0001), OA (t(4) = 17.9, p < 0.0001), Tyr 
(t(4) = 29.5, p < 0.0001), DOPAC (t(4) = 11.0, p < 0.0001), TyrA (t(4) = 13.1, p < 
0.0001), DA (t(4) = 27.2, p < 0.0001). Of particular note was a nearly 5-fold increase of 
octopamine in starved flies relative to sated flies. Increased octopamine activity has been 
reported in flies upon starvation, and has been linked to foraging-like behaviors as the 
flies presumably try to locate food213, 214. The roles of other implicated metabolites are 
currently undergoing further investigation. 
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Figure 2-7 Metabolites showing significant differences between sated and starved states in fly hemolymph. 
Metabolite concentrations were normalized to total protein content, and then normalized to the sated 
sample. Each sample was run in triplicate. Unpaired two-tailed Students t tests were performed, and the 
Holm-Bonferroni correction was used. Data expressed as average ± SD. *p < 0.05; **p < 0.01; ***p < 
0.001. 
Protein removal prior to analysis of bodily fluids and tissue homogenate prevents 
column contamination and exposure of the HPLC-MS to high protein concentrations. 
Many extraction techniques are used in metabolomics215-217. These methods vary in 
effectiveness based on the sample type and target metabolites, and require optimization 
for each assay. Solvent precipitation with cold acetonitrile was selected for its simplicity 
and reproducibility. To evaluate the effect of protein precipitation on recovery and 
reproducibility we spiked known amounts of isotopically labeled glutamate, GABA, 
serotonin, and dopamine into serum prior to solvent precipitation. We then measured 
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concentrations of the isotopically labeled compounds after solvent precipitation and 
derivatization, and compared these measured concentrations to the known amount spiked 
into serum to determine the relative recovery (Figure 2-8). The recovery varied for each 
tested metabolite, but was reproducible (RSD < 8%). As such, we concluded that fair 
comparison could be made between samples analyzed using this method, though 
comparisons to other methods would require correction for recovery. 
 
 
Figure 2-8 Recovery of four isotopically labeled metabolites spiked into plasma prior to solvent 
precipitation and derivatization. Percent recovery calculated as measured concentration after precipitation, 
relative to concentration spiked into serum. The average of three extraction replicates is shown. Error bars 
represent the standard error of the mean.  
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Table 2-6 Application of 70 compound method to analyze rat dialysate and human CSF. The average of 3 
repeated injections with standard deviation is reported below. Values for analytes were reported only if 
they were above the limit of detection. 
  Concentration (nM)   Concentration (nM) 
Analyte Rat Dialysate Human CSF Analyte Rat Dialysate Human CSF 
ACh 12.2 ± 0.1 1.19 ± 0.04 Thr 691 ± 7 65 ± 2 
Ch 1212 ± 5 14 ± 2 VMA       
CA 2170 ± 90 300 ± 30 Trp 141 ± 4 20.9 ± 0.2 
His 930 ± 10 91.4 ± 0.8 MOPEG 4.3 ± 0.3    
Ans       Kyo       
Carn 14.0 ± 0.4    Cys 503 ± 9    
HTau       KA       
Tau 1820 ± 70 33 ± 2 Spd 2.38 ± 0.08 0.19 ± 0.02 
Arg 1380 ± 70 211 ± 6 PhEt 0.53 ± 0.02    
Hist 0.76 ± 0.08 0.20 ± 0.03 TrpA       
Asn 40 ± 1 6.6 ± 0.3 NAS 0.23 ± 0.02    
Ser 4100 ± 250 570 ± 40 5HIAA 390 ± 6 2.4 ± 0.2 
Gln 37300 ± 1300 4080 ± 60 5HTOL 1.9 ± 0.1    
HSer 2920 ± 20 266 ± 7 HCY 4.91 ± 0.03    
Cit 390 ± 10    3HAA       
ETA 6980 ± 310 124 ± 4 HCA 1050 ± 30 4.7 ± 0.3 
Asp 108 ± 7 15 ± 2 HVA 1130 ± 40 4.4 ± 0.4 
Agm       DOMA 0.47 ± 0.02    
Glc 633000 ± 85000 55400 ± 840 Kyn 7.1 ± 0.3    
Gly 690 ± 10 52 ± 5 Spm 2.9 ± 0.1    
Glu 21 ± 1 4.9 ± 0.1 DOPEG 1.26 ± 0.03    
BAla 5.8 ± 0.9    5HTP       
Ala 5260 ± 160 306 ± 8 OA       
NAP 1.0 ± 0.1 0.74 ± 0.02 NM 0.30 ± 0.01    
GABA 40.5 ± 0.6 3.3 ± 0.2 Tyr 350 ± 20 76.6 ± 0.3 
Pro 1326 ± 8 13.8 ± 0.2 3HK       
Ado 112.8 ± 0.6    Syn       
Val 1760 ± 20 104 ± 2 5HT 0.89 ± 0.02    
Met 855 ± 6 26.2 ± 0.5 DOPAC 598 ± 5 0.6 ± 0.1 
Orn 196 ± 3 54.9 ± 0.8 3MT 8.5 ± 0.2    
GSH 74 ± 2    LDOPA 4.00 ± 0.04    
Lys 4030 ± 170 249 ± 7 TyrA 0.21 ± 0.02    
Put 0.83 ± 0.03 0.41 ± 0.03 NE 1.00 ± 0.08    
Leu 2200 ± 140 102 ± 4 E       
Phe 710 ± 5 66.9 ± 0.8 DA 29.4 ± 0.8    
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Table 2-7 Application of 70 compound method after protein precipitation for human serum. The average of 
3 repeated injections with standard deviation is reported below. Values for analytes were reported only if 
they were above the limit of detection (LOD).  
  LoD Concentration (nM)   LoD Concentration (nM) 
Analyte (nM) Human Serum Analyte (nM) Human Serum 
ACh 4 380 ± 10 Thr 30 62000 ± 5000 
Ch 50 15200 ± 200 VMA 20 
 
 
 CA 50 
 
 
 
Trp 30 51000 ± 3000 
His 30 37000 ± 1000 MOPEG 5 20 ± 5 
Ans 3 160 ± 20 Kyo 5 31 ± 3 
Carn 6 14 ± 3 Cys 30 1600 ± 100 
HTau 500 160000 ± 10000 KA 40 220 ± 30 
Tau 60 115000 ± 2000 Spd 2 41 ± 0.6 
Arg 10 7100 ± 300 PhEt 1 
 
 
 Hist 2 41 ± 2 TrpA 2 
 
 
 Asn 70 20900 ± 800 NAS 2 5 ± 4 
Ser 700 45000 ± 4000 5HIAA 5 67 ± 4 
Gln 10 180000 ± 10000 5HTOL 10 16 ± 2 
HSer 100 65000 ± 2000 HCY 30 
 
 
 Cit 20 9400 ± 200 3HAA 20 76 ± 6 
ETA 10 6300 ± 100 HCA 10 56 ± 7 
Asp 200 2300 ± 200 HVA 20 57 ± 1 
Agm 20 
 
 
 
DOMA 6 
 
 
 Glc 500 1050000 ± 90000 Kyn 40 2380 ± 50 
Gly 200 102000 ± 4000 Spm 2 39 ± 3 
Glu 30 21800 ± 700 DOPEG 2 
 
 
 BAla 20 2300 ± 400 5HTP 30 
 
 
 Ala 70 254000 ± 8000 OA 2 
 
 
 NAP 7 24 ± 2 NM 2 
 
 
 GABA 4 115 ± 4 Tyr 40 56000 ± 1000 
Pro 30 24300 ± 3000 3HK 200 
 
 
 Ado 3 
 
 
 
Syn 4 
 
 
 Val 40 160000 ± 10000 5HT 3 300 ± 40 
Met 8 21800 ± 300 DOPAC 5 
 
 
 Orn 200 27400 ± 300 3MT 4 
 
 
 GSH 90 
 
 
 
LDOPA 2 390 ± 20 
Lys 40 37000 ± 1000 TyrA 8 
 
 
 Put 0.4 13 ± 1 NE 3 3.2 ± 0.7 
Leu 40 139000 ± 3000 E 4 
 
 
 Phe 30 63000 ± 3000 DA 2 
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Table 2-8 Application of 70 compound method with a protein precipitation step for fly bodies and heads. 
The average of 3 repeated injections with standard deviation is reported below. Values for analytes were 
reported only if they were above the limit of detection. 
  Amount (pmol/fly)   Amount (pmol/fly) 
Analyte Fly Bodies Fly Heads Analyte Fly Bodies Fly Heads 
ACh 2.64 ± 0.08 0.212 ± 0.011 Thr 18.4 ± 1.8 0.98 ± 0.04 
Ch 312 ± 8.8 66.36 ± 1.14 VMA       
CA       Trp 17.1 ± 0.9 0.44 ± 0.02 
His 2.7 ± 0.1 0.27 ± 0.04 MOPEG       
Ans       Kyo       
Carn       Cys       
HTau 21 ± 6    KA 1.9 ± 0.1 0.4 ± 0.04 
Tau 278.5 ± 4.1 88.81 ± 3.19 Spd 0.03 ± 0.002 0.01 ± 0.0003 
Arg 0.45 ± 0.01 0.06 ± 0.004 PhEt 0.336 ± 0.015 0.005 ± 0.0004 
Hist 1.92 ± 0.13 0.772 ± 0.011 TrpA 1.85 ± 0.09 0.024 ± 0.002 
Asn 6.5 ± 0.7 0.74 ± 0.04 NAS 29.61 ± 0.7 4.24 ± 0.242 
Ser    0.8 ± 0.4 5HIAA 0.47 ± 0.07 0.025 ± 0.001 
Gln 54.99 ± 0.59 5.61 ± 0.14 5HTOL       
HSer 4.5 ± 1.1 0.4 ± 0.01 HCY       
Cit       3HAA       
ETA 44.03 ± 0.92 5.56 ± 0.27 HCA 0.07 ± 0.01    
Asp       HVA       
Agm       DOMA       
Glc 3170 ± 295 1111.5 ± 0.2 Kyn 8 ± 0.7    
Gly 8 ± 1 0.8 ± 0.004 Spm       
Glu 1.1 ± 0.2 0.21 ± 0.03 DOPEG       
BAla 83.5 ± 0.7 3.04 ± 0.13 5HTP 184.1 ± 3.6 1.83 ± 0.04 
Ala 90.4 ± 5.4 22.84 ± 2.69 OA    0.003 ± 0.0002 
NAP 0.16 ± 0.01 0.009 ± 0.0001 NM       
GABA 6.25 ± 0.18 1.661 ± 0.055 Tyr 8.4 ± 0.2 0.35 ± 0.007 
Pro 614.3 ± 2.8 100.46 ± 2.2 3HK 36 ± 3 1.7 ± 0.1 
Ado 31.1 ± 0.12 2.599 ± 0.038 Syn       
Val 22.3 ± 0.3 2.17 ± 0.1 5HT 81.66 ± 10.34 5.98 ± 0.666 
Met 16.17 ± 0.58 1.186 ± 0.025 DOPAC 0.09 ± 0.003 0.013 ± 0.001 
Orn       3MT       
GSH       LDOPA 1.5 ± 0.13 0.541 ± 0.026 
Lys 0.2 ± 0.02    TyrA 11.89 ± 0.64 0.062 ± 0.001 
Put 0.08 ± 0.001 0.0074 ± 0.0003 NE       
Leu 53.6 ± 1.9 3.84 ± 0.04 E       
Phe 18.4 ± 0.3 1.02 ± 0.03 DA 0.22 ± 0.01 0.005 ± 0.0001 
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Conclusions 
These results demonstrate the utility of BzCl derivatization with HPLC-MS/MS 
for targeted neurochemical metabolomics. Improvements to the benzoylation of small 
neurochemicals resulted in a comprehensive, robust, and quantitative method to monitor 
70 neurochemicals. This modified method improves sensitivity for compounds containing 
1,2-diols and early eluting peaks such as acetylcholine, and was expanded to 4-fold more 
neurochemicals compared to prior studies. The method is suitable for multiple samples 
types, including CSF, serum, and tissue homogenate. 
The results also indicate considerable potential for even wider use of BzCl as a 
MS labeling reagent. For example, the Michigan Regional Comprehensive 
Metabolomics Resource Core maintains a library of over 1,000 metabolites. Based on the 
reactivity of BzCl towards amines, phenols, thiols, and some alcohols, we estimate it 
could be used to label approximately 25% of these compounds. BzCl labeling is fast and 
simple to implement. Benzoylation improves sensitivity, retention, and quantification (via 
easily generated internal standards) with few drawbacks compared to direct detection of 
analytes. 
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CHAPTER 3: VENTRAL TEGMENTAL AREA NEUROTENSIN SIGNALING 
LINKS THE LATERAL HYPOTHALAMUS TO LOCOMOTOR ACTIVITY AND 
STRIATAL DOPAMINE EFFLUX IN MALE MICE 
Reproduced in part from Patterson, Wong et al. Endocrinology 2015, 156, 1692 - 700.  
Copyright 2015 Endocrine Society. Equal authorship was awarded to Patterson and Wong. Specific 
contributions from Wong to this work included development and optimization of a capillary liquid-
chromatography mass spectrometry neurotensin peptide assay, and monoamine and amino acid analysis in 
mouse microdialysate. 
 
Introduction 
Dopamine (DA)-containing neurons of the ventral tegmental area (VTA) project 
widely in the forebrain, including to the nucleus accumbens (NAc); the release of DA 
within the NAc mediates motivation and is required for volitional activity218. Indeed, 
artificial activation of the VTA→NAc mesolimbic DA (MLDA) circuit underlies the 
motivating properties of natural rewards and drugs of abuse. Under normal conditions, a 
variety of physiologic and environmental parameters modulate NAc DA release to 
control motivation appropriately for conditions. Many physiologic parameters (including 
those related to fluid balance, energy stores, endocrine status, and infection) are initially 
sensed in the hypothalamus219, which integrates these inputs and relays a composite 
signal to the MLDA and other effector systems. 
The lateral hypothalamic area (LHA) represents the major link between the 
hypothalamus and the MLDA system. Indeed, animals will self-administer electrical or 
optogenetic stimulation of lateral hypothalamic neurons (intrahypothalamic self-
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stimulation), consistent with the motivating properties of LHA output220, 221. Specific 
subsets of LHA neurons likely mediate distinct aspects of MLDA regulation. LHA 
neurons that contain the neuropeptide hypocretin (HCRT) (also known as orexin) project 
to the VTA and promote MLDA activity222, 223. Melanin-concentrating hormone-
containing LHA neurons project to the NAc (among other places) and modulate 
motivated behaviors such as feeding224. 
The peptide neurotensin (NT) has been implicated in control of feeding and the 
MLDA system. A substantial percentage of VTA DA neurons express NT receptor 1 
(NTR1), administration of NT in rodents activates VTA DA neurons and stimulates DA 
release in the NAc, and NT injection acutely decreases feeding and alters locomotor 
activity225-229. NT neurons are found throughout the brain, including the LHA. LHA NT 
neurons innervate and inhibit local LHA HCRT neurons, as well as projecting directly to 
the VTA220, 230, 231. Many LHA NT neurons express the leptin receptor (LepRb) and thus 
respond directly to leptin (an adipokine that signals the repletion of body energy stores); 
ablation of LepRb from LHA NT neurons prevents the inhibition of HCRT neurons by 
leptin and blunts MLDA function and locomotor activity231. Furthermore, many VTA DA 
neurons contain NTR1 and NT can augment the activity of VTA DA neurons (by 
enhancing the postsynaptic response to glutamate (Glu) on N-methyl-D-aspartate 
receptors)227. Similarly, intrahypothalamic self-stimulation for optogenetic activation of 
LHA neurons is blunted by NTR1 antagonists220. Thus, LHA NT neurons, by releasing 
NT into the VTA, could modulate MLDA function to link hypothalamic signals to NAc 
DA release. Here, we interrogate this putative circuit by pharmacogenetically activating 
LHA NT neurons to examine VTA and NAc neurotransmitter release, along with 
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resultant locomotor behavior. 
Materials and Methods 
Animals 
Adult mice (8–12 wk of age) were used for all experiments. All animals were 
bred in our colony in the Unit for Laboratory Animal Medicine at the University of 
Michigan in accordance with the guidelines and approval of the University Committee on 
the Care and Use of Animals. Mice were housed in a temperature and humidity 
controlled room with 12-hour light, 12-hour dark cycles with access to food and water ad 
libitum. Adequate measures were taken to prevent animal pain and discomfort throughout 
the course of the experiments. In addition, all animal experiments were conducted within 
the guidelines of Animal Research Reporting in vivo Experiments. The Ntcre, 
Rpl22tm1.1Psam (Rpl22-HA reporter), Gt(ROSA)26Sortm14(CAG-tdTomato)Hze (ROSA26-
tdTomato), and GAD1-GFP mouse lines have been previously described231-233. The Ntcre 
and Rpl22tm1.1Psam or Gt(ROSA)26Sortm14(CAG-tdTomato)Hze mice were intercrossed to generate 
compound heterozygous reporter mice (Ntcre-HA and Ntcre-tdTomato, respectively).  
 
Stereotaxic injection and VTA cannulation 
Ntcre mice were anesthetized via isoflurane before the initiation of surgical 
procedures. Stereotaxic viral injections were made bilaterally into the LHA with a guide 
cannula and injector using the next coordinates: anterior-posterior −1.34, medial-lateral 
±1.13, dorsal-ventral −5.2. Three hundred nL of adenovirus-associated virus (AAV)-
hM3Dq-mCherry110, 234 (prepared by the University of Iowa or University of North 
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Carolina Vector Core) was injected into the LHA using a 500-nL Hamilton syringe at the 
rate of 20 nL/min. Bilateral injections were performed in animals receiving AAV-hM3Dq 
to ensure adequate infection. After 5 minutes of time after injection, the injector and 
cannula were removed from the animal and the incision site was closed. Mice were 
allowed 1–2 weeks to recover before experimentation. 
For experiments requiring intra-VTA injection of the water soluble NTR1 
antagonist, SR142948A (Sigma), mice were implanted with an indwelling 26-guage 
stainless steel cannula with a removable dummy injector (Plastics One) aimed at the VTA 
using the next coordinates: AP −3.2, ML −0.5, DV −4.3. After 1 week of recovery, the 
dummy was removed and replaced with an injector with a 4.4-mm projection used to 
deliver 65 nL of SR142948A (5μM), 15 minutes before ip clozapine-N-oxide (CNO) 
administration.  
 
Metabolic and behavioral profiling 
Ntcre;LHA-hM3Dq-mCherry mice (n = 5) were analyzed via the Comprehensive 
Laboratory Monitoring System (Columbus Instruments), as previously described231. 
Briefly, mice were placed into the sealed chambers with ad libitum access to food and 
water. After 2 days of acclimation, animals were treated with vehicle for 2 days and then 
with CNO (0.3 mg/kg, IP) for 2 days; treatments were every 12 hours (6 am and 6 pm). 
Oxygen consumption (VO2), carbon dioxide production (VCO2), spontaneous motor 
activity, and Z-activity were monitored continuously during this time. Data shown are for 
the first 12 hours after each treatment. 
Open-field activity was determined in separate cohorts of Ntcre;LHA-hM3Dq-
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mCherry mice (n = 6–8). Mice were removed from their home cages during the light-
cycle and acclimated for 2 hours in an open-field arena (ENV-017M; Med Associates, 
Inc.) in the absence of food and water. After acclimation, open-field activity was 
recorded every minute after 30 minutes of baseline, 30 minutes after saline injection, 30 
minutes after antagonist injection (when applicable), and 90 minutes after CNO. For 
experiments involving dopamine receptor 1 (D1R) antagonism, mice were pretreated 
with the D1R antagonist, SCH23390 (0.1 mg/kg, ip, dissolved in PBS; Sigma), 30 
minutes after vehicle administration and 30 minutes before CNO treatment. 
Mouse locomotor behavior during microdialysis (n = 6) was monitored using 
Logitech webcams above a Raturn (Bioanalytical Systems, Inc.) as previously 
described68, 235. Webcams used a custom motion-monitoring program (Mark Dow) 
through image acquisition toolbox in Matlab 2009 (Mathworks, Natick) software. 
Threshold of motion detection software was selected to not detect small motions (such as 
breathing or whisker movement) but only large motions such as walking, running, and 
rearing. Data were collected every 1 min and then binned into longer intervals to 
correlate to facilitate comparisons with data from neurochemical assays. 
 
Perfusion fixation and immunohistochemistry 
After experimentation, all mice were perfused with fixative to verify viral, 
indwelling cannula, and/or microdialysis probe placement. Mice were only included in 
the results if mCherry expressing cell bodies were confined to the LHA, and histological 
analysis revealed correct cannula placement. 
Animals received an overdose of sodium pentobarbital and were then perfused 
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transcardially with phosphate buffered saline (PBS; pH 7.4) followed by 10% formalin. 
The brain was removed and postfixed in 10% formalin for 2–4 hours and then dehydrated 
in 30% sucrose in PBS until the time of sectioning. Brains were cut on a freezing sliding 
microtome in 30-μm coronal sections on a sliding microtome, collected in 4 
representative series, and stored at −20°C in cryoprotectant. Sections were thoroughly 
washed with PBS to remove the cryoprotectant before immunostaining. 
To immunostain for the product of the Fos gene (cFos), free-floating brain 
sections were pretreated consecutively with the next reagents in PBS: 1% H2O2, 0.3% 
glycine, and 0.03% sodium dodecyl sulfate. Samples were then blocked in 3% normal 
donkey serum/3% Triton X-100 in PBS and then incubated with goat anti-cFos (1:1000; 
Santa Cruz Biotechnology, Inc.) overnight in the same buffer. Sections were washed in 
PBS, incubated in biotinylated donkey-antigoat (1:200; Jackson ImmunoResearch) for 2 
hours, followed by avidin-biotin-complex labeling (Vectastain Elite kit; Vector 
Laboratories). Signals were developed with metal-enhanced diaminobenzidine (Thermo-
Pierce) resulting in a brown precipitate. 
For mCherry/tdTomato and hemaglutinin (HA) immunostaining, sections were 
blocked as described above and then incubated in rabbit anti-red fluorescent protein 
(dsRed) (1:1000; Clontech) or mouse anti-HA (1:1000; Covance) overnight, respectively. 
Brain sections were washed and then incubated with Alexa Fluor-conjugated secondary 
antibodies (1:200; Invitrogen). Sections were mounted onto gelatin-coated slides and 
coverslipped with ProLong Antifade mounting medium (Life Technologies). 
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Microscopy and image analysis 
Microscopic images were obtained using an Olympus BX-51 microscope with a 
DP30BW camera (Olympus). Images from fluorescent labeling experiments were 
pseudocolored and merged using Adobe Photoshop. 
 
Microdialysis, analysis of amino acid (AA) and neuropeptide concentrations. 
Custom-made side-by-side microdialysis probes (1-mm dialyzing membrane) 
were inserted into NAc or VTA using the next coordinates: AP +1.30, ML ±1.20, DV 
−4.85; and AP −2.98, ML ±0.48, DV −5.17, respectively. For the monoamine and AA 
assay, probes were made using regenerated cellulose (Spectrum Laboratories) and 
inserted bilaterally in the NAc. For neuropeptide measurement in the VTA, probes were 
made using AN69 membrane (Hospal) and a single probe was inserted. For NT 
antagonist experiments, a dialysis probe was implanted in the NAc and a microinjection 
cannula (Plastics One) was implanted in the ipsilateral VTA. Probes and cannulae were 
secured with skull screws and acrylic dental cement. After surgery, mice were allowed to 
recover for 24 h with free access to food and water. 
Experiments were performed 24 h after probe implantation. Microdialysis probes 
were flushed at a flow rate of 2 μL/min with artificial cerebrospinal fluid for 30 min 
using a Fusion 400 syringe pump (Chemyx). Perfusion flow rate was then reduced to 1 
μL/min for monoamine and AA assay or 0.6 μL/min for the NT assay and allowed to 
flush for an additional 1.5 h before baseline collections. 
Samples were collected every 5 min for monoamine and AA assay in the NAc and 
every 20 min for the monoamine and AA and NT assays in the VTA. The total volume of 
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dialysate for VTA NT was 12 μL, of which 3 μL were removed, and 1 μL acetonitrile 
was added for analysis by the monoamine and AA assay described below. 
 
Monoamine and AA analysis  
Samples were analyzed according to a slightly modified version of a recently 
described method31. To 5 μL samples, we added 2.5 μL of 100 mM sodium tetraborate, 
2.5 μL of benzoyl chloride (2% in acetonitrile vol/vol), 2.5 μL of internal standard, and 
2.5 μL d4-acetylcholine internal standard before liquid chromatography-mass 
spectrometry (LC-MS) analysis. For VTA, 3-μL samples 1.5 μL of each reagent listed 
above were added before LC-MS analysis. Samples were analyzed using a Waters 
nanoAquity UPLC equipped with an Acquity HSS T3 C18 column (1 × 100 mm, 1.8 μm, 
100-Å pore size) interfaced to an Agilent 6410 triple quadrupole mass spectrometer. 
Mobile phase A consisted of 10mM ammonium formate and 0.15% (vol/vol) formic acid 
in water. Mobile phase B was acetonitrile. The flow rate was 100 μL/min, and sample 
injection volume was 5 μL. The mobile phase gradient was: initial, 0% B; 0.01 min, 23% 
B; 2.51 min, 23% B; 3 min, 50% B; 5.2 min, 60% B; 6.46 min, 65%; 6.47 min, 100% B; 
7 min, 100% B; 7.01 min, 0% B; and 8.0 min, 0% B. Peaks were processed using Agilent 
MassHunter Workstation Quantitative Analysis for QQQ version B.05.00.  
 
Neurotensin detection with capillary LC-MS 
NT was measured using a capillary LC-MS method similar to that previously 
described67, 68. Capillary columns and electrospray ionization emitter tips were made in-
house68. Five-microliter samples were injected using a WPS-3000TPL autosampler, 
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desalted by rinsing the column with 0.1% formic acid in water at 3500 psi for 8 minutes 
using a 100DM high pressure syringe pump (Teledyne ISCO), and then separated by a 
gradient elution with an Agilent 1100 HPLC pump. For the gradient, mobile phase A was 
0.1% formic acid in H2O and mobile phase B was 0.1% formic acid in MeOH. The 
mobile phase gradient was as follows: initial, 10% B; 2 min, 100% B; 6 min, 100% B; 
6.1 min, 10% B; and 8 min, 10% B. A Valco 6-port valve was used to switch between 
loading/desalting and elution. Assays were controlled automatically using Thermo-Fisher 
Xcalibur software. 
The column was interfaced to a PV-550 nanospray electrospray ionization source 
(New Objective) coupled to a Thermo-Fischer LTQ XL linear ion trap mass 
spectrometer. The MS2 pathway for NT (doubly charged) was mass-to-charge ratio (m/z) 
558.7 → 579.0 m/z with an isolation width set at 3 m/z. Standard addition tests with NT 
showed that there was no significant effect of artificial cerebrospinal fluid matrix. In vitro 
recovery of NT was 14 ± 1%. 
 
Statistics 
Student's t test was used when only 2 groups were compared. One-way ANOVA 
with Bonferroni post hoc analysis was used when comparing 3 or more groups. Data 
were analyzed and graphs were generated using GraphPad Prism software. Differences 
were deemed significant if P < .05. Activity data are binned and presented as mean ± 
SEM. All in vivo microdialysis data are expressed as percent baseline ± SEM.  
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Results 
Activation of LHA NT neurons promotes DA-dependent activity 
LHA NT neurons respond to a variety of physiologic signals (including 
nutritional cues, dehydration, and inflammation), and are hypothesized to play a role in 
the modulation of motivated behaviors, including locomotor activity, in response to these 
signals231, 236, 237. To understand the function of LHA NT cells and the neural mechanisms 
by which they mediate their effects, we employed the stereotaxic injection of AAVs that 
mediate the cre-dependent expression of designer receptors exclusively activated by 
designer drugs (DREADDs) (expressed as DREADD-mCherry fusion proteins)110, 234. 
DREADDs are genetically engineered muscarinic receptor variants that are insensitive to 
endogenous ligands, but which are activated by the otherwise biologically inert CNO110, 
234; CNO activates neurons containing the Gq-coupled hM3Dq DREADD variant. To 
confirm the cre-dependent expression of hM3Dq-mCherry in LHA NT neurons after viral 
injection, we performed unilateral injections of AAV-hM3Dq-mCherry into the LHA of 
Ntcre-HA mice, which express an HA epitope-tagged ribosomal protein233. 
Immunostaining against HA and mCherry demonstrated the restriction of hMD3q-
mCherry to LHA NT-HA neurons (Figure 3-1 A). 
To examine the response to activation of LHA NT cells, we injected the activating 
AAV-hM3Dq-mCherry bilaterally into the LHA of Ntcre animals (Figure 3-1 B) and, 
after at least 1 week of recovery, treated these Ntcre;LHA-hM3Dq-mCherry animals with 
vehicle or CNO (Figure 3-1 C and D). CNO treatment increased cFos-immunoreactivity 
(IR) in the LHA; this cFos-IR was mainly restricted to mCherry-IR neurons (Figure 3-1 
C and D), consistent with the CNO-dependent activation of hM3Dq-mCherry-expressing 
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LHA NT cells. CNO also increased cFOS-IR in the NAc, consistent with the notion that 
LHA NT neurons modulate the MLDA system (Figure 3-1 E and F). 
We also treated Ntcre;LHA-hM3Dq-mCherry animals with vehicle or CNO in a 
metabolic chamber to determine the potential effect of LHA NT cell activation on 
locomotor activity and VO2 (Figure 3-2 A-G). Pharmacogenetic activation of LHA NT 
cells nearly doubled ambulatory activity, and increased Z-axis activity by 8-fold during 
the 3 hours after CNO. Activation of LHA NT cells also increased VO2 and VCO2, 
consistent with the increased locomotor activity exhibited by these animals. Thus, the 
activation of LHA NT cells promotes locomotor activity in vivo. 
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Figure 3-1 Activation of LHA NT neurons increases cFOS in LHA NT cells and in the NAc. Cre-inducible 
AAV-hM3Dq-mCherry was injected unilaterally into the LHA of male Ntcre HA (A, A', and A”) or 
bilaterally into the LHA of Ntcre mice (B–F). A, A', and A”, Representative image showing NT-HA-IR (A), 
mCherry-IR (A'), and merged channels (A”) in the LHA. Arrows denote representative colocalized cells. B, 
Representative image of mCherry-IR in the hypothalamus after bilateral injection. C and D, Animals were 
injected with vehicle (Veh; ip) (C) or CNO (0.3 mg/kg, ip) (D) and perfused 2 hours later. Shown are 
representative images of mCherry-IR (red) and cFOS-IR (purple, pseudocolored). Arrows denote 
colocalized neurons. F, fornix; 3v, third cerebral ventricle. E and F, Representative images showing cFOS-
IR (black) after Veh (E) or CNO (F) in the NAc. aca, anterior commissure. 
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Figure 3-2 Activation of LHA NT neurons increases ambulatory activity and energy expenditure. 
Ntcre;LHA-hM3Dq-mCherry mice were acclimated to the Comprehensive Laboratory Monitoring System 
(CLAMS) for 2 days and treated with vehicle (Veh; ip) or CNO (0.3 mg/kg, ip) on separate days. 
Ambulatory activity (A and C), Z-activity (B), VO2 (D) and VCO2 (E) (both corrected for lean body mass), 
food intake (F), and change in body weight (G) are plotted for the subsequent 12 hours. All data are plotted 
at mean ± SEM, n = 8. Significance was determined by Student's t test. *, P < .05; **, P < .01; ***, P ≤ 
.001. 
We have previously shown that, outside of the LHA, synaptic terminals from 
LHA NT cells primarily target midbrain regions, including the VTA231. Because NT can 
enhance the activity of VTA DA cells220, 238 and the release of VTA-derived DA into the 
striatum promotes locomotor activity239, and we observed increased cFOS-IR in the NAc 
after activation of LHA NT cells, we examined the potential role for DA in the locomotor 
activity that accompanies the hM3Dq-mediated activation of LHA NT cells (Figure 3-3). 
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Systemic administration of the D1R antagonist, SCH23390, did not significantly reduce 
baseline locomotor activity of animals in activity chambers but blunted the hM3Dq-
mediated increase in activity to baseline levels. Thus, the activation of LHA NT cells 
promotes DA-dependent locomotor activity, suggesting that activation of LHA NT 
neurons promotes DA release in the NAc. 
To assess this possibility, we performed in vivo microdialysis to examine the 
release of DA and its metabolites in the NAc of mice after the pharmacogenetic 
activation of LHA NT neurons in Ntcre;LHA-hM3Dq-mCherry animals (Figure 3-4 and 
 
Figure 3-3 Blockade of ambulatory activity induced by hM3Dq-mediated activation of LHA NT neurons is 
blocked by peripheral administration of a D1R antagonist. Ntcre;LHA-hM3Dq-mCherry mice were 
acclimated to an open field area for 2 hours during the light cycle, after which time, their activity was 
monitored for 30 minutes after vehicle or CNO (0.3 mg/kg, ip) administration. Additional animals were 
pretreated with an ip injection (0.1 mg/kg) of the D1R antagonist, SCH23390 (SCH), 30 minutes before 
CNO administration. Activity (counts per min) is binned for the 30 minutes after vehicle (+/− SCH) and 
averaged per 30 minutes for CNO treatment (+/− SCH). All data are plotted as mean ± SEM, n = 7–8. 
Significance was determined by repeated measures ANOVA followed by Bonferroni post hoc analysis. 
Different letters indicate significant differences (P ≤ .001); all other comparisons P > .05.  
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Figure 3-5). Locomotor activity was acutely increased by the injection of vehicle, 
although activity returned to baseline before the injection of CNO, which promoted a 
larger and sustained increase in locomotor activity (Figure 3-4A, consistent with Figure 3-2 and Figure 3-3). Although neither the extracellular concentration of DA nor its 
metabolites (3,4-dihydroxyphenylacetic acid (DOPAC), 3-methoxytyrosine (3MT), and 
homovanillic acid (HVA)) were altered by the injection of vehicle, CNO doubled the 
extracellular concentration of DA, which (like locomotor activity) peaked 30 minutes 
after CNO injection and remained elevated for at least the next 90 minutes. CNO also 
significantly increased the extracellular concentrations of DOPAC, 3MT, and HVA; the 
peaks of 3MT and HVA were prolonged relative to DA and DOPAC, consistent with the 
requirement for the cellular uptake of DA or DOPAC for the production of 3MT and 
HVA by intracellular monoamine oxidase. The increase in these metabolites also 
supports the notion that the increased extracellular DA observed reflects enhanced release 
rather than decreased DA reuptake. Thus, the activation of LHA NT neurons promotes 
NAc DA efflux, consistent with the DA dependence of the enhanced locomotor activity 
exhibited by mice after the activation of LHA NT cells. 
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Figure 3-4 Extracellular DA and metabolites in NAc of Ntcre;LHA-hM3Dq-mCherry mice. Bilateral 
microdialysis probes were implanted into the NAc to monitor the effect of hM3Dq-mediated activation of 
LHA NT neurons. Vehicle was administered at t = −30 minutes, followed by CNO (0.3 mg/kg, ip, at t = 0 
min) (arrows). Locomotor behavior from quantification of video (A) during microdialysis. Dialysate was 
assessed for (B) DA, (C) DOPAC, (D) 3MT, and (E) HVA. Locomotor behavior is shown as movement 
counts ± SEM. All in vivo microdialysis data are expressed as percent baseline ± SEM; n = 6–8. Left 
panels show data in 5-minute bins; right panels show 30-minute bins. Significance was determined by one-
way ANOVA followed by Bonferroni post hoc analysis. Different letters indicate significant differences (P 
≤ .05). 
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Figure 3-5 Microdialysis probe and indwelling cannula placement. A-B) Representative images of NAc 
microdialysis probe placement (A) and VTA cannula placement (B). Arrows indicate termination of probe 
(A) or acute injector tip (B). aca= anterior commissure , IP=interpeduncular nucleus.  
 
Our finding that LHA NT cells project to the VTA, but not the NAc231, suggests 
that neurotransmitters released by LHA NT neurons into the VTA act on DA neurons to 
promote the release of DA in the NAc. Because NT can postsynaptically increase N-
methyl-D-aspartate-dependent Glu signaling in VTA DA neurons220, we implanted 
microdialysis cannulae in the VTA of Ntcre;LHA-hM3Dq-mCherry animals and measured 
the extracellular concentration of NT (as well as GABA and Glu) in the VTA at baseline, 
after vehicle treatment, and after CNO administration (Figure 3-6). Although LHA NT 
neurons express Gad1 (a marker of GABA neurons) (Figure 3-6A), CNO did not 
detectably increase the extracellular concentrations of GABA or Glu in the VTA (Figure 3-6, B and C). In contrast, however, the extracellular concentration of NT increased by 
almost 2-fold during the 20 minutes after CNO treatment (Figure 3-6D), demonstrating 
that the activation of LHA NT neurons promotes NT efflux into the VTA. Importantly, 
VTA NT concentrations return to baseline within 20 minutes of stimulation, suggesting 
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that CNO-mediated activation of LHA NT cells promotes acute (rather than prolonged) 
VTA NT release. 
To directly examine the possibility that LHA NT neurons may promote NAc DA 
efflux by acutely releasing NT into the VTA, we implanted VTA injection cannulae 
along with NAc microdialysis cannulae in Ntcre;LHA-hM3Dq-mCherry animals to 
examine extracellular DA in the NAc in the presence of VTA-applied SR14298A (an 
antagonist of NT1 receptors) (Figure 3-7 and Figure 3-5). Although the application of 
SR14298A into the VTA did not alter NAc DA concentrations in the absence of CNO 
treatment, it abrogated the ability of activated LHA NT cells to promote NAc DA efflux. 
Thus, the acute release of NT into the VTA by LHA NT neurons promotes prolonged 
NAc DA efflux. 
 
Figure 3-6 Neurotransmitter content and release by LHA NT neurons. Ntcre mice were bred to the 
ROSA26-tdTomato and Gad1-GFP backgrounds to generate animals expressing tdTomato in in NT 
neurons and GFP in Gad1 cells. A, Representative images showing tdTomato-IR (NT; purple, left), GFP-IR 
(Gad1; green, middle) and merged (right) channels in the LHA of Ntcre tdTomato;GAD1-GFP mice. 
Arrowheads indicate examples of colocalization. B–D, Extracellular concentrations of (B) GABA, (C) Glu, 
and (D) NT in the VTA of Ntcre;LHA-hM3Dq-mCherry mice. Vehicle (t = −60 min) and CNO (0.3 mg/kg, 
ip; t = 0 min) were administered systemically. In vivo microdialysis data are expressed as percent baseline 
± SEM; n = 6. Significance was determined by one-way ANOVA followed by Bonferroni post hoc 
analysis; ***, P ≤ .001 vs other times. 
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Figure 3-7 Effect of NT1R antagonism on LHA NT-DREADD-evoked NAc DA release. Unilateral 
microdialysis probes were implanted into the NAc with ipsilateral cannulation of the VTA. Vehicle, NtsR1-
antagonist SR142948A (SR; dose via intra-VTA injection) and CNO (0.3 mg/kg, ip; t = 0 min) were 
administered at the indicated times. A, Extracellular DA concentrations in the NAc. B, Data from A plotted 
in 15- or 30-minute bins. Data are expressed as percent baseline ± SEM; n = 6. Significance was 
determined by one-way ANOVA followed by Bonferroni post hoc analysis. *, P < .1; **, P < .01; ***, P < 
.001. C, Model of the control of the MLDA system via LHA NT neurons. LHA NT neurons contain the 
neurotransmitter GABA. Some of these NT neurons express the LepRb and locally regulate HCRT 
neuronal function, via the neuropeptide Gal. A potentially separate population of LHA NT neurons may 
directly project to the VTA and release NT onto NTR1-expressing DA neurons to regulate the MLDA 
system through projections to the NAc. Note that although the figure is simplified for easier viewing, it is 
possible that interneurons could lie between LHA NT neurons and OX or DA neurons. 
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Discussion 
Our present results reveal that LHA NT neurons stimulate NAc DA release to 
promote motivated behaviors such as ambulatory activity, thus revealing an important 
function for these cells. Additionally, we have mapped the circuits and mechanisms by 
which LHA NT neurons mediate this effect: LHA NT neurons project to the VTA, where 
they promote acute NT release; NT acts on NTR1 in the VTA to promote prolonged NAc 
DA release (Figure 3-7). 
In addition to the use of genetic (e.g., Ntcre, AAV-hM3Dq-mCherry) and 
pharmacologic techniques, this analysis required the fabrication and use of microdialysis 
probes small enough to permit the neuroanatomically precise sampling of extracellular 
fluid in the mouse NAc and VTA, as well as the development of techniques to 
quantitatively measure NT at physiologic concentrations in the resultant samples. To our 
knowledge, this represents the first report to measure changes in neuropeptide release in 
the intact mouse; this technique enabled us to directly assess the timing and amplitude of 
intra-VTA NT release induced by pharmacogenetic activation of LHA NT neurons. The 
requirement that we collect sufficient sample volume to permit NT detection by 
subsequent MS analysis dictates a prolonged (20 min) sampling time, thus limiting 
temporal resolution. Even so, it is clear that DREADD-mediated activation of LHA NT 
neurons promotes acute NT release and also that VTA NT concentrations return to 
baseline by 20 min after stimulation. 
In contrast to the rapid rise and fall of VTA NT concentrations, the hM3Dq-
promoted increase in NAc DA concentration (which requires VTA NT signaling) 
continues for at least 2 h, much longer than the increase in VTA NT. These findings 
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suggest that VTA NT promotes a durable increase in NAc DA release (and 
accompanying locomotor behavior) that continues long after VTA NT has returned to 
baseline and that the action of LHA NT cells mediates the long-term rather than acute 
modulation of the MLDA system. Consistent with this long-term activation, Kempadoo 
et al220 showed that NTR1 antagonism blocks the increase postsynaptic NDMA response 
of VTA DA neurons to the optogenetic activation of LHA→VTA fibers. That LHA NT 
neurons should mediate lasting effects on MLDA function makes teleological sense, 
because many LHA NT cells respond directly to leptin231, which reflects long-term 
energy stores and mediates largely chronic (rather than acute) effects on neural 
systems240. 
Although we have recently demonstrated that the hM3Dq-mediated activation of 
LHA NT neurons also inhibits LHA HCRT neurons230, the mechanism for this effect is 
distinct from that by which LHA NT neurons promote NAc DA efflux. Not only do the 
neural connections by which these responses occur differ (intra-LHA vs LHA→VTA 
projections) but also NT (which is required for increased NAc DA efflux) is not 
responsible for controlling the activity of HCRT cells. Rather, the inhibitory 
neuropeptide, galanin (Gal), which is found in some LHA NT neurons, inhibits the firing 
of HCRT cells230. Thus, LHA NT neurons mediate their effects on HCRT cells and the 
MLDA via distinct neurotransmitters. We do not know whether these distinct 
mechanisms of LHA NT neuron action reflect different patterns of neurotransmitter 
release by these cells in the LHA and VTA, or merely the innate responsiveness of HCRT 
and VTA neurons to the different neuropeptides. 
Interestingly, although LHA NT neurons display markers of gamma amino 
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butyric acid (GABA) production and release (Gad1 and Slc32a1), we did not detect VTA 
GABA release upon activation of these neurons. Although it is possible that the long 
collection times for VTA microdialysis samples (which are required for NT detection) 
could fail to detect a transient increase in VTA GABA after the activation of LHA NT 
cells, this technique readily detects prolonged release of DA and its metabolites 
downstream in the NAc. We were also unable to detect a role for GABA in the acute 
inhibition of HCRT neurons by LHA NT cells230. Thus although LHA NT neurons are 
genetically GABAergic, GABA release by these cells may play less important roles than 
their neuropeptide transmitters. 
Because LHA NT neurons respond to a variety of physiologic signals (such as 
leptin, dehydration, and inflammation), this LHA NT→VTA NTR1→NAc DA circuit 
that we have mapped may link these stimuli to the long-term modulation of VTA DA 
neurons, NAc DA efflux, and thus locomotor activity and other DA-dependent behaviors. 
Indeed, disruption of LepRb in LHA NT cells diminishes locomotor activity and 
measures of MLDA function231, suggesting that leptin action on LHA NT cells may 
control MLDA function by modulating NT release in the VTA. Additional work will be 
required to understand the contribution of NT signaling to the control of MLDA function 
by the various stimuli that modulate the activity of LHA NT neurons. 
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CHAPTER 4: SIMULTANEOUS IN VIVO MICRODIALYSIS AND LOCAL 
OPTOGENETIC STIMULATION TO MEASURE OPIOID PEPTIDE RELEASE 
IN DYNORPHIN CONTAINING CELLS IN MOUSE NUCLEUS ACCUMBENS 
SHELL 
Introduction 
 The mesocorticolimbic pathway, a major component of the brain’s reward circuit, 
is comprised of neuronal projections from the ventral tegmental area, medial prefrontal 
cortex, basolateral amygdala, and hippocampus to the nucleus accumbens (NAc)241, 242. 
Disruption of the mesocorticolimbic pathway is implicated in diseases including mood 
disorders and addiction. Studies have linked both positive and negative reinforcement 
behavior responses to discrete sub nuclei in the NAc243-245. To fully understand what 
drives these opposing behaviors, it is important to monitor neurochemical changes that 
correlate with behavioral output.  
 Opioid neuropeptides are key neuromodulators in the regulation of mood 
disorders. There are four G protein-coupled receptors that bind endogenous opioids: 
kappa, mu, delta, and opioid receptor like-1 (also referred to as nociceptin or orphaninFQ 
receptors)90, 246, 247. Kappa opioid receptors (KOR) are expressed on GABAergic medium 
spiny neurons in the NAc and are the receptors for the endogenous peptide dynorphin 
(Dyn)248-250. Mu and delta opioid receptors are also present on GABAergic medium spiny 
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neurons in the striatum, with a high affinity for endogenous enkephalins (ENK), leu-
enkephalin (LE) and met-enkephalin (ME)251.  
Opioids in the brain are derived from three prohormones, proopiomelaocortin, 
prodynorphin, and proenkephalin. The precursor peptide prodynorphin is cleaved into 
Dyn and three copies of LE88, 249. Proenkephalin is cleaved into one LE, four ME, and 
two extended-ME peptides88. These biosynthetic pathways that generate bioactive 
peptides are important for opioid-related neuromodulation, and are not fully understood 
in studies using current analytical techniques. Methods to selectively modulate opioid 
containing neurons combined with muliplex analytical techniques will allow a broader 
understanding of these processes. 
Endogenous opioid activity modulates a wide variety of behaviors. For example, 
KOR agonists induce place aversions, depression-like behavior, and dysphoria in both 
human and animal models252-254. Dyn-containing axon terminals and cell bodies are 
located in the NAc243, 255, and regulate monoamine cells via presynaptic KOR. However, 
the mechanisms underlying endogenous Dyn regulation of KOR-mediated negative 
affective behaviors are unclear243, 256, 257. 
 Current technologies utilizing genetics and optics (optogenetics), allow selective 
activation or inhibition of specific subsets of neurons with photostimulation258. Previous 
work demonstrated that photostimulation of distinct subpopulations of ventral NAcSh 
(NAc shell) DYN-expressing cells results in aversive behavioral responses such as 
conditioned place aversion and a reduction in operant self-stimulation243. In contrast, 
photostimulating dorsal NAc Dyn-expressing cells caused positive reinforced behaviors. 
All of these behaviors were blocked by selective KOR antagonist administration243. To 
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determine if these behaviors correlate with release of Dyn, we selectively activated 
discrete Dyn-expressing cell in the NAcSh using optogenetic photostimulation and 
monitored endogenous opioid peptides (Dyn fragment A1-8 (DYN), LE, and ME) and 
small molecule release into the extracellular space to determine if actual release of DYN 
occurred. We developed a capillary liquid chromatography-mass spectrometry (LC-MS) 
method, incorporating an isotopically labeled internal standard to monitor opioid peptides 
DYN (fragment dynorphin A1-8), LE, and ME, and developed a custom in-house 
optogenetic-microdialysis (opto-dialysis) probe to simultaneously photostimulate and 
sample neurochemical release locally within the stimulated region. We applied this 
method and sampling technique to investigate regional differences between the ventral 
NAcSh (vNAcSh) and dorsal NAcSh (dNAcSh).  
 
Methods 
Chemicals 
Dynorphin A1-8 (abbreviated DYN) and LE were purchased from American 
Peptide (Sunnyvale, CA); ME was purchased from Sigma Aldrich (St. Louis, MO). 
Isotopically labeled leucine (13C615N1-leucine) was used to create an isotopically labeled 
dynorphin A 1-8 internal standard (DYN*) through the University of Michigan’s protein 
synthesis core. Water, methanol, and acetonitrile for mobile phases are Burdick & 
Jackson HPLC grade purchased from VWR (Radnor, PA). All other chemicals were 
purchased from Sigma Aldrich (St. Louis, MO) unless otherwise noted. Artificial 
cerebrospinal fluid (aCSF) consisted of 145 mM NaCl, 2.67 mM KCl, 1.4 mM CaCl2, 
1.01 mM MgSO4, 1.55 mM Na2HPO4, and 0.45 mM Na2H2PO4 adjusted to pH 7.4 with 
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NaOH. Ringer solution consisted of 148 mM NaCl, 2.7 mM KCl, 2.4mM CaCl2, and 0.85 
mM MgCl2 adjusted pH to 7.4 with NaOH. In experiments that used high K+ ringer 
solution NaCl was adjusted to 48 mM and KCl was adjusted to 100 mM, all other 
chemicals remained the same. 
 
Animals 
 Adult male C57BL/6 mice (Envigo, 5 – 6 weeks of age) were used for initial 
experiments to determine perfusion media conditions and effects of probe design. For 
optogenetic studies, adult male preprodynorphin-IRES-cre (dyn-Cre) mice were provided 
by the Michael Bruchas lab at the Washington University in St. Louis, MO243. Mice were 
unilaterally injected with 300 nL of AAV5-DIO-ChR2-eYFP (Washington University in 
St. Louis, Hope Center Viral Vector Core, viral titer 2 × 1013 vg/mL) into either the 
dNAcSh or vNAcSh and were allowed to recover from surgery at Washington University 
in St. Louis 1 week prior to shipment. Mice were then acclimated for 2-3 weeks at the 
University of Michigan before microdialysis probe implantation.  
 
In vivo microdialysis 
Mice were group housed in temperature and humidity controlled rooms with 12 h 
light/dark cycles with access to food and water ad libitum. The University of Michigan 
Unit for Laboratory Animal Medicine approved animal procedures and they were in 
accordance with the National Institute of Health Guidelines for the Care and Use of 
Laboratory Animals. All experiments were conducted within the guidelines of Animal 
Research Reporting in vivo Experiments. Surgical procedures for inserting probes were 
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similar to previous described259. Briefly, mice were anesthetized in an induction chamber 
with 5% isoflurane prior to surgical procedures and placed in a Model 963 stereotaxic 
frame (David Kopf Instruments, Tujunga, CA, USA) equipped with a mouse ear and bite 
bar. Mice were maintained under anesthesia with 1-2% isoflurane during cannulation 
procedures. A custom-made 1 mm polyacrylonitrile membrane (Hospal AN69) 
concentric probe, with or without fiber optics (provided by the Michael Bruchas lab from 
Washington University in St. Louis), was inserted into either the dNAcSh (stereotaxic 
coordinates from bregma: +1.3 anterior-posterior [AP], ±0.5 medial-lateral [ML], -4.5 
mm dorsal-ventral [DV]) or vNAcSh (stereotaxic coordinates from bregma: +1.3 [AP], 
±0.5 [ML], -5.0 mm [DV]). Light power from a 473-nm laser was measured at the 
membrane to ensure satisfactory light power (defined as ≥ 5 mW at a distance of 1 mm 
from the end of fiber optic) before implantation of microdialysis probes integrated with 
fiber optic (opto-dialysis probe). Implanted probes were secured using two bone screws 
and dental cement. Mice were allowed to recover 24 h with free access to food and water 
prior to baseline collection for microdialysis studies. 
For microdialysis studies, the fiber optic was connected to the laser via a tether 
running through a Ratturn (Bioanalytical Systems, Inc.) along with microdialysis 
perfusion lines. Microdialysis probes were flushed for 1 h using a Fusion 400 syringe 
pump (Chemyx, Stafford, TX USA) at a flow rate of 2 μL/min. The flow rate was 
lowered to 0.8 μL/min and flushed for an additional 1 h prior to fraction collection. 
Microdialysis fractions were collected every 15 min, resulting in a 12 μL sample. Two 
μL of sample was removed for benzoyl chloride (BzCl) derivatization to monitor small 
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molecules, and the remaining 10 μL was spiked with 1.1 μL of 100 pM isotopically 
labeled DYN* (10 pM final concentration) and was used for peptide analysis. 
When experiments were completed, mice were euthanized and perfused with 
paraformaldehyde. Brains were extracted to confirm probe placement and virus 
expression by histology. Mice with verified virus expression and correct probe placement 
were included in the data set.  
 
Optogenetic stimulation 
 On the day of the experiment, mice were connected to a laser via a tether 
alongside the microdialysis perfusion lines. An Arduino was programmed and connected 
to the 473-nm laser to provide stimulation frequency of 10 Hz, 10-ms pulse width. The 
laser was manually operated and turned on and off during a single 15 min fraction after 4 
baseline collections. Six additional fractions were collected after the photostimulation, 
followed by two fractions with high 100 mM K+ ringer solution. High K+ ringer solution, 
which elicits exocytosis in neurons, was perfused following photostimulation to confirm 
functionality of local neuronal activity. 
 
Peptide assays with capillary LC-MS 
An assay was developed to monitor opioid peptides (DYN, LE, and ME) using 
capillary LC-MS67, 73, 259, 260. Capillary columns and electrospray ionization emitter tips 
were prepared in-house73, 259, 260. Capillary columns were prepared using a 10 cm length 
of 50/360 μm (inner diameter/outer diameter) fused silica capillary packed with 5 μm 
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AltimaTM C18 particles to a bed length of 3.5 cm. The column was connected to a fused 
silica ESI emitter tip using a Teflon connector. 
Five μL samples were injected, onto the capillary column as described in the 
materials and methods section in Chapter 3. An Agilent 1100 HPLC pump (Santa Clara, 
CA) to deliver the elution gradient containing water with 0.1% FA for mobile phase A 
and mobile phase B was MeOH with 0.1% FA delivered as initial 0% B; 1 min, 30 %B; 4 
min, 50% B; 4.1 min 100% B; 7 min, 100% B; 7.1 min, 0%B; and 10 min, 0% B. 
The capillary column was interfaced to a linear ion trap (LTQ XL, Thermo 
Scientific), operating in positive mode. The MS2 pathway for opioid peptides DYN, LE, 
and ME were detected using m/z values of 491  435, 556  397, and 574  397 
respectively. Isotopically labeled DYN* (+7 mass shift, isotopically labeled 13C615N1-
leucine) internal standard was detected using m/z values of 495  438. In vitro recovery 
of a 1 mm probe for DYN, LE, and ME were 12 ± 2%, 13 ± 3%, and 13 ± 2%.  
Fresh DYN, LE, and ME standards, spiked with DYN* for the opioid assay were 
prepared daily. Standards were analyzed with capillary LC-MS at 0.01, 0.05, 0.1, 1, 10, 
20, 50, and 100 pM concentrations in triplicate to determine linearity, reproducibility, and 
limits of detection209. Opioid analytes were normalized to DYN*. Limits of detection for 
DYN, LE, and ME were 0.2 ± 0.04, 0.5 ± 0.3, and 0.6 ± 0.4 pM in 5 μL determined each 
day of experimentation.  
Mice that had average basal levels above the limits of detection and had 
appropriate probe placement and virus expression were used for the study. In total, 37 
mice were run for the optogenetic experiments: 21 dNAcSh and 16 vNAcSh. From these 
37 mice, 10 were excluded due to inadequate virus expression or probe placement: 6 
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dNAcSh and 4 vNAcSh. The remaining mice were then excluded if their average basal 
concentration was below the limit of detection for each analyte, determined the day of the 
experiment with triplicate calibration curves. For DYN, of the 27 remaining mice, 7 were 
excluded due to basal levels below the limit of detection: 4 from the dNAcSh shell study 
and 3 from the vNAcSh study. For LE 4 mice were excluded, and for ME 2 mice were 
removed. 
 
Small molecule analysis using benzoyl chloride (BzCl) LC-MS 
For small molecule analysis, dialysate samples were derivatized with BzCl and 
analyzed by LC-MS31, 128. This BzCl assay targeted choline (Ch), acetylcholine (ACh), 
histamine, taurine, glutamine, serine, aspartate, glycine, glutamate, glucose, 4-
aminobutyric acid (GABA), adenosine, phenylalanine, serotonin and metabolite 5-
hydroxyindoleacetic acid, norepinephrine and metabolite normetanephrine, tyrosine, and 
dopamine and metabolites 3,4-dihydroxyphenylacetic acid, 3-methoxytyramine, and 
homovanillic acid. Two µL dialysate were aliquoted from the peptide samples and were 
derivatized with 1.5 µL sodium carbonate, 100 mM; 1.5 µL BzCl, 2% (v/v) BzCl in 
acetonitrile; 1.5 µL isotopically labeled internal standard mixture diluted in 50% (v/v) 
acetonitrile containing 1% (v/v) sulfuric acid, and spiked with deuterated ACh and Ch 
(C/D/N isotopes, Pointe-Claire, Canada). Derivatized samples were analyzed using 
Thermo Fisher Accela UHPLC system interfaced to a Thermo Fisher TSQ Quantum 
Ultra triple quadrupole mass spectrometer fitted with a HESI II ESI probe, operating in 
multiple reaction monitoring. Five µL samples were injected onto a Phenomenex core-
shell biphenyl Kinetex HPLC column (2.1 mm x 100 mm). Mobile phase A was 10 mM 
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ammonium formate with 0.15% formic acid, and mobile phase B was acetonitrile. The 
mobile phase was delivered an elution gradient at 450 µL/min as follows: initial, 0% B; 
0.01 min, 19% B; 1 min, 26% B; 1.5 min, 75% B; 2.5 min, 100% B; 3 min, 100% B; 3.1 
min, 5% B; and 3.5 min, 5% B. Thermo Xcalibur QuanBrowser (Thermo Fisher 
Scientific) was used to automatically process and integrate peaks. Each peak was visually 
inspected to ensure proper integration. 
 
Statistical analyses 
Statistics were performed in Graphpad Prism 7.0a (for Student’s t-test and two-
way ANOVA) or IBM SPSS Statistics software. The University of Michigan Center for 
Statistical Consultation and Research (CSCAR, consultant Yumeng Li) helped design a 
linear mixed model analysis appropriate for the optogenetic-dialysis study. The linear 
mixed model analysis was chosen to account for variations within and between mice and 
to account for missing data points within individual animals following sample loss or 
mechanical failure of the instrument. The linear mixed model was used to determine 
differences in basal conditions, effect of photostimulation relative to basal conditions, 
and prolonged effects after photostimulation relative to basal conditions. Linear mixed 
models were used to compare between genotypes within each region sampled, and 
between regions within dyn-Cre + and dyn-Cre – genotypes. In all cases, significance 
was defined as p ≤ 0.05.
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Results and Discussion 
Detection of opioid peptides  
We established a method to measure the opioid peptides DYN, LE, and ME using 
an isotopically labeled DYN* as an internal standard for quantitative analysis. High 
concentration injections of DYN* did not result in cross talk with endogenous DYN 
(Figure 4-1) demonstrating that the addition of DYN* does not contribute to endogenous 
DYN signal. DYN, LE, and ME standards were prepared in ringer solution, spiked with 
DYN*, and detected within 5 min after loading and desalting steps as shown by the 
capillary LC-MS reconstructed ion chromatographic trace (Figure 4-2). Standard 
addition tests with opioid peptides indicated no significant effect of dialysate matrix for 
any targeted analyte (Figure 4-3).  
 
Figure 4-1 High concentration injections of DYN* did not show significant traces of endogenous DYN. A 
500 pM sample of DYN* was injected while monitoring both the endogenous DYN (491  435 m/z) and 
isotopically labeled DYN* (495  438 m/z) mass-to-charge transitions. 
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Figure 4-2 LC-MS chromatograms of 100 pM standards. Total ion chromatogram (top) and reconstructed 
ion chromatograms ME, DYN, isotopically labeled DYN*, and LE (lower), in order of retention time. 
Standards were made in ringer solution. 
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Figure 4-3 Bulk dialysate was collected and spiked with known amounts of standard. A linear response 
shows no effect of ionization suppression from the matrix. Four replicates per sample; data shown as 
average ± SD. 
We previously applied a variation of this method for the detection of neurotensin, 
orexins, oxytocin, and vasopressin73, 259, 260. The addition of the DYN* isotope to our 
assay improves quantification by improving relative standard deviation (RSD) for 
repeated injections of standards (Figure 4-4). The internal standard accounts for 
variability during the LC injection and ionization into the mass spectrometer. If the 
internal standard is consistently added to each sample, it can be used in a ratio of 
analyte/internal standard to account for variability during analysis. We custom 
synthesized an isotopically labeled DYN* with a mass shift of +7 with a +3.5 m/z shift, 
because we detect the +2 charge state. DYN* is fully resolved by our linear ion trap and 
is not present in the dialysate (Figure 4-1). Ratios of DYN, LE, and ME to a consistent 
 101 
DYN* were used for calibrations and analysis of standards for quantitative analysis for 
experiments. An ideal assay would include isotopically labeled internal standards for 
each analyte of interest. However, the addition of analytes to detect in the ion trap 
reduces points per peak and custom labeled isotopes are cost prohibitive. Because of the 
structural similarity between ME/LE and DYN, we included DYN* as our only internal 
standard. This method was therefore suitable to apply towards studying basal and evoked 
neuropeptide concentrations.  
 
Figure 4-4 Addition of isotopically labeled DYN* results in better quantification. Peak area (left) and peak 
area ratios of DYN, LE, and ME, to isotopically labeled DYN* (right) are shown with triplicate standard 
injections. Signals were normalized to their respective averages. RSD for DYN, LE, and ME was 27, 21, 
and 19%, respectively, when only using peak area (left). RSD was reduced to 3, 6, and 9% when a ratio of 
analyte to internal standard, DYN*, peak area was used (right). Data shown as average ± SD. 
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Effect of Ca2+ in perfusion media 
 To validate the developed capillary LC-MS method for detecting dynamic 
changes in vivo, we monitored basal DYN, LE and ME, and locally K+ stimulated release 
in the NAcSh. Pilot studies were performed using aCSF perfusion through the 
microdialysis probe to monitor basal conditions, followed by 30 min of 75 mM K+ aCSF 
for local depolarization studies. Infusion of media with elevated K+ through the 
microdialysis probe causes a steep concentration gradient across the membrane that 
allows the diffusion of K+ into the extracellular space. This influx of K+ ions disrupts the 
equilibrium of ions outside and inside the cell, which causes the neuron’s resting 
membrane potential to depolarize, resulting in vesicular exocytosis. Local depolarization 
of neurons with K+ is normally a reliable way to confirm that neurons are viable and 
responsive to stimuli. However, pilot studies using standard aCSF conditions with 75 mM 
K+ aCSF resulted in measurable positive changes from basal DYN measurements in only 
half of the animals (7 of 14 pilot mice; Figure 4-5), whereas LE and ME were 
consistently stimulated to >1000% baseline in mice, indicating the K+ stimulation did 
result in exocytosis as expected. 
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Figure 4-5 Effect of 75 mM K+ aCSF on DYN from local depolarization of the NAcSh in individual mice A 
– N, normalized to their average baseline. Of the 14 mice tested, only 7 mice demonstrated increased 
dynorphin following K+ stimulation. 
A previous study showed that dynorphin B, another fragment from the precursor 
prodynorphin, was released in a Ca2+ dependent manner, and could be stimulated with 
100 mM K+ ringer solution26. You ZB et al. tested media with 1.2 mM Ca2+ or without 
Ca2+ followed by 100 mM K+ stimulation in the rat striatum and substantia nigra, and 
found that the effect of K+ local depolarization was Ca2+ dependent. We repeated this 
experiment using media with either 1.2 mM or 2.5 mM Ca2+ followed by a 100 mM K+ 
local stimulation in the NAcSh of mice while monitoring DYN, LE, and ME (Figure 4-6). We demonstrated that mice infused with 2.5 mM Ca2+ followed by a 100 mM K+ 
local stimulation resulted in reliable release of opioid peptides.  
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Figure 4-6 Effect of Ca2+ concentration in perfusion media followed by 100 mM K+ stimulation. Filled 
circles represent 1.2 mM Ca2+, and open squared indicate 2.5 mM Ca2+ ringer solution. Three baseline 
fractions were collected, followed by local depolarization of mouse NAcSh. Data shown as average ± 
SEM, n = 4 for each group of mice. Significance was determined by two-way ANOVA followed by 
Bonferroni post hoc analysis. * indicates P ≤ 0.05. 
 
Increased Ca2+ in the perfusion media resulted in stable DYN baseline, and 
elevated LE (t(6) = 1.20, p < 0.05), and ME (t (6) = 3.43, p < 0.05) baseline (Figure 4-7A). While the basal LE and ME levels were increased, there was no difference in the 
effect of 100 mM K+ stimulation when normalized to its baseline (Figure 4-7B). Based 
on these results we decided to run all subsequent experiments using 2.5 mM Ca2+ ringer 
solution as the perfusion media. 
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Figure 4-7 Effect of basal Ca2+ concentration in perfusion media (A) and 100 mM K+ evoked release 
normalized to each animal’s average baseline (B). Elevated Ca2+ results in elevated LE and ME, and has no 
effect on DYN (A). When normalized to its baseline, there is no significant difference between 1.2 or 2.5 
mM Ca2+ perfusion media. Data shown as average ± SEM, n = 4 for each group of mice. Significance was 
determined by Student’s t-test. * indicates P ≤ 0.05. 
While stimulated responses were consistently observed for all opioid peptides in 
both conditions, DYN appeared to be delayed relative to LE and ME. This delay could be 
due to delayed neuronal release or slow peptide collection due to peptide adsorption 
anywhere from the probe membrane to vial storage. We tested adsorption in vitro and 
found that probes responded to changes in peptide stocks as expected (Figure 4-8). 
 
Figure 4-8 Trace of an in vitro step change from low to high stock concentrations showing peptides 
response. Probes were equilibrated in a 100 pM of DYN, LE, and ME stock, before 3 fractions were 
collected. Probes were quickly moved to a stock containing 1 nM Dyn and 400 pM LE and ME, and 4 
additional fractions were collected to determine if there was a delay in response to the concentration 
change. The arrow indicates the first fraction in which the peptide was expected to change. Data was 
normalized to fraction 4, the fraction expected to reflect elevated concentration stock change. Data shown 
as average ± SD, n = 2 or 4 probes. 
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We previously reported that polyethylenimine (PEI) surface modification 
increases recovery of positively charged peptides by neutralizing the negatively charged 
AN69 membrane75. We hypothesized that PEI modification would increase DYN 
recovery, whereas neutral LE and ME would be unaffected. We attempted to increase 
relative recovery of DYN by performing a surface modification of the AN69 PAN probe 
membrane and fused silica collection lines with the polycation PEI. While DYN has a 
positive net charge of 2.0 at pH 7.0, we found that PEI modification of AN69 probes did 
not result in significant improvements in DYN, LE, or ME (Table 4-1). 
Table 4-1 In vitro recovery for opioid peptides with or without PEI-modification to AN69 membrane and 
fused silica collection lines. Net charge was estimated using equation 
 , where N represents number of reside/termini and i and j represent 
basic or acidic residue/termini, respectively. Data expressed as average ± SD, n = 2 probes per group.  Peptide MW Net Charge Recovery (%)  Untreated AN69 probe Recovery (%)  PEI-AN69 probe 
DYN 981 2 9.4 ± 0.8 9.7 ± 0.7 
LE 556 0 9.5 ± 1 9.6 ± 3 
ME 574 0 11.8 ± 1 11.6 ± 3 
 
 
Optogenetic-dialysis probe design 
 We developed a customizable microdialysis probe with an integrated fiber optic 
to locally sample near the site of optogenetic photostimulation in the brain. Traditional 
dialysis probes incorporate an inlet and outlet tubing ensheathed in a semi-permeable 
membrane enclosed with epoxy, and further ensheathed in a stiff cannula for rigidity and 
robustness. Our initial design encased both an inlet-outlet dialysis assembly and fiber 
optic probe protruding 1-2 mm beyond a protective cannula (Figure 4-9 A and B). When 
the probe was fully assembled, the smallest stainless steel cannula that could be used 
resulted in 812 μm outer diameter. Pilot studies with this probe resulted in poor or 
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undetectable levels of opioid peptides even with high K+ stimulation, likely due to severe 
tissue damage. We re-designed the probe, removing the outer cannula and used the 
natural rigid property of the fiber optic to support the dialysis inlet-outlet assembly. 
Removing the outer cannula decreased the diameter of the probe approximately 1.5-fold 
to 480 μm outer diameter (Figure 4-9 A and C). In vivo tests showed that the probe was 
rigid enough to be stereotactically inserted into the brain, and that high K+ reliably 
resulted in an increase of all opioid peptides using the modified shaft-less design. This 
“opto-dialysis” probe was used in all experiments (Figure 4-10). 
 
 
Figure 4-9 Two iterations of the optogenetic-dialysis probe incorporating microdialysis membrane 
assembly and fiber optic. The first generation of the optogenetic-dialysis probe used a stainless steel 
cannula encasing the inlet-outlet-membrane assembly and the fiber optic (bottom A, B). A top view of the 
first generation probe shows the fiber optic (orange arrow) next to the microdialysis membrane and encased 
in the stainless steel cannula (B). By removing the outer cannula support for the second generation, we 
reduced the diameter of the probe from 812 to 480 μm while maintaining enough support to be implanted in 
the brain (top A, C). 
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Figure 4-10 Optogenetic probe design in vivo tests show reliable K+ depolarization stimulation. Data shown 
as average ± SEM, n = 2 mice 
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Photostimulation of DYN-containing cells elicits opioid peptide release 
 A previous study showed that photostimulation of DYN-expressing cells in 
distinct NAcSh sub-regions resulted in contrasting behavior responses. Photostimulation 
of vNAcSh DYN-expressing neurons produced a robust aversive behavioral response, 
whereas photostimulation of dNAcSh engaged positive reinforced behaviors, which were 
blocked by local administration of a KOR antagonist243.  
A proof of concept ELISA tissue slice experiment showed that photostimulation 
of channelrhodopsin (ChR2)-expressing DYN neurons in the NAcSh significantly 
increased Dyn-A release relative to non-ChR2 neurons in controls243. While this 
important ex vivo study showed that photostimulation can elicit Dyn-A release, the entire 
NAcSh region was stimulated without differentiating behaviorally relevant dorsal and 
ventral NAcSh sub-regions, and neuronal circuitry was not intact, which precludes any 
secondary effects of output nuclei. While ELISA assays provide valuable information and 
have low limits of detection, they are subject to cross-reactivity and non-specific signals, 
and require large sample volumes to probe a single analyte. Discrete region-specific 
measurement of a wide neurochemical panel in the intact brain during photostimulation 
will better elucidate the mechanisms driving opposing behaviors in the dNAcSh and 
vNAcSh. To this end, we applied our capillary LC-MS method and optogenetic-dialysis 
probes to locally photostimulate and sample from ChR2-expressing neurons in the 
dNAcSh and vNAcSh. 
 For optogenetic-dialysis experiments, fractions were collected on ice at 15 min 
intervals with a flow rate of 0.8 μL/min flow rate, generating 12 μL volumes. Three 
baseline fractions were collected prior to a 15 min photostimulation at 10 Hz (10 ms 
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pulse width). Six additional fractions were collected after the photostimulation to 
determine if there was a delayed or prolonged effect, followed by 2 fractions of 100 mM 
high K+ stimulation to confirm that neurons were still viable and sensitive to stimuli. 
Mice were included in the study if 100 mM K+ stimulation resulted in a positive increase 
in analytes at the end of the experiment and if correct probe placement and viral 
expression were confirmed. For each analyte, data from each mouse were included if the 
average basal concentration was at or above the limit of detection determined the day of 
the experiment (see Methods for further details).  
 To determine if there was a difference in basal concentrations between genotypes 
(Cre + and Cre -) and between regions (dorsal and ventral), average basal concentration 
for each mouse was averaged together within their respective groups (Figure 4-11). 
When basal levels were compared between genotypes within specific regions, 
concentrations of DYN were elevated in vNAcSh (t (10) = 4.675, p < 0.01), LE (t (10) = 
2.271, p < 0.05), and ME (t (10) = 2.454, p < 0.05) in dyn-Cre - mice. There were no 
significant differences for peptides in the dNAcSh. When basal levels were compared 
between regions, there was elevated DYN (t (12) = 2.4, p < 0.05) and ME (t (12) = 2.183, 
p < 0.05) in dNAcSh dyn-Cre + mice compared to vNAcSh dyn-Cre + mice, and 
elevated LE (t (9) = 2.416, p < 0.05) in vNAcSh dyn-Cre - mice compared to dNAcSh 
dyn-Cre - (Figure 4-11). These changes in basal conditions show an effect of genotype 
for all opioid peptides in vNAcSh. When comparing between regions, we observed 
elevated DYN and ME, and similar LE in dNAcSh, associated with the previously 
reported positive place preference behavior. This elevated DYN is unexpected, as DYN is 
associated with negative emotional states252-254. 
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Figure 4-11 Average basal opioid peptide concentrations for each group of mice tested. Data shown as 
average ± SEM for each group of mice, n = 5 – 7 mice per group. Significance was determined by unpaired 
Student’s t-test. * indicates P ≤ 0.05.  
While the average basal levels are informative of the resting state of neurons, 
observing dynamic changes in response to photostimulation of DYN-containing neurons 
in the vNAcSh and dNAcSh revealed intriguing opioid peptide results. Three basal 
fractions were collected prior to a 10 Hz (10 ms pulse width) photostimulation in all 
groups. An additional 6 fractions were collected after the laser photostimulation was 
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terminated (Figure 4-12). A significant increase of photostimulated DYN in dyn-Cre + 
mice was observed in both the vNAcSh (interaction effect; t = 3.941, p < 0.001) and 
dNAcSh (interaction effect; t = 3.012, p = 0.003), compared with dyn-cre - mice. There 
was also a significant difference between the dyn-Cre + and dyn-Cre - mice in the six 
post-stimulated fractions in the vNAcSh (interaction effect; t = 2.499, p = 0.014). As 
DYN is associated with negative emotional states, it is interesting that the increase of 
DYN in the dyn-Cre + vNAcSh, associated with the aversive behavior phenotype. For 
dyn-cre + mice, DYN in the vNAcSh is elevated relative to dNAcSh stimulated release 
(interaction effect; t = 2.749, p = 0.007) and post collection (interaction effect; t = 2.806, 
p = 0.006). The DYN increase and prolonged elevation relative to basal fractions was 
only observed in the aversive behavior phenotype mice, stimulated in the vNAcSh. 
Increased ME was associated with photostimulation in dyn-Cre + mice (interaction 
effect; t = 2.824, p = 0.006). This is somewhat surprising, as the photostimulation should 
only directly activate DYN-containing neurons that express ChR2, and DYN-containing 
neurons do not co-localize with pre-enkephalin (the precursor to ME)261. However, with 
15 min fractions, it is possible that this increase in ME is a downstream response to DYN 
release or there is a differential cleavage of DYN forming the LE peptide. 
The BzCl derivatization LC-MS method monitored 22 small molecules, however 
only GABA, Glu, and DA results are discussed in these results (Figure 4-12). Small 
molecule analysis revealed that GABA was increased (t = 2.363, p = 0.020) and had a 
prolonged response (t = 4.744, p < 0.0001) following vNAcSh photostimulation. This 
increase was greater in dyn-Cre + mice than dyn-Cre - mice. GABA in the dNAcSh did 
not have an effect from the stimulation, but there was a significance in overall between 
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dyn-Cre + mice and dyn-Cre – mice (t = 2.910, p = 0.004). Stimulation of Glu in both 
vNAcSh and dNAcSh were not significant. The increased and prolonged change in 
vNAcSh GABA is not surprising as vNAcSh DYN had significant and prolonged effect 
of stimulation, as DYN-containing neurons are GABAergic.  
Photostimulation of dNAcSh DYN-containing neurons gives rise to a preference 
behavior phenotype. This corresponds to an increase in LE (interaction effect; t = 5.384, 
p < 0.0001) in dyn-Cre + mice stimulated in the dNAcSh. The magnitude of this 
stimulation-mediated LE effect is greater in the dNAcSh compared to the vNAcSh 
(interaction effect; t = -2.552, p = 0.12). Photostimulation also resulted in an immediate 
DA increase (interaction effect; t = 5.007, p < 0.0001) and a prolonged elevation 
(interaction effect; t = 2.081, p = 0.039). This surge in LE and DA specifically in the 
dNAcSh is interesting as ENK and DA increases in the striatum are associated with 
reward74, 262 and stimulation elicits a positive preference behavior. 
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Figure 4-12 Extracellular opioid peptides and small molecules in vNAcSh and dNAcSh in dyn-Cre mice. Custom-made integrated optogenetic-dialysis probes 
were implanted into sub-regions of the NAcSh to measure the effect of photostimulation (indicated by arrow), and potential delayed or prolonged effects. Data 
normalized to average basal concentration and shown as average ± SEM for each group of mice, n = 5 – 7 mice per group. Significance was determined using a 
linear mixed model analysis. * indicates P ≤ 0.05. 
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Conclusions 
We developed and applied an integrated optogenetic-microdialysis probe and a 
capillary LC-MS assay to sample and detect photostimulated release of the opioid 
peptides DYN, LE, and ME, and small molecules in two discrete sub-regions within the 
NAcSh in dyn-Cre mice. While a preliminary ex vivo ELISA assay showed Dyn-A 
release, it did not distinguish between discrete sub-regions and precluded detection of 
changes in other analytes such as LE, ME and monoamines. This report builds on the 
previous findings and provides sub-region-specific data for a large panel of analytes. We 
show that basal levels differ between regions, and that photostimulation elicits distinct 
changes in dorsal and ventral sub-regions of the NAcSh. Specifically, the vNAcSh 
associated with aversion behavior and resulted in an immediate increase and prolonged 
effect for DYN and GABA, whereas in dNAcSh associated with positive reinforcement 
and saw a robust increase in LE and DA.  
This study provided valuable information on neurochemical dynamics of specific 
opioid peptide fragments in sub-regions of the NAcSh. It is likely that monitoring other 
opioid fragments would give a better and more complete understanding of the dynamics 
associated with opposing behaviors. Monitoring release at downstream projection sites 
would further elucidate the role of endogenous opioids in negative and positive affective 
behaviors.  
This study demonstrates the ability to measure locally stimulated release of opioid 
peptides and small molecules using a multiplex technique. This approach provides a 
comprehensive understanding of the complex and unique local dynamic changes 
occurring with photostimulation.
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CHAPTER 5: IN VIVO QUANTIFICATION OF STRIATAL OPIOID PEPTIDES 
FOLLOWING 6-HYDROXYDOPAMINE LESIONS  
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
characterized by the loss of nigrostriatal dopamine (DA) neurons. The cardinal motor 
features of PD are slowness of movement (bradykinesia), tremor, rigidity, and postural 
instabilities. Loss of striatal DA severely impacts signaling throughout the basal ganglia – 
a group of subcortical structures essential for executing normal movements. The striatum 
is the largest structure and primary input of the basal ganglia, where (among other 
inputs), cortical glutamate and midbrain DA converge to impact downstream nuclei. DA 
acts on D1-like (D1R) and D2-like receptors (D2R) on striatal GABAergic medium spiny 
neurons (MSNs), which represent 95% of the total neurons in the striatum263. In addition 
to GABA, striatal MSNs contain and release neuropeptides. Approximately half of MSNs 
express D1R and contain mRNA for substance P and prodynorphin261, 264. These neurons 
project to the substantia nigra pars reticulata (SNr) and globus pallidus internus (GPi), 
and comprise the “direct pathway” of the basal ganglia265-267. The other subtype of MSNs 
express D2R and contain proenkephalin mRNA261, 264. These neurons project to the 
globus pallidus external segment (GPe) and make up the first portion of the “indirect 
pathway” of the basal ganglia265-267 (Figure 5-1).  
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Figure 5-1 Simplified basal ganglia diagram showing excitatory (glutamatergic), inhibitory (GABAergic), 
and dopaminergic neuron pathways that are involved in coordinated movement. The indirect pathway is 
comprised of striatal GABAergic neurons that express D2 receptors and project to the globus pallidus 
external segment (GPe). Direct pathway GABAergic neurons originating in the striatum contain D1 
receptors and project to the substantia nigra pars reticulata (SNr) and globus pallidus internus (GPi). 
Striatum-projecting dopaminergic neurons from the substantia nigra pars compacta (SNc) are lost in 
Parkinson’s disease, possibly leading to imbalances in the output of direct and indirect pathway projection 
neurons. Other structures shown are the subthalamic nucleus (STN), which is part of the indirect pathway, 
and the ventral tegmental area (VTA), a major component of the mesolimbic circuit. 
Opioid peptide processing and effects in Parkinson’s disease 
Both prodynorphin and proenkephalin are inactive pro-hormone precursors that 
require protease processing to produce biologically functional peptides85, 86. Protease-
mediated propeptide processing into functional neuropeptides likely occurs during axonal 
transport of the propeptides in dense core vesicles268. Prodynorphin products include neo-
endorphin, dynorphin A (produces dynorphin A1-8; abbreviated DYN throughout the 
text), dynorphin B, and bridge peptide domain sequences86. Proenkephalin contains four 
copies of met-enkephalin (ME), two extended copies of ME, and one copy of leu-
enkephalin (LE)87, 88. Although prodynorphin contains five LE sequences, prodynorphin 
products (i.e. dynorphin A and dynorphin B) rarely co-localize with LE due to the lack of 
cleavage of the dibasic Arg-Arg sequence85, 86, 89; therefore, it is generally believed that 
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prodynorphin is not a source of LE. Proenkephalin is the primary source of LE, even 
though it only contains one copy of the LE sequence86. These peptide precursors 
(proenkephalin and prodynorphin) are present in the brain, and processing produces many 
potential peptides, including opioid and non-opioid fragments. The extent of pro-
hormone processing depends on the available endoproteases in a given cell type and brain 
region. Disruption of opioid peptide metabolism has been implicated in depression, 
anxiety, addiction, and diseases such as PD90-93. One study of dynorphin A1-17 
metabolism in the unilateral 6-hydroxydopamine (6OHDA) lesion rat model of PD 
suggested disrupted enzymatic degradation between hemispheres91. 
The four opioid receptors, kappa, mu, delta, and opioid receptor like 1 (also called 
ORL1, nociceptin, or orphaninFQ receptors) have high affinities for dynorphin, β-
endorphin and endomorphin, enkephalins, and nociceptin, respectively (Table 5-1).  
 
Table 5-1 Endogenous opioid peptides and their receptors. 
Precursor Endogenous peptide Affinity for opioid receptors 
Pro-opiomelanocortin β-endorphin δ, μ 
δ >> μ 
Pro-enkephalin Met-enkephalin Leu-enkephalin 
μ, δ 
μ = δ 
Pro-dynorphin 
Dynorphin A 
Dynorphin B 
Neoendorphin 
κ, μ, δ 
κ >> μ and δ 
Pro-nociceptin Nociceptin ORL1 
 
DA signaling affects the expression of opioid peptide mRNA within MSNs. 
Chronic DA agonist administration decreases enkephalin (ENK) mRNA269 and increases 
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dynorphin expression in rodents270. Conversely, DA antagonists or striatal DA lesions 
decrease prodynorphin mRNA and increase proenkephalin mRNA271, 272. Similar patterns 
are also observed in monkeys following MPTP-induced DA depletion273, 274 and in 
human PD patients275.  
DA modulates mRNA expression of striatal opioid neuropeptide precursors, but it 
is not clear how this relates to extracellular neuropeptide concentrations (i.e., tonic levels) 
and release dynamics. mRNA expression studies provide insight into neuronal content, 
but do not necessarily reflect the specific fragments or the levels of proteins and peptides 
generated or released. It is unknown how the influence of DA on peptide expression 
relates to neurotransmitters such as 4-aminobutyric acid (GABA), glutamate and other 
signaling molecules within the striatum. DA exerts significant neuromodulatory influence 
on multiple transmitter systems and overall striatal activity, and its loss contributes to 
abnormal movements in PD. It is therefore important to understand the interaction 
between these neurotransmitters and neuropeptides in order to develop novel therapies 
counteracting abnormal pathological neurochemical processes.  
The interplay between DA and opioids, and their selective expression in striatal 
neurons, has given rise to research targeting opioid systems as PD therapeutics. For 
example, delta opioid receptor (whose endogenous ligands are ENK) agonists enhance 
locomotor activity in rat and non-human primate models of PD276-278. Likewise, delta 
opioid receptor knockout mice display attenuated motor responses to psychostimulants279. 
Therefore, activating delta opioid receptors can rescue some of the motor deficits induced 
by DA depletion. A wide variety of opioid modulating drugs have been evaluated for L-
DOPA induced dyskinesias (LIDs, involuntary movements) alleviation280-284. Selective 
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mu receptor antagonists285, 286, and kappa agonists287 reduce LIDs in primates. Limited 
human clinical trials using kappa agonists288, and non-selective opioid antagonists283, 289 
show potential promise.  
 Although measurement of neuropeptide mRNA precursors with tissue content 
experiments provides insight into single time points, monitoring extracellular 
neuropeptides in vivo provides information on their temporal dynamics and specific 
peptide products. Microdialysis is a versatile sampling tool that allows for repeated 
collection of extracellular neurochemicals, but many challenges arise when applying 
microdialysis for neuropeptide collection. Neuropeptide concentrations are typically in 
the low pM range in the extracellular space. This low concentration, coupled with low 
peptide recovery in microdialysis requires an analytical method that is sensitive and 
selective. We applied direct monitoring of endogenous peptides and small molecules 
using microdialysis and capillary liquid chromatography-mass spectrometry (LC-MS) to 
gain additional insight into actions of DA on striatal opioid peptide neurochemistry.  
We first established a sensitive method to detect basal ME, LE, and dynorphin 
fragment A1-8 (DYN) opioid neuropeptide concentrations. We then used the 6OHDA 
hemilesion model of PD to unilaterally ablate nigrostriatal DA neurons and probed 
neurochemical concentration differences between lesioned and unlesioned hemispheres. 
We also investigated how evoked changes (i.e., K+ stimulations) were differentially 
affected between the hemispheres. Our findings suggest a bidirectional dysregulation of 
direct and indirect pathway opioid neuropeptides in the striatum following loss of DA 
input. Furthermore, our results show enhanced inhibitory tone and loss of energy 
metabolism in the DA depleted striatum.   
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Methods 
Chemicals 
DYN and LE were purchased from American Peptide (Sunnyvale, CA), and ME 
was purchased from Sigma Aldrich (St. Louis, MO). Isotopically labeled DYN (DYN* 
13C6 15N1-mass shift +7 Da) was contracted through the University of Michigan’s protein 
synthesis core. Water, methanol, and acetonitrile for mobile phases are Burdick & 
Jackson HPLC grade purchased from VWR (Radnor, PA). All other chemicals were 
purchased from Sigma Aldrich (St. Louis, MO) unless otherwise noted. Ringer solution 
consisted of 148 mM NaCl, 2.7 mM KCl, 2.5 mM CaCl2, and 0.85 mM MgCl2 adjusted 
pH to 7.4 with NaOH. 
 
Animals 
Adult male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing between 
150-175 g were used for all 6OHDA lesion experiments. Rats were housed with access to 
food and water ad libitum in a temperature and humidity controlled room with 12 h 
light/dark cycles. For surgeries, animals were anesthetized using 1-4% isoflurane with 
400 mL/min oxygen. Following the procedure, animals were given the antibiotic 
Gentamycin (2.5 mg/mL, i.p.) in a saline solution, to prevent dehydration and infection. 
All animals were treated as approved by the Unit for Laboratory Animal Medicine at the 
University of Michigan, the National Institute of Health Guidelines for the Care and Use 
of Laboratory Animals. All precautions were taken to prevent animal discomfort through 
the course of the experiments. In addition, all animal experiments were conducted within 
the guidelines of Animal Research Reporting in vivo Experiments. 
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Unilateral lesion with 6OHDA 
Unilateral nigrostriatal lesions used 8 μg of 6OHDA (Sigma Aldrich, St. Louis, 
MO) dissolved in 4 μL of saline containing 0.02% ascorbic acid260, 290. Dissolved 
6OHDA was injected into the medial forebrain bundle using stereotaxic coordinates from 
bregma, AP -4.0 mm, ML ±1.3 mm, and DV -7.6 mm from top of skull. A 30G guide 
needle was connected to a 50 μL syringe with a 50 cm length of fused silica capillary 
(200/360 µm inner diameter/outer diameter). 6OHDA was infused at a rate of 1 μl/min 
over a 4 min period. After infusion, the injection needle was left in place for an additional 
1 min before retracting from the brain. Betadine solution (Purdue Products, Stamford, 
CT) was used to clean the surgical site and a steel wound clip was used to close the 
incision. Following surgery, rats were housed individually in a temperature and humidity 
controlled room with 12 h light/dark cycles with food and water available ad libitum. 
Two weeks after the lesion, animals were tested with amphetamine (5 mg/kg i.p.) to 
determine the number of ipsilateral turns. This test has previously shown that animals 
which exhibit > 7 ipsilateral turns/1 min had > 95% loss of DA291. Animals that turned > 
7 ipsilateral turns/1 min were enrolled in the study. 
 
Microdialysis 
For all studies, 6OHDA lesioned rats that passed the amphetamine rotation test 
were included. Custom-made concentric microdialysis probes (3mm dialyzing 
membrane) were implanted bilaterally into the 6OHDA lesioned and non-lesioned 
dorsolateral striatum. Rats were anesthetized with 1-4% isoflurane and placed into a 
stereotaxic frame (David Kopf, Tujunga, CA). A burr hole was placed above the striatum 
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using the AP +0.5 mm and ML ±3.4 mm coordinates from bregma, and microdialysis 
probes were lowered -7.0 mm from top of skull. Probes were made using AN69 
membrane (Hospal, Bologna, Italy) and were secured with skull screws and acrylic dental 
cement. Following surgery, rats were allowed to recover for 24 h with free access to food 
and water. 
Experiments were performed 24 h after probe implantation. Microdialysis probes 
were flushed with ringer solution for 1 h at a flow rate of 2 μL/min using a Fusion 400 
syringe pump (Chemyx, Stafford, TX). Flow rate was reduced to 0.8 μL/min and allowed 
to flush for an additional 1 h prior to baseline collections.  
Dialysate samples were treated in a similar manner as described in the methods 
section of Chapter 4. Briefly, 12 μL dialysate were collected, and 2 μL were removed for 
the monoamine and amino acid assay and 1.1 μL DYN* was added for peptide assay. 
Peptide assay samples were immediately injected on the capillary LC-MS system 
following collection. The 2 μL dialysate aliquoted for the monoamine and amino acid 
assay were derivatized using a modified method, and described in Chapter 4, before LC-
MS analysis31, 128.  
For high K+ ringer solution perfusion, the perfusion media was modified to 
contain 100 mM KCl and 48 mM NaCl. CaCl2 and MgCl2 concentrations were not 
changed.  
At the completion of the experiment, animals were euthanized and brains were 
extracted and stored in 4% paraformaldehyde at 4 °C. Probe placement was confirmed 
with histology. Animals were included in the data set if both probes were flowing and 
had confirmed probe placements. 
 124 
Peptide assays with capillary LC-MS 
The capillary LC-MS assay described in the methods section of Chapter 4 was 
applied to monitor opioid peptides (DYN, LE, and ME) with internal standard DYN*67, 68, 
70, 73. The MS2 pathway for opioid peptides DYN, LE, and ME were detected using m/z 
values of 491.5  435, 556  397, and 574  397 respectively. Isotopically labeled 
DYN* internal standard was detected using m/z values of 495  438. Animals that had 
average basal levels above the limits of detection were used for the study. 
 
Small molecule neurochemical analysis using QQQ MS 
Dialysate samples were derivatized with benzoyl chloride (BzCl) and analyzed by 
LC-MS as described in the methods section of Chapter 431, 128.  
 
Statistical analyses 
All statistical analyses were performed in Prism 7 (GraphPad, La Jolla, CA). 
Two-way ANOVA with Bonferroni post hoc analysis, and paired Student’s t test were 
used. In all instances, differences were deemed significant if P < 0.05. Data presented as 
mean ± SEM unless otherwise noted. Animals were included in the data set if both 
6OHDA lesion and non-lesion probes in the dorsolateral striatum were confirmed 
through histology. 
Results and Discussion 
Effects of 6OHDA on basal striatal concentrations of opioid neuropeptides 
Basal striatal DYN and ENK concentrations were compared between 6OHDA-
lesioned and intact hemispheres (Figure 5-2). Striatal DA lesions resulted in opposing 
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regulation of DYN and ENK (Figure 5-3). DYN concentrations were reduced 25% 
relative to the intact hemisphere, while LE and ME were both increased in the lesioned 
striatum 80% and 133% respectively (paired two-tailed t-tests: DYN t6 = 2.7, p = 0.04; 
LE t6 = 3.7, p = 0.01; ME t6 = 3.6, p = 0.02). These data demonstrate that an opposing 
dysregulation of striatal opioid peptides occurs in the absence of DA. This result is 
consistent with opioid peptide mRNA expression studies261, 270, and is the first 
demonstration of extracellular opioid peptide levels following DA lesions. Although the 
mechanisms underlying these changes are not fully understood, our results suggest that a 
lack of tonic DA receptor stimulation results in enhanced proenkephalin synthesis and 
decreased prodynorphin synthesis. These changes could be a direct effect of DA on 
synthesis, or a longer-term compensatory mechanism as the 6OHDA rats have chronic 
DA depletion. Because DA inhibits the indirect pathway, it is plausible that increased 
ENK release and subsequent activation of delta and mu opioid receptors (which are 
inhibitory G-protein coupled receptors) could autoregulate MSNs to potentiate cellular 
inhibition in the absence of DA. Striatal MSNs are rich in opioid receptors261, 292, 293 and 
delta opioid agonists have antiparkinsonian effects in rat260, 276-278, 294-297 and non-human 
primate models277. Similarly, decreased striatal DYN following DA loss could reflect a 
kappa opioid receptor-mediated disinhibition of the direct pathway. Further studies 
should examine the potential antiparkinsonian effects of kappa opioid receptor 
antagonists to more clearly establish the mechanism of down regulated DYN and its 
effects in the direct and indirect pathways. 
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Figure 5-2 Bilateral probe placement in unilateral 6OHDA lesioned striatum. Tyrosine hydroxylase 
immunohistochemistry of unilateral 6OHDA lesioned rat coronal brain sections shows the lack of striatal 
DA terminals (left, light) and presence of DA terminals (right, brown). Representative probe placements 
indicated by gray boxes. 
 
 
 
Figure 5-3 Effect of lesion on basal peptide concentrations. Comparison of lesion (black bars) vs. 
unlesioned (open bars) side demonstrates decreased DYN and increased LE and ME release in lesioned 
striatum. Paired two-tailed Student’s t test statistics were performed to compare basal levels. All data 
expressed as percent non-lesion ± SEM. *p-value < 0.05, n = 7 rats. 
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Effects of 6OHDA on basal small molecule concentrations 
The 6OHDA hemisphere had basal extracellular levels of 1, 0.4, 30, 55, 260, and 
80 nM for DA, 3MT, DOPAC, HVA, Glc, and GABA respectively, while the intact 
hemisphere showed 14, 7, 2000, 3000, 220, and 50 nM (not corrected for probe 
recovery). As expected following 6OHDA lesions, we detected an 83% reduction in DA 
(t6 = 15, p < 0.0001) and major reductions in DA metabolites (Figure 5-4) relative to the 
contralateral intact hemisphere. Specifically we found an 85% decrease in 3MT (t6 = 47, 
p < 0.0001), 94% decrease in DOPAC (t6 = 47, p < 0.0001) and 90% decrease in HVA (t6 
= 130, p < 0.0001) in the lesioned hemisphere compared to the intact hemisphere (Fig. 6). 
The 6OHDA-lesioned hemisphere showed significantly elevated glucose (40%, t6 = 2.6, p 
= 0.04) and GABA (222%, t6 = 2.7, p = 0.03) compared to the intact hemisphere. Trends 
for increased 5HT, DOPA and NM in the depleted hemisphere were also present, but not 
significant. These results complement previous studies showing adaptive changes in gene 
expression of DYN, ENK, and the GABA biosynthesis enzyme GAD67298, 299.  
 
 
Figure 5-4 Effect of 6OHDA lesion on small molecule concentrations. Small molecule assay normalized to 
intact non-lesion hemisphere (open bars) show complete depletion of DA and metabolites in 6OHDA 
lesion hemisphere (black bars). Glc and GABA are up regulated in 6OHDA lesion hemisphere. Paired two-
tailed Student’s t test statistics were performed to compare basal levels. All data expressed as percent non-
lesion ± SEM. *p-value < 0.05, n = 7 rats.  
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Concentrations of the inhibitory transmitter GABA and ENKs were higher in the 
lesioned hemisphere compared to the non-lesioned control side. These are likely related 
because opioids and GABA are co-expressed in both direct and indirect pathway 
MSNs94. Therefore, DA loss results in processes consistent with inhibition of striatal 
output. Our findings do not address the effects of these neurochemical changes in 
downstream brain regions because we only sampled from the striatum and not from the 
GPe or the SNr/GPi output nuclei.  
The finding that 6OHDA lesions elevate extracellular glucose was unanticipated 
and demonstrates the power of our comprehensive approach to neurochemical 
measurements. The glucose increase may reflect underutilized energy reserves due to 
greater neuronal inhibition in this hemisphere. Imaging studies show glucose 
hypometabolism in PD brains relative to healthy individuals205, 300-303. Many of these 
studies were performed in humans with various stages of PD compared to healthy 
individuals. Our results are unique, demonstrating alterations within individual animals. 
We show elevated extracellular striatal glucose in the DA-depleted striatum as compared 
to the intact hemisphere, suggesting reduced glucose metabolism. 
PD has also been linked to glucose intolerance and diabetes304-307. It is estimated 
that 50-80% of patients with PD have abnormal glucose tolerance307. Several studies have 
attempted to link the likelihood of developing PD with the onset of diabetes with mixed 
results308-310. 
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K+ stimulated release of striatal opioid peptides  
To test the amount of opioid peptides readily releasable in neurons, we perfused a 
100 mM K+ ringer solution through the probes to induce depolarization. We perfused K+ 
for 30 min to investigate the effects of lesion on initial stimulated peptide release, 
allowed 1 h recovery, and then perfused K+ for another 30 min to examine peptide 
repackaging (Figure 5-5). The first K+ perfusion resulted in higher peptide release than 
the second perfusion, indicating no priming effects (contrary to previously reported 
potentiation with other neuropeptides, including oxytocin and vasopressin)311, 312. DYN, 
LE, and ME increased by 380%, 3100% and 3900% respectively in the lesioned 
hemisphere following the first K+ stimulation. There were no significant differences in 
opioid peptide release between the lesioned and unlesioned hemispheres (two-way 
ANOVA).  
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Figure 5-5 Effect of multiple K+ stimulations on striatal peptide release. Unilaterally lesioned rats received 
two 30-minute K+ stimulations (left, gray boxes). No differences in K+ stimulated peptide release were 
observed between lesioned (black circles) and non-lesioned (open circles) sides (two-way ANOVA). 
Highest concentration achieved during first and second K+ stimulation for each probe is shown (right) for 
each peptide. Paired two-tailed Student’s t test statistics were performed to compare lesion and non-lesion 
sides and showed no significance for all peptides. All data expressed as average concentration ± SEM. n = 
7 rats 
 
Intact and DA depleted striata released the same amount of peptide following the 
initial K+ induced depolarization; 0.8 ± 0.2 and 1 ± 0.2 pM DYN, 120 ± 50 and 140 ± 30 
pM LE, and 280 ± 140 and 360 ± 50 ME, respectively. Evoked release was reduced in 
both hemispheres following the second K+ stimulation (Figure 5-5). This suggests that 
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there is no absolute difference in intracellular stores of the targeted peptides and that the 
observed extracellular differences reside in basal release probability. This is consistent 
with the conclusion that DA tonically modulates striatal MSNs269-272. However, previous 
studies showed increased proenkephalin mRNA expression and reduced prodynorphin 
expression in DA lesioned animals298, 299. While these mRNA findings suggest altered 
intracellular neuropeptide stores, no differences were observed with K+ stimulation. It is 
important to note that we only monitored one fragment of dynorphin. Previous studies 
show changes to opioid peptide mRNA expression in PD models, so it is possible that 
other dynorphin fragments are affected. It is possible that DA lesions elevate ME and LE 
and reduce DYN at resting conditions, but that strong stimuli (e.g., high K+ perfusion) 
cause recruitment of additional intracellular peptides via increased packaging or 
production. These results also demonstrate that priming does not occur in striatal ME, 
LE, and DYN systems, as it does with other neuropeptides such as hypothalamic OT and 
vasopressin313. Understanding fundamental neurochemical differences will be imperative 
for the development and understanding of future opioid-based drugs to treat PD. 
Conclusions 
Applying advanced in vivo microdialysis sampling and LC-MS measurements, we 
showed that 6OHDA lesions alter extracellular opioid neuropeptide concentrations in the 
striatum. Loss of DA increased ENK and reduced DYN release. These data align with 
and corroborate two decades of mRNA expression studies suggesting that DA signaling 
regulates striatal neuropeptide dynamics. We also found parallel small molecule changes 
(GABA, and glucose), confirming that dopaminergic influence over striatal networks is 
multifaceted and may affect both neuronal activity and energy metabolism. We 
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investigated one fragment of dynorphin (DYN; dynorphin A1-8), but it is possible that 
metabolism via enzymatic cleavage of the prohormone precursors of dynorphin and 
enkephalin could be altered, and were not investigated in this study. Previous results 
show differences in the biotransformation of exogenous dynorphin A 1-17 in 6OHDA 
rats91, but did not address the exogenous in vivo fragments in the extracellular space. The 
present data demonstrate key features of neuropeptide release dynamics under basal and 
stimulated conditions and are important for understanding how DA loss in PD affects 
striatal circuits.  
These findings relate abnormal opioid peptide signaling with striatal 
dysregulation following DA depletion. These studies further our understanding of the 
complex physiological processes underlying basal ganglia function and dysfunction, and 
may lead to alternative therapeutic targets and treatments for PD beyond the standard DA 
replacement therapy. 
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CHAPTER 6: A POTENTIAL OXYTOCIN TREATMENT FOR L-DOPA 
INDUCED DISKINESIAS  
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
characterized by the loss of nigrostriatal dopamine (DA) neurons. The cardinal motor 
features of PD are slowness of movement (bradykinesia), tremor, rigidity, and postural 
instabilities. Current therapies aim to relieve PD symptoms, but do not slow disease 
progression, and often cause significant side effects. The primary treatment for PD is DA 
replacement therapy. For example, administration of the DA precursor L-DOPA supplies 
the brain with exogenous DA to compensate for DA depletion. L-DOPA treatment 
controls many PD motor symptoms, but remains ineffective for psychiatric, 
gastrointestinal and olfactory impairments314, 315. Chronic DA replacement therapy causes 
L-DOPA induced dyskinesias (LIDs) within 10 years of treatment in the majority of PD 
patients316-318. LIDs are associated with the severity of dopamine loss, dysregulation of 
dopamine neurons, abnormal neuronal firing patterns, aberrant basal ganglia-thalamo-
cortical signaling, and excessive DA D1-like receptor (D1R) activation (for 
comprehensive review see Bastide et al., 2015)319, 320. Selective DA D2-like receptor 
(D2R) agonists, such as ropinirole, produce fewer dyskinesias than L-DOPA, suggesting 
that alternative treatments to shift toward D2R activation could be important alternative 
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therapies. However, D2R agonists are less effective at improving PD symptoms 
compared to L-DOPA321.  
 
Oxytocin in the striatum 
Endogenous neuropeptide oxytocin (OT) receptors are expressed in brain regions 
that regulate movement, including the striatum, subthalamic nucleus, globus pallidus, and 
substantia nigra322. OT is a 9 amino acid polypeptide with wide ranging actions 
throughout the nervous system and periphery and is commonly studied for its role in 
maternity, affiliative behaviors and pair bonding81. The significance of OT in dopamine-
mediated movement and PD is unclear, but PD patients have lower brain OT levels post 
mortem323. Rodent studies have shown that systemic OT treatment modulates DA-
stimulated stereotypies and hyperactivity induced by cocaine or amphetamine324. This 
suggests that OT may counter abnormal movements associated with increased brain DA 
levels. D2R and OT receptors (OTR) can form heteromers within the striatum, which are 
expressed on “indirect pathway” medium spiny neurons projecting to the globus 
pallidus325. Therefore, OT may modulate DA-mediated activity in the indirect pathway. 
OT-based treatments have not been studied for the potential to decrease chronic L-DOPA 
induced AIMs, but showed promise in a pilot study (Michael J Fox Foundation, 
Dyskinesia Challenge 2013). It was hypothesized that exogenous OT administration 
would activate the indirect pathway to balance the dysregulated striatal output pathways 
during L-DOPA treatment. 
To test this hypothesis and further examine striatal OT, a method was developed 
to monitor striatal OT levels, and to quantitatively assess abnormal involuntary 
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movements (AIMs) in 6-hydroxydopamine (6OHDA) lesioned, L-DOPA treated 
dyskinetic rats. Systemic OT was administered to 6OHDA rats that were chronically 
treated with L-DOPA (to induce dyskinesias), revealing an inverse correlation between 
OT dose and AIMs elicited by L-DOPA treatments. These findings demonstrate that OT 
may be a promising therapy to be used in conjunction with current L-DOPA regimens.  
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Methods 
Chemicals 
OT, and isotopically labeled OT (OT* 13C215N1-mass shift +3 Da) were purchased 
from American Peptide (Sunnyvale, CA). Water, methanol, and acetonitrile for mobile 
phases are Burdick & Jackson HPLC grade purchased from VWR (Radnor, PA). All 
other chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
noted. Ringer solution consisted of 148 mM NaCl, 2.7 mM KCl, 2.5 mM CaCl2, and 0.85 
mM MgCl2 adjusted pH to 7.4 with NaOH. 
 
Animals 
Adult male Sprague-Dawley rats (Envigo, Indianapolis, IN) weighing between 
150-175 g were used for all 6OHDA lesion experiments as described in Chapter 5. All 
animals were treated as approved by the Unit for Laboratory Animal Medicine at the 
University of Michigan, the National Institute of Health Guidelines for the Care and Use 
of Laboratory Animals. In addition, all animal experiments were conducted within the 
guidelines of Animal Research Reporting in vivo Experiments. 
 
Unilateral lesion with 6OHDA 
Unilateral nigrostriatal lesions used 8 μg of 6OHDA (Sigma Aldrich, St. Louis, 
MO) dissolved in 4 μL of saline containing 0.02% ascorbic acid, and the protocols for 
surgery and selection criteria were described in the methods section of Chapter 5. 
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L-DOPA treatment and AIMs rating 
Two weeks after amphetamine testing, unilaterally lesioned rats received 21 d of 
L-DOPA treatment (levodopa 6 mg/kg + benserazide 15 mg/kg, s.c., once daily) to 
induce AIMs. Following 3 weeks of treatment, animals were assessed for dyskinetic 
behaviors according to a modified method developed by Cenci and colleagues326, 327. 
Dyskinetic movements were classified based on four subtypes: (i) locomotor AIMs (ii) 
axial AIMs, i.e. twisted posture or choreiform twisting of the neck and upper body 
contralateral to the lesion; (iii) forelimb AIMs, i.e. jerky or dystonic movements in 
contralateral forelimbs and/or purposeless grabbing movement of the contralateral paw; 
(iv) orolingual AIMs, i.e. orofacial muscle twitching, empty masticatory movements and 
tongue protrusion. Each AIM subtype was rated on a severity scale from 0 to 4 (0 = not 
observed; 1 = occasional; 2 = frequent; 3 = continuous but interrupted by sensory 
distraction; 4 = continuous, severe and not interrupted by sensory distraction, i.e. tapping 
on the animal’s cage) at each monitored period. AIM scores were counted as the sum of 
all 4 subtypes for each period and were plotted across each individual time point. 
Maximum AIM score for each time point was 16. All rats enrolled in these studies had 
developed moderate-severe AIMs (severity grade ≥ 2 on each of the first 3 AIM 
subtypes) within the 3 weeks of chronic treatment prior to experiments. Approximately 
20% of rats did not meet these criteria and were excluded from the study. AIM scoring 
was performed 8 times during the L-DOPA treatment period (8 measurements every 20 
min for 2 h). During the experiments, students performing the AIM scoring were blinded 
to the dose the rat was given. 
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Microdialysis 
Rats were enrolled in the L-DOPA study if they were lesioned, passed the 
amphetamine rotation tests described in the methods section of Chapter 5, and were 
stably dyskinetic after chronic L-DOPA treatment. 
Custom-made concentric microdialysis probes (3 mm dialyzing membrane) were 
implanted bilaterally into the 6OHDA lesioned and non-lesioned dorsolateral striatum as 
described in Chapter 5. Microdialysis probes were flushed with ringer solution for 1 h at 
a flow rate of 2 μL/min using a Fusion 400 syringe pump (Chemyx, Stafford, TX). Flow 
rate was reduced to 0.9 μL/min and allowed to flush for an additional 1 h prior to baseline 
collections. Samples were collected every 15 min. Samples were immediately injected on 
the capillary LC-MS system following collection (45 min baseline and 2 h post 
treatment).  
For high K+ ringer solution perfusion, the perfusion media was modified to 
contain 100 mM KCl and 48 mM NaCl. CaCl2 and MgCl2 concentrations were not 
changed.  
At the completion of the experiment, animals were euthanized and brains were 
extracted and stored in 4% paraformaldehyde at 4 °C. Probe placement was confirmed 
with histology. Animals were included in the data set if both probes were flowing and 
had confirmed probe placements. 
 
Oxytocin assays with capillary LC-MS 
OT was detected using the capillary LC-MS described in the materials and 
methods section of Chapter 367, 68, 70, 73. An Agilent 1100 HPLC pump (Santa Clara, CA) 
 139 
was used to deliver the elution gradient containing water with 0.1% FA for mobile phase 
A and mobile phase B as MeOH with 0.1% FA delivered as initial 0% B; 1 min, 30 %B; 
4 min, 50% B; 4.1 min 100% B; 7 min, 100% B; 7.1 min, 0%B; and 10 min, 0% B. 
The capillary column was interfaced to a linear ion trap (LTQ XL, Thermo 
Scientific). The MS2 pathway for endogenous OT and isotopically labeled OT were 1007 
 723 and 1010  993 m/z, respectively. In vitro recovery of a 2.5 mm probe for OT 
was 32 ± 9%. 
OT standards were prepared daily. Calibration curves were run in triplicate to 
determine linearity, reproducibility, and limits of detection. The limit of detection for OT 
was 11 pM, respectively, in 5 μL. Animals that had average basal levels above the limits 
of detection were used for the study. 
 
Statistical analyses 
All statistical analyses were performed in Prism 7 (GraphPad, La Jolla, CA). 
Two-way ANOVA with Bonferroni post hoc analysis, and paired Student’s t test were 
used. In all instances, differences were deemed significant if P < 0.05. Data presented as 
mean ± SEM unless otherwise noted. Only rats that had correct probe placements were 
included in the data set.  
Results and Discussion 
Systemic OT as a potential treatment of L-DOPA induced dyskinesia 
 To determine if OT mitigates AIMs, we performed a dose-response behavioral 
and microdialysis experiment targeting the dorsolateral striatum of 6OHDA lesioned rats 
that developed stable dyskinetic behavior (AIM score > 6) with 3 weeks of chronic L-
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DOPA. Following three baseline microdialysis collections, rats received a final injection 
of L-DOPA (levodopa 6 mg/kg + benserazide 15 mg/kg, s.c.) to induce dyskinesia and an 
acute injection of saline or OT (0.01, 0.1, 1.0, and 10.0 mg/kg, i.p.). AIM scores were 
assessed at the beginning of each fraction (by a student blinded to treatment conditions) 
and OT levels were monitored (Figure 6-1). 
 As expected, higher OT doses produced higher OT concentrations in the 
dorsolateral striatum (Figure 6-1A). Specifically, 1.0 mg/kg was higher than saline  
(F (2,20) = 4.731, p =0.02) at fraction 5 (p < 0.001), fraction 6 (p < 0.001), fraction 7  
(p <0.01), and 10.0 mg/kg is higher than saline (F (2,20) = 6.637, p =0.006), at fraction 4 
(p < 0.001) and fraction 5 (p < 0.01). While there was no significant interaction at  
0.1 mg/kg (F (2,20) = 0.8614, p =0.4), the post hoc analysis showed that fraction 5  
(p < 0.01) was higher than saline. A dose response curve was generated from this data by 
summing the measured OT from fractions 4 – 11 for each rat, and plotting against the 
logarithmic dose (Figure 6-1B). The dose response curve demonstrates increasing dose 
effects from 0.01 to 10.0 mg/kg, but does not plateau. Higher doses were not used, in 
order to reduce the number of animals required and the associated costs of the 
experiment, and because higher doses are not relevant in humans. OT is administered to 
humans at sub-μg/kg doses (via intravenous328 and intranasal administration329, 330) for 
labor induction and for social cognition treatment in autism and schizophrenia. The OT 
doses used in this study are significantly higher because i.p. administration results in 
partial degradation of OT prior to reaching the brain. 
LIDs were reduced in animals co-treated with OT. AIMs were recorded after the 
rat received saline or OT treatment with L-DOPA, but not prior to the treatment, as the 
 141 
rats were in a baseline resting state. All doses tested were significantly different from 
control saline treatment (Figure 6-2A). Post hoc analysis is summarized in Figure 6-2C. 
A dose response curve for the sum of AIM score from fractions 4 – 11 (i.e. post drug 
treatment) for each animal, plotted against the logarithmic dose (Figure 6-1B). Analysis 
of the best fit shows the bottom and top thresholds are 27 and 67, respectively, and the 
half maximal effective concentration (EC50) is 0.01 mg/kg (Figure 6-2B).  
These results show that an acute administration of OT with L-DOPA treatment 
decreases AIMs in LIDs. One possible mechanism underlying the beneficial effects of 
OT on AIMs is altered indirect pathway signaling. Indeed, OTR form heteromers with 
D2R in the indirect pathway325, and may facilitate D2R-mediated signaling325. Systemic 
OT may therefore potentiate DA-mediated inhibition of striatopallidal GABA release 
compared to L-DOPA alone. Accordingly, OT may shift the balance of striatal output to 
favor indirect pathway signaling. Additional measurements of small molecule transmitter 
release in downstream basal ganglia nuclei are needed to test this hypothesis. It is 
possible that the effect of systemic OT on motor output may be due to OTR activation in 
other brain regions outside of the striatum. To confirm a striatal origin, local striatal OT 
administration would need to reduce AIMs, or local application of an OT receptor 
antagonist could be used to block OT. It is also possible that OT alters the bioavailability 
or pharmacodynamics of L-DOPA. Striatal microdialysate measurement of L-DOPA 
following OT administration would help rule out this possibility. 
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Figure 6-1 Effect of acute systemic OT dose on measured OT in the dorsal lateral striatum (A) and 
transformation into dose response curve (B). Rats were given a single dose of OT after three baseline 
measurements. The arrow indicates the first fraction that OT is expected to be present in the dialysate (A). 
A dose response curve was generated by the sum of OT measured in fractions 4 -11, plotted against the 
dose (B). While this study only tested to a maximum of 10.0 mg/kg, higher doses would be required to 
achieve a plateau on the dose response that was cost prohibitive and would be higher than relevant doses. A 
multiple comparison two-way ANOVAs with Bonferroni post hoc were run on each data set comparing 
each dose to the saline. Data shown as average ± SEM.* p < 0.05, ** p < 0.01, and *** p < 0.001. 
 
 
 
Figure 6-2 Effect of AIM score on dose. AIM score was measured from fractions 4 – 11 because rats were 
in a resting state during baseline conditions. Rats were given a single dose of OT after three baseline 
measurements, and AIM score was accessed at each time point by a student blinded to treatment conditions 
(A). A dose response curve was generated by the sum of AIMs measured in fractions 4 -11, plotted against 
the dose (B) Two-way ANOVAs were run on each data set comparing each dose to the saline summarized 
in a table (C). Data shown as average ± SEM.* p < 0.05, ** p < 0.01, and *** p < 0.001. 
 143 
Isotopically labeled OT crosses the blood brain barrier 
To confirm that our OT measurements in the dorsolateral striatum reflected OT 
injection and were not due to a secondary central response to L-DOPA or OT treatment, 
we injected isotopically labeled OT* (1.0 mg/kg, i.p.) and monitored both the isotopically 
labeled m/z transition (1010 > 993 m/z) and the endogenous OT transition (1007 > 723 
m/z) (Figure 6-3A). After treatment, increases in OT* (F (1, 11) = 7.596, p = 0.01) were 
significantly different than endogenous OT, demonstrating that striatal OT measurements 
primarily reflect injected OT, and not secondary downstream release. No differences in 
concentration were observed following equivalent injections of either isotopically labeled 
OT* or endogenous OT (Figure 6-3B), demonstrating that the isotopically labeled 
compound exhibits similar kinetics and is not processed differently in rats. 
Our results show that isotopically labeled OT* is measurable in the rat brain, but 
do not address how systemic OT* reaches the microdialysis probe, which is 
controversial. The brain is protected by a selectively permeable barrier (the blood brain 
barrier; BBB) separating circulating blood from brain extracellular fluid. Mechanical 
insertion of a microdialysis probe compromises the integrity of the BBB, raising the 
possibility that our OT* and OT measurements reflected OT that ‘leaked’ into the brain, 
rather that OT that crossed the BBB. A recent microdialysis and radioimmunoassay study 
suggest that systemically administered i.p. OT reaches the mouse amygdala and 
hippocampus331. The authors also state, that even if the BBB was leaking, the calculated 
maximum contribution of OT in the brain due to the leak would be minimal331. Other 
studies suggest OT crosses the BBB by showing increases in OT cerebrospinal fluid 
following intranasal OT administration331-335. 
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 Another study used blood oxygenation level dependent imaging to monitor brain 
activity in areas with OT receptors333. Subjects received either i.p. or 
intracerebroventricular (ICV, which circumvents the BBB) injection of OT and activation 
profiles were observed. The study hypothesized that activation profiles would be similar 
if both routes of administration allowed equivalent access of OT in the brain. Different 
profiles were observed between the i.p. and ICV injections groups, suggesting that i.p. 
OT does not cross the BBB at the same efficiency as ICV injection333. However, NAc 
shell activity was significantly increased 20 min post i.p., corresponding with our 15 min 
collection fractions.  
Several reports demonstrate biphasic BBB permeability changes, with increased 
permeability directly following microdialysis probe insertion, restored BBB integrity 
from 8 – 48 h, and a second permeability increase after 24 – 48 h153, 336-345. Our 
microdialysis experiments were performed 18 – 24 h after probe insertion to minimize 
alterations in BBB permeability. To confirm BBB integrity during this period, systemic 
injections of BBB-impermeable compounds 18 – 24 h after probe insertion should be 
performed. A pilot study from our lab administered systemic injections of dopamine 
(which does not cross the BBB), and did not alter measured dopamine concentrations in 
the dorsolateral striatum (data not shown). This pilot study suggests that the BBB is intact 
during this period following microdialysis probe implantation (pilot data from Omar 
Mabrouk, manuscript in preparation), but more rigorous tests should be performed with 
OT.  
 145 
 
Figure 6-3 Systemic injection of isotopically labeled OT* measured in the dorsal lateral striatum. Systemic 
injection of OT* results in an increase of isotopically labeled OT* at the probe, but not change endogenous 
OT (A). Similar doses of OT* and OT are overlaid (B). Two-way ANOVA statistics with Bonferroni post 
hoc, data shown as average ± SEM. *** p < 0.001. 
Conclusions 
Applying advanced in vivo microdialysis sampling and LC-MS measurements, we 
showed that OT administration reduces dyskinesia associated with chronic L-DOPA 
treatment. Our studies demonstrate the first direct evidence that systemically 
administered OT produces antidyskinetic effects in an established rat model of PD. We 
showed that systemic OT could potentially be used in conjunction with traditional L-
DOPA treatment to reduce the dyskinetic symptoms associated with chronic L-DOPA 
exposure. This preliminary study shows promising results, but significant further 
preclinical testing must be performed to confirm the validity of this approach and to 
determine safety, efficacy, route and frequency of administration, and appropriate dosing 
in humans before it can be translated into patient treatment. OT may therefore alleviate 
the symptoms associated with chronic L-DOPA treatment, and prolong the ability to use 
DA replacement therapy to treat PD symptoms without causing disabling side effects. 
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CHAPTER 7: FUTURE DIRECTIONS 
This thesis describes the development and application of liquid chromatography-
mass spectrometry (LC-MS) techniques to interrogate small molecule and neuropeptide 
dynamics in vivo. A simple and robust derivatization method was optimized and 
expanded to label 70 small molecule neurochemicals in various biological media with 
improved analysis by LC-MS. This improved method is widely applicable and has the 
potential to be customized and optimized to monitor compounds with primary and 
secondary amines, as well as phenols, in various media. Capillary LC-MS methods to 
monitor neurotensin, oxytocin, and opioid neuropeptides in microliter volumes of 
dialysate were also developed. This goal was achieved by optimizing capillary LC-MS 
conditions for low limits of detection, improving recovery of neuropeptides across the 
dialysis membrane with surface modifications, and reducing adsorption of peptides to 
surfaces from storage to detection with simple organic addition. 
Microdialysis sampling and LC-MS techniques were also used in 
pharmacogenetic (designer receptors exclusively activated by designer drugs; 
DREADDs) and optogenetic experiments to study small molecules and neuropeptides, 
leading to the discovery and confirmation of previously unrecognized neuronal circuits. 
DREADDs experiments revealed a population of neurons implicated in the control of 
feeding (lateral hypothalamic area neurons containing the peptide neurotensin) and 
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demonstrated that activity of these neurons modulates mesolimbic dopamine release in 
the nucleus accumbens (NAc). This modulation of dopamine release promotes motivated 
behaviors and locomotor activity70. We monitored ventral tegmental area neurotensin 
release and prolonged elevated dopamine in the NAc using complementary LC-MS 
techniques70. In a separate study, we used optogenetics to stimulate dynorphin-containing 
neurons in two discrete regions in the NAc shell, which produced opposing behaviors. 
Results obtained using our LC-MS method demonstrated that both basal levels of opioid 
peptides and stimulated release were different between NAc shell sub-regions, showing 
that sub-regional neurochemical profiles can drive opposing behaviors.  
These complementary LC-MS techniques provide a more comprehensive 
understanding of neurochemical mechanisms in multiple brain circuits. These methods 
can be further expanded to monitor other neurochemicals of interest, and could be applied 
to a multitude of future relevant studies. Future improvements in temporal and spatial 
resolution, and improved analytical methods for analyte detection will advance our 
understanding of brain circuitry.  
 
Understanding the composition of neuropeptide fragments in vivo 
 Neuropeptides are involved in various homeostatic processes and serve as 
transmitters in the central nervous system. Given their complex biosynthetic and 
metabolic pathways, understanding the enzymatic processing of precursor neuropeptides 
and metabolites by monitoring their intra- and extracellular composition would give 
researchers valuable insight into normal physiological functions and abnormalities in 
disease. It is important to study neuropeptides, but in vivo research is limited due to low 
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picomolar concentrations in the brain and inadequate detection techniques. Most 
commercially available immunoassay techniques offer low limits of detection, but only 
target one analyte, require large sample volumes, are time consuming, and can be non-
specific due to cross-reactivity. Commonly used immunoassays, such as 
radioimmunoassays and enzyme linked immunosorbent assays, detect analytes based on 
the molecular recognition and binding of antigens to antibodies. Cross-reactivity of 
interfering compounds with similar binding affinity to the antibody generates signal, 
reducing the sensitivity and accuracy of the assay, and leading to over-estimation of the 
analyte. To improve sensitivity and accuracy (by reducing cross-reactivity interferences), 
two-site immunoradiometric assays utilize two analyte specific antibodies and have been 
used to study brain natriuretic peptide346, 347, alpha-1-foetoprotein348, and parathyroid 
hormone-related peptide349.  
Some of the limitations of traditional immunoassays are being overcome by 
efforts in miniaturization and multiplexing. Advancements in immunoassays include 
bead-based techniques, nanoparticles, and microarrays (Refer to Woolley and Hayes 
2013, and Roper and Guillo 2009 for a comprehensive review)350, 351. One type of 
microarray, the micromosaic immunoassay, immobilizes a series of antibodies or 
antigens on a solid surface with a second set of channels perpendicular to the patterned 
lines352. Sample is flowed over the pattern, allowing for multiple screens to be run in 
parallel351, 352. These micromosaic immunoassays have been used to detect C-reactive 
protein, myoglobin, and troponin I353, 354, but require long incubation times and should be 
improved by coupling with signal amplification. Even with advancement in immunoassay 
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development, many of the same challenges are present and often require multiple 
optimized assays for a comprehensive analysis. 
  An advantage of the capillary LC-MS setup is pre-concentration of microliters of 
peptide to nanoliters, with nano-ESI prior to MSn detection. The work in this thesis 
employed targeted assays that rely on known mass-to-charge (m/z) transition pathways to 
unique identify a known peptide. However, targeted approaches preclude the detection of 
other fragments of possible interest. Additionally, low sample throughput due to 
instrument limitations, and varying sensitivity among peptides is problematic for in vivo 
studies, which may generate many samples. The benefits that arise from multiplexing 
capabilities of MSn detection, and high selectivity and sensitivity of known analytes 
(resulting from characteristic retention times and unique m/z transitions of the peptides of 
interest), outweigh these setbacks. 
 As discussed in Chapter 5, the opioid peptides dynorphin and enkephalins are 
dysregulated in Parkinson’s disease and represent potential therapeutic targets. 
Dynorphin peptides are produced by endoproteolytic processing of the precursor 
polypeptide prodynorphin, which results in multiple endogenous fragments other than the 
specific endogenous dynorphin fragment focused on in this thesis85. Previous dynorphin 
peptide metabolite studies were primarily performed in tissue extracts85, 92, 93, 355 and in 
vivo investigations into dynorphin peptides and metabolites have been limited by 
technical challenges. Several studies infused opioid neuropeptide dynorphin A1-17 into 
striatum-targeted microdialysis probes in rats and detected the resulting fragments 
secondary to enzymatic cleavage in the dialysate91, 356. When applied to unilateral 6-
hydroxydopamine (6OHDA) lesioned rats, the biotransformation of a single dynorphin 
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fragment A1-17 into various fragments was altered relative to the intact DA hemisphere91. 
These in vivo studies did not address endogenous fragments prior to peptide infusion and 
did not monitor other fragments from prodynorphin, such as dynorphin B1-13, big 
dynorphin1-32, or their metabolites. 
 A fundamental study to detect and monitor multiple extracellular endogenous 
peptide fragments in vivo can be performed using our capillary LC-MS and microdialysis 
techniques. Preliminary work to develop a method to monitor 12 commercially available 
dynorphin fragments with capillary LC-MS shows promise for at least 8 fragments, but 
has yet to be tested in vivo (Table 7-1). Further capillary LC-MS optimization, 
improvements in recovery with microdialysis, and reduction in peptide loss due to 
adsorption would contribute to a more sensitive and selective analytical assay. 
With further development and validation focused on improving sensitivity, 
collection, and detection, this method could be used to examine differences between 
6OHDA lesioned and non-lesioned hemispheres, monitor the differential release of 
fragments from photostimulation in multiple brain regions, study the effects of kappa-
agonist and antagonist administration on dynorphin metabolism, and to confirm neuronal 
tetrodotoxin sensitivity. Other fundamental dynorphin studies should examine 
mechanisms underlying delayed dynorphin A1-8 release with high potassium stimulation, 
and determine if this effect is specific to a single fragment or more broadly affects the 
precursor, or enzymatic processing. It is possible that the dynorphin in released vesicles 
following stimulation is not fully cleaved,
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Table 7-1 Summary of dynorphin fragments with limits of detection (LOD) and calibration curve slope. Five μL injections of standards prepared in aqueous 
ringer solution or standards prepared in aqueous ringer solution with optimal acetonitrile (ACN) were run in triplicate to determine LOD and slope. Direct 
infusion of peptides below the horizontal dashed line yield unique m/z transitions, but were not successfully detected using capillary LC-MSn at concentrations ≤ 
1 nM. LOD was calculated using equations: 𝐿𝐿𝐿𝐿𝐿𝐿 = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 + 1.645(𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑆𝑆𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏), and 𝐿𝐿𝐿𝐿𝐿𝐿 = 𝐿𝐿𝐿𝐿𝐿𝐿 + 1.645(𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑆𝑆𝑏𝑏𝑙𝑙𝑙𝑙 𝑐𝑐𝑙𝑙𝑏𝑏𝑐𝑐𝑐𝑐𝑏𝑏𝑐𝑐𝑐𝑐𝑏𝑏𝑐𝑐𝑐𝑐𝑙𝑙𝑏𝑏 𝑠𝑠𝑏𝑏𝑠𝑠𝑠𝑠𝑏𝑏𝑐𝑐), where LOB 
represents the limit of the blank, and Stdev represents the standard deviation209. 
Net charge was calculated using equation 𝑧𝑧 =  ∑ 𝑁𝑁𝑐𝑐 10𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝10𝑝𝑝𝑝𝑝+10𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑐𝑐 − ∑ 𝑁𝑁𝑗𝑗 10𝑝𝑝𝑝𝑝10𝑝𝑝𝑝𝑝+10𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑗𝑗 , where N represents number of residue/termini and i and j represent basic or 
acid residue/termini, respectively357. 
Dynorphin 
Fragment MW 
Net 
charge MS1 MS2 
Optimal 
ACN % 
LOD (pM) 
with 0% 
ACN 
LOD (pM) 
with optimal ACN 
% 
Slope (pM-1) 
with 0% 
ACN 
Slope (pM-1) 
with optimal 
ACN% 
A 1-6 712 1 357 492 5 1.2 0.8 82 111 
A 1-7 868 2 435 426 5 37 11 40 63 
A 1-8 981 2 491 435 5 2.8 2.8 265 601 
A 1-9 1137 3 380 488 5 19 7.8 126 205 
A 1-10 1234 3 412.5 528 15 21 15 38 206 
A 9 -17 1184 2 396 520 5 12 4.7 22 51 
B 1-9 1142 2 382 491 15 3 1.4 67 212 
B 1-13 1571 3 524.5 726.5 15 46 102 5.5 94 
A 1-17 2147.5 4 538 529.4 
A 2-17 1983 4 497 488.5 
A 1-13 1604 5 402 475 
Big 1-32 3985 9 570.5 645 
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Improvement to benzoyl chloride derivatization workflow (Advancements in small 
molecule detection in the brain) 
 The benzoyl chloride (BzCl) derivation method described in Chapter 2 has many 
advantages but is limited by the slow, repetitive pipetting of multiple reagents. The 
technical challenges associated with collecting and derivatizing a large number of 
samples underscores the need to automate the derivatization procedure. For example, one 
collaborative microdialysis study used BzCl derivatization to monitor 20 
neurotransmitters of interest with 1 min temporal resolution and aimed to correlate 
neurotransmitter dynamics simultaneously from two discrete brain regions during an 
adaptive choice behavior assay (Pettibone JR 2016, in preparation). A single experiment 
produced 200 samples (100 from each brain region), each requiring three manually 
pipetted reagents into each vial. Over the course of 25 experiments, over 5,000 samples 
were derivatized and analyzed with LC-MS.  
Automating the BzCl reaction would save time offline, reduce human error by 
minimizing sample handling (thereby improving reproducibility), and could potentially 
enable online derivatization to achieve real time analysis. Reagent addition could be 
automated using a sample prep autosampler programmed to pick up and disperse μL 
volumes of the reagents into programmed vial locations immediately after collection. 
Another alternative is to use a microfluidic device, made of either glass or 
polydimethylsiloxane (PDMS), in which the reagents are added sequentially with mixing 
channels between each addition. While commercial reagent tees are available, a single 
chip customized to integrate all reagent additions, would simplify the overall setup and 
reduce dead volumes that increase sampling rise times (Figure 7-1). This chip could be 
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used as a standalone set-up incorporated into the dialysis lines, and fractions could be 
collected offline in vials before being injected onto a column with an autosampler.  
With integrated reagent addition, the temporal resolution would be limited to the 
lowest sample volume accurately handled by instrumentation (i.e., if 1 μL sample 
volumes could be reproducibly injected onto a column and levels were detectable, a 
minimum of 1 μL derivatized sample would be collected). If the collection time and 
separation-analysis time could be matched along with reasonable scan rates, online LC-
MS analysis could be achieved. An eight-port valve could be incorporated into the flow 
path in order to switch between sample loading and injection onto the LC column to 
prevent sample loss (Figure 7-1B). A similar experiment was conducted in which non-
derivatized endogenous serotonin was measured with 1 min temporal resolution using 
microdialysis coupled to capillary UHPLC with electrochemical detection358. By using 
MS instead of electrochemical detection, the number of analytes that can be detected 
increases significantly. While MS can detect neurotransmitters directly without a 
dedicated separation step35, LC separation would reduce interferences that ultimately 
reduce the number of ions reaching the detector.  
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Figure 7-1 Potential microfluidic chip design to integrate microdialysis sampling with online benzoyl 
chloride derivatization. Microdialysate would flow through the chip (A) and three reagents would be added 
and mixed in the serpentine channels, between additions. The mixture could be collected offline into 
individual vials or integrated into an online set up for real-time analysis (B). An eight-port valve would 
switch between loading and elution of the dialysate. Artist Becca Weisz created images of the syringes, 
mouse, and probe. 
 
Improvements in spatial resolution of microdialysis  
Advancements in LC-MS detection of a variety of neurochemicals at low levels 
have allowed for the development of new miniaturized microdialysis sampling probes. 
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One advantage of making probes in house is the potential to create probes that integrate 
microstimulators with the ability to sample near the site of stimulation. For example, 
probes combined with platinum wire electrodes can be used to study local neurochemical 
dynamics during deep brain stimulation (DBS). Sample collection within the site of 
activation is critical for understanding local mechanisms of action, which may contribute 
to the beneficial effects of DBS for symptomatic treatment of Parkinson’s disease, 
dystonia, tremor, and depression. Custom probes may also be integrated with fiber optics 
for concurrent microdialysis with optogenetic stimulation or inhibition of specific 
neuronal classes, as described in Chapter 4.  
Conventional microdialysis probes have limited spatial resolution in the brain 
because they are 1-4 mm in length with 200-500 μm diameters. Improvements in 
microdialysis spatial resolution would allow the investigation of extracellular 
concentration gradients within small brain structures, which are currently not possible 
with conventional probes. Electrochemical detection methods have shown catecholamine 
differences across ~150 μm distances in the nucleus accumbens shell359. Push-pull probes 
sample from discrete areas (~ 4 nL sampled volume) and have shown chemical 
differences between midbrain regions less than 200 μm apart (i.e., red nucleus vs. ventral 
tegmental area)360. Further miniaturization of sampling probes361, 362 through 
microfabrication is a promising approach that will improve spatial resolution and 
minimize tissue damage363-367.  
Microfabrication in silicon by bulk micromachining and lithography has been 
used to produce push-pull sampling probes 85 μm wide by 70 μm thick by 11 mm 
long362. These microfabricated push-pull sampling probes were successfully used to 
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sample basal concentrations from the striatum of anesthetized rats. Push-pull probes 
allow the sampling of small and large molecular weight neurochemicals and proteins, but 
are prone to clogging due to the lack of membrane. Furthermore, push-pull methods 
require vacuum pumps to draw samples, further complicating the sampling setup. A 
miniaturized sampling probe with an incorporated membrane would circumvent these 
issues, but fabrication is challenging. A polysilicon semipermeable membrane was 
fabricated in a miniaturized microdialysis probe and was expected to exclude large 
molecular weight compounds367. However, these probes were never tested for 
neurochemical sampling in vitro or in vivo. Our lab developed microfabricated dialysis 
probes with embedded nanoporous anodic aluminum oxide membranes and used them to 
sample an anesthetized rat striatum in vivo361 (Figure 7-2). As compared to the small 
conventional probe, the microfabricated probes have 75% less surface area and 83% less 
sampling area, indicating a 6-fold improved spatial resolution and less tissue disruption.  
While the merits of miniaturized sampling probes are appealing, employing these 
probes in vivo presents many challenges. For example, low flow rates are needed to 
mitigate pressure (due to the structural strength of the membrane), resulting in either 
small sample volumes (nL) or reduced temporal resolution for larger volume collections. 
Small sample volumes (nL) are cumbersome to manipulate manually and challenge the 
sensitivity of current analytical technologies. Currently, temporal resolution is sacrificed 
to produce μL sample volumes for LC-MS analysis. For example, 20 min were required 
to collect 2 μL of dialysate for analysis361, 362. The use of segmented flow for droplets 
with direct-MS detection could be used to preserve temporal resolution35. Segmented 
flow could be achieved by incorporating a third channel into the microfabricated probe to 
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create droplets close to the sampling area. Droplets could also be generated after probe 
outlet by using a commercially available reagent tee, or microfabricating a tee to reduce 
volume requirements. If segmented flow is achieved, it may be possible directly detect 
neurotransmitters with MS.  
 
 
Figure 7-2 Comparison of different dialysis probes. The top probe is a conventional microdialysis probe 
that is commercially available. The mini-dialysis probe is fabricated in-house for routine use in rodents. 
The ‘deep brain stimulator’ integrates a platinum wire electrode, which can be used to deliver electrical 
pulses in brain tissue. The ‘optogenetic mini-dialysis’ probe integrates a fiber optic probe along side the 
dialysis membrane allowing for sampling of locally stimulated tissue. No sheath is required for the 
optogenetic mini-dialysis probe as it can withstand insertion into the brain as is. ‘μFab dialysis’ and ‘μFab 
push-pull’ are silicon-based probes fabricated by lithography and bulk micromachining techniques. The 
‘μFab dialysis’ probe directly integrates a 4 mm long nanoporous anodic aluminum oxide membrane at the 
tip. The ‘μFab push-pull’ consists of two 20 m square orifices at the tip.  
 
 
 158 
Conclusions 
Studying the complexity and intricacy of neuronal circuitry requires analytical 
techniques with high sensitivity and selectivity. This thesis work developed methods to 
monitor a wide range of small molecule neurochemicals and low picomolar levels of 
neuropeptides. We applied these methods to study previously unconfirmed neuronal 
circuits and to examine neurochemical alterations in Parkinson’s disease models. 
Advances in LC-MS technologies will allow for the improved application of 
microdialysis. These advancements will allow sampling and detection within discrete 
sub-regions of the brain with the potential for online analysis. These techniques will 
provide the precise measurements needed for modern neurobiological experiments to 
examine brain circuits and neurochemical changes in normal behavior and disease. 
Further refinement of these techniques will enable fundamental neurochemical studies 
and will expand the scope of neuroscientific analyses.  
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APPENDIX A: Preparation of Benzoyl Chloride Standards and Internal Standards 
Note: This is an example preparation of standards and 13C6-benzoyl chloride (BzCl) 
labeled internal standards (IS) that can be used for calibrations and reagents. The 
concentrations can be adjusted to meet the needs of ones’ experimental parameters. 
 
Main Stock (Refer to ) 
1. Make all ‘Stock’ solutions (mM concentration) using HPLC-grade water. 
2. Add all ‘Volume of Stock’ to a 2 mL plastic vial EXCEPT ACh + Ch*. 
3. Add HPLC-water to bring the final volume to 2000 μL (Main Stock). 
4. Check that all analytes in the Main Stock are present with your LC-MS method by 
derivatizing with standard BzCl (2% v/v): 
a. Make derivatizing solutions: 
i. Carbonate buffer (100 mM); 12.4mg : 1000 μL HPLC-water 
ii. BzCl (2% v/v); 12 μL BzCl : 588 μL acetonitrile 
iii. ‘Pseudo IS’; 248 μL water : 247 μL acetonitrile : 5 μL sulfuric acid                                                         * ACh and Ch are not added to the Main Stock because the Main Stock is used to generate 13C6-BzCl labeled IS. ACh and Ch are not labeled since they do not have the correct functional groups for derivatization. Since the IS mixture is a reagent that is added to samples, unlabeled ACh and Ch would generate high background signals during analysis since they would not have an isotope shift relative to endogenous ACh and Ch m/z. 
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b. Prepare top calibration sample 
i. Dilute ‘Main Stock’ 100-fold; 99 μL HPLC-water : 1 μL ‘Main Stock’ 
ii. Dilute this solution 5-fold further in aCSF/media; 40 μL aCSF : 10 μL 
c. Derivatize top calibration sample by sequentially adding 25 μL of each 
reagent to 50 μL of sample (i.e. 25 μL carbonate buffer : 25 μL BzCl (2% v/v) 
: 25 μL ‘Pseudo IS’). Vortex between each reagent addition. 
d. Run derivatized standard on LC-MS and make sure all expected peaks are 
present in the chromatogram (except ACh + Ch, since they are not present in 
‘Main Stock’). 
e. If all analytes are present, proceed to making 13C6-BzCl IS mixture and 
calibration standard mixture. If not, remake or adjust levels accordingly by 
remaking the ‘Main Stock’ (Steps 1-3) until satisfactory.    
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 Table A-1 Preparation of Main Stock 
 
Stock Volume of Stock Final Concentration 
Analyte (mM) (μL) in Main Stock (μM) 
ACh 25 --- --- 
Ch 1000 --- --- 
Gly 20 100 1000 
GABA 20 10 100 
Ser 20 250 2500 
Hist 20 5 50 
Tau 40 100 2000 
Asp 20 20 200 
Glu 20 100 1000 
Ado 5 40 100 
5HT 20 1 10 
NE 20 1 10 
DA 20 1 10 
HVA 20 25 250 
5HIAA 10 20 100 
NM 20 1 10 
3MT 20 1 10 
DOPAC 20 100 1000 
Gln 100 100 5000 
L-DOPA 20 1 10 
E 20 1 10 
GSH 100 2 100 
Tyr 2 250 250 
Phe 20 100 1000 
5HTP 20 10 100 
Glc 100 500 25000 
 
Analyte Volume 1739 μL 
 
 
HPLC-Water 261 μL 
 
 
Total Volume 2000 μL 
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13C6-BzCl labeled internal standard mixture (No ACh or Ch) 
1. Prepare 13C6-BzCl (2% v/v) in acetonitrile (6 μL 13C6-BzCl : 294 μL acetonitrile). 
2. Dilute 250 μL Main Stock with 250 μL HPLC-water. 
3. Derivatize 500 μL sample by sequentially adding 250 μL carbonate buffer, 250 μL 
13C6-BzCl (2% v/v), and 1 μL formic acid. Vortex between each reagent addition. 
If precipitate does not dissolve with vortexing, small volumes (1 μL increments) of 
additional formic acid can be added with vigorous vortexing until solution is clear. 
4. Aliquot 20 μL in individual vials and store in -80°C freezer. Use a frozen aliquot each 
day and discard after single use. 
Internal standards for ACh and Ch, d4-ACh and d4-Ch respectively, are added separately 
since they do not label with BzCl. 
 
d4-ACh and d4-Ch stock 
1. Prepare 1 mM stocks of d4-ACh and d4-Ch in HPLC-water. 
2. Dilute both stocks into a single vial to a final concentration of 12.5 μM d4-ACh and 
500 μM d4-Ch (390 μL HPLC-water : 10 μL d4-ACh : 400 μL d4-Ch). 
3. Aliquot 10 μL in individual vials and store in -80°C freezer. Use a frozen aliquot each 
day and discard after 2-3 freeze-thaw cycles. 
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Calibration standard mixture (with ACh and Ch) 
1. Make a vial of ‘Concentrated Standard’ 
a. Take 998 μL of Main Stock, and add 1 μL ACh (25 mM) and 1 μL Ch (1 M). 
2. Dilute the ‘Concentrated Standard’ 100-fold in aCSF; 990 μL aCSF : 10 μL 
Concentrated Standard. 
3. Aliquot 20 μL in individual vials and store in -80°C freezer. Use a frozen aliquot each 
day and discard after single use. 
 
  
 
Figure A-1 Overview of 13C6-BzCl IS and Calibration Standard procedure.  
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Example calibration curve procedure in aCSF (Refer to Figure A-2 and Table A-2) 
Calibration standards are designated L1 (lowest concentration) – L6 (highest 
concentration) in the XCalibur QuanBrowser software. For consistency with this scheme, 
all six points of the standards will be referred to L1 – L6, followed by Table A-2 with 
correlated concentrations (based on the Main Stock prepared from ).  
 
1. Take a single aliquot of frozen ‘Calibration Standard’ and thaw to room temperature. 
2. Prepare samples L6 – L1 prior to derivatization 
a. Dilute thawed Calibration Standard 5-fold in aCSF to yield highest 
calibration point L6 
b. Dilute L6 2-fold into aCSF to yield L5 
c. Dilute L5 2-fold into aCSF to yield L4, and 10-fold to yield L3 
d. Dilute L4 10-fold into aCSF to yield L2 
e. Dilute L3 10-fold into aCSF to yield L1 
 
Figure A-2 Calibration curve standard preparation. 
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3. Aliquot a volume of standard representative to the experimental conditions and 
derivatize using prepared reagents in a 2 : 1 : 1 : ratio, vortexing between each 
reagent addition (i.e. if the samples generated in the experiment are 3 μL, then aliquot 
3 μL and derivatize with 1.5 μL of each reagent).  
a. Reagents 
i. Carbonate buffer (100 mM); 12.4 mg : 1000 μL HPLC-water 
ii. BzCl (2% v/v); 12 μL BzCl : 588 μL acetonitrile 
iii. IS mixture; 245 μL HPLC-water : 245 μL acetonitrile : 5 μL sulfuric 
acid : 5 μL 13C6-BzCl labeled IS mixture : 1 μL d4 Stock  
Table A-2 Final concentration in each calibration standard, vials L6 – L1. 
 Concentration (nM) 
Analyte L6 L5 L4 L3 L2 L1 
ACh 50 25 12.5 2.5 1.25 0.25 
Ch 2000 1000 500 100 50 10 
3MT 20 10 5 1 0.5 0.1 
5HIAA 200 100 50 10 5 1 
5HT 20 10 5 1 0.5 0.1 
5HTP 200 100 50 10 5 1 
Ado 200 100 50 10 5 1 
Asp 400 200 100 20 10 2 
DA 20 10 5 1 0.5 0.1 
DOPAC 2000 1000 500 100 50 10 
E 20 10 5 1 0.5 0.1 
GABA 200 100 50 10 5 1 
Glc 50000 25000 12500 2500 1250 250 
Gln 10000 5000 2500 500 250 50 
Glu 2000 1000 500 100 50 10 
Gly 2000 1000 500 100 50 10 
GSH 200 100 50 10 5 1 
Hist  100 50 25 5 2.5 0.5 
HVA 500 250 125 25 12.5 2.5 
LDOPA 20 10 5 1 0.5 0.1 
NE 20 10 5 1 0.5 0.1 
NM 20 10 5 1 0.5 0.1 
PA 2000 1000 500 100 50 10 
Ser 5000 2500 1250 250 125 25 
Tau 4000 2000 1000 200 100 20 
Tyr 500 250 125 25 12.5 2.5  
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APPENDIX B: Microdialysis Probe Fabrication 
A. Side-by-side microdialysis probe fabrication 
Materials 
• Inlet = 40/100 (i.d./o.d.) fused silica capillary (5 cm) 
• Outlet = 75/150 fused silica capillary (6 cm) 
• Shaft = 250/360 fused silica capillary (11 mm)* 
o Covered with 30G thin wall Teflon tubing (5 mm) 
• Inlet cover = 150/360 fused silica capillary (8 mm) 
o Covered with 30G thin wall Teflon tubing (7mm) 
• Outlet cover = 180/360 fused silica capillary (10 mm) 
o Covered with 30G thin wall Teflon tubing (9 mm) 
• Microdialysis semi-permeable membrane  
• Glue: 
o Thin cyanoacrylate glue 
o Five minute epoxy *Can be adjusted to appropriate length required for surgical needs   
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Instructions 1. Place the inlet and outlet capillaries side-by-side and slide the outlet capillary down equal to the length of the desired active area (i.e. if you want to make a 1 mm probe, offset the outlet 1mm below the inlet). 2. Using a needle, apply thin liquid glue to adhere capillaries together. a. Only apply the least amount of glue needed 3. Carefully slide a piece of microdialysis membrane over both the inlet and outlet, avoiding pinching and kinking of membrane. Cut excess membrane off. a. Cutting the membrane at a 45° angle can help if it is problematic to slide over both capillaries 4. Mix a small amount of 5-minute epoxy, and let slightly harden to a consistency that is able to hold stiff peaks. Once the correct consistency is achieved, use a clean hypodermic needle and carefully fill the end of the membrane to create a complete glue plug (~100 – 150 μm thickness). a. If you use the epoxy too early you will get a large glue plug. If you use the epoxy too late, it will be too stiff and not fill the tip of the membrane completely, leaving you with a hole for perfusion media to leak out of. b. Be careful not to get epoxy on the exterior of the membrane. c. Let the glue plug dry for 2-3 h before proceeding. 5. Once the glue plug is dry, gently tap/move the membrane down the capillary until the inlet is ~100 μm away from the glue plug. 
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6. Mix a small amount of 5-minute epoxy and carefully apply a small amount around the entire backside of the membrane. You should see the glue fill the back. Let dry overnight. a. If you apply too much, the glue can wick up the membrane and clog the outlet. If you are careful you can create an even seal around the entire membrane. b. If you do not let the epoxy completely dry before proceeding to the next step, I have found that when wet epoxy comes in contact with the thin cyanoacrylate glue, the epoxy never fully dries and can be easily removed with minimal effort (i.e. fluid from perfusion media).  
 
Figure B-1 Side-by-side microdialysis probe, steps 1 – 6.  7. Take 30G thin walled Teflon tubing and slide over the joint side of the 250/360 capillary shaft until the top 5 mm is covered. a. Use a sharp razor blade and gently score the Teflon closest to the joint. This scoring will help glue to hold Teflon in place. 
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8. Carefully slide the 250/360 capillary shaft over the membrane, and adjust the until the desired membrane active area (distance between the glue plug and shaft, where molecules can diffuse). 9. Use a pipette and apply a drop of thin cyanoacrylate to the back of the shaft.  10. Take 30G thin walled Teflon tubing and slide over the inlet and outlet cover capillaries until all but ~ 1mm of capillary is covered. a. Use a sharp razor blade and gently score the Teflon closest to the exposed capillary. This scoring will help glue to hold Teflon in place. 
 
Figure B-2 Side-by-side microdialysis probe, steps 7 – 10. 11. Slide the inlet and outlet covers over the respective inlet and outlet, forming a Y-junction with the shaft. 12. Apply thin cyanoacrylate glue using a needle to the Y-joint to secure the inlet and outlet covers. 13. Use a plastic pipette tip, and cut a small piece off the pipette tip to use as a junction cover. 
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14. Mix a small amount of 5-minute epoxy and quickly apply a liberal amount around the entire joint. 15. Carefully slide the small pipette tip over the membrane and up to the joint with epoxy. a. It’s helpful to bring the epoxy up the inlet and outlet to better reinforce the probe. 16. Let dry overnight. 17. Cut excess inlet and outlet capillaries as close to the inlet and outlet covers right before use. 
 
Figure B-3 Side-by-side microdialysis probe, steps 11 – 15. 
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B. Concentric microdialysis probe fabrication 
Materials 
• Inlet = 40/100 (i.d./o.d.) fused silica capillary (5 cm) 
• Outlet = 75/150 fused silica capillary (4 cm) 
• Shaft = 24G stainless steel tubing (11 mm)* 
• Inlet cover = 150/360 fused silica capillary (8 mm) 
o Covered with 30G thin wall Teflon tubing (7mm) 
• Outlet cover = 180/360 fused silica capillary (10 mm) 
o Covered with 30G thin wall Teflon tubing (9 mm) 
• Microdialysis semi-permeable membrane  
• Glues: 
o Thin cyanoacrylate glue 
o Gel superglue 
o Five minute epoxy 
o Glue accelerator *Can be adjusted to appropriate length required for surgical needs  
Instructions 1. Take 30G thin walled Teflon tubing and slide over the inlet and outlet cover capillaries until all but ~ 1mm of capillary is covered. a. Use a sharp razor blade and gently score the Teflon closest to the exposed capillary. This scoring will help glue to hold Teflon in place. 
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2. Slide the inlet and outlet covers over the respective inlet and outlet and secure with thin cyanoacrylate (applied to the joint side/exposed capillary side of inlet/outlet cover) 3.  Trim the outlet capillary so that it is approximately half the length of the shaft when measured from joint to tip (i.e. if shaft is 11 mm, cut so the outlet is approximately 5.5 mm). 
 
Figure B-4 Concentric microdialysis probe, steps 1 – 3. 
 4. Take the inlet and the trimmed outlet and slide into the cannula until the inlet and outlet covers form a Y-joint. 5. Use gel glue and liberally apply around the Y-joint to secure the inlet and outlets. a. I twist the cannula at the joint to ensure that the glue is fully around the joint. b. If you use the thin cyanoacrylate it will wick up the cannula and clog the probe. 
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6. Once the joint is secured, use a pipette to apply the glue accelerator around the joint. Let dry for a few minutes. 
 
Figure B-5 Concentric microdialysis probe, steps 4 – 6. 7. Use a plastic pipette tip, and cut a small piece off the pipette tip to use as a junction cover. 8. Mix a small amount of 5-minute epoxy and quickly apply a liberal amount around the entire joint. 9. Carefully slide the small pipette tip up to the joint and secure with epoxy. a. It’s helpful to bring the epoxy up the inlet and outlet to better reinforce the probe. 10. Let dry overnight. 11. Cut the excess inlet to ~100 μm less than desired area length (i.e. if you want a 1 mm probe, cut the inlet so ~0.9 mm is exposed). 12. Slide microdialysis membrane into the cannula over the protruding inlet. 
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a. I like to make sure the membrane goes in at least > 2 mm into the shaft so glue does not clog the membrane. 
 
Figure B-6 Concentric microdialysis probe, steps 7 – 12. 13. Mix a small amount of 5-minute epoxy and carefully apply a small amount around the entire backside of the membrane while the epoxy is fluid. a. If you apply too much, the glue can wick up the membrane and clog the probe. If you are careful you can create an even seal around the entire membrane. Be careful not to get too much glue onto the actual membrane. 14. Wait until the 5-minute epoxy is at a consistency that is able to hold stiff peaks. Once the correct consistency is achieved, use a clean hypodermic needle and carefully fill the end of the membrane to create a complete glue plug (~ 100 – 150 μm thickness). a. If you use the epoxy too early you will get a large glue plug. If you use the epoxy too late, it will be too stiff and not fill the tip of the membrane completely, leaving you with a hole for perfusion media to leak out of. 
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b. Be careful not to get epoxy on the exterior of the membrane. 15. Use a clean hypodermic needle to gently position the membrane so that the glue plug is ~ 100 μm away from the inlet.   
 
Figure B-7 Concentric microdialysis probe, steps 13 – 15. 16. Let dry overnight. 17. Cut excess inlet and outlet capillaries as close to the inlet and outlet covers right before use.
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C. Optogenetic-dialysis probe fabrication 
Materials 
• Inlet = 40/100 (i.d./o.d.) fused silica capillary (5 cm) 
• Outlet = 75/150 fused silica capillary (6 cm) 
• Holder = 450/670 fused silica capillary (5 mm) 
• Inlet cover = 150/360 fused silica capillary (8 mm) 
o Covered with 30G thin wall Teflon tubing (7mm) 
• Outlet cover = 180/360 fused silica capillary (10 mm) 
o Covered with 30G thin wall Teflon tubing (9 mm) 
• Microdialysis semi-permeable membrane  
• Fiber optic fiber (14 mm) with attached ferrule* 
• Glue: 
o Thin cyanoacrylate glue 
o Gel superglue 
o Five minute epoxy 
o Glue accelerator *Can be adjusted to appropriate length required for surgical needs  
Instructions 1. Place the inlet and outlet capillaries side-by-side and slide the outlet capillary down equal to the length of the desired active area (i.e. if you want to make a 1 mm probe, offset the outlet 1mm below the inlet). 2. Using a needle, apply thin liquid glue to adhere capillaries together. 
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a. Only apply the least amount of glue needed 3. Carefully slide a piece of microdialysis membrane over both the inlet and outlet, avoiding pinching and kinking of membrane. Cut excess membrane off. a. Cutting the membrane at a 45° angle can help if it is problematic to slide over both capillaries 4. Mix a small amount of 5-minute epoxy, and let slightly harden to a consistency that is able to hold stiff peaks. Once the correct consistency is achieved, use a clean hypodermic needle and carefully fill the end of the membrane to create a complete glue plug. a. If you use the epoxy too early you will get a large glue plug. If you use the epoxy too late, it will be too stiff and not fill the tip of the membrane completely, leaving you with a hole for perfusion media to leak out of. b. Be careful not to get epoxy on the exterior of the membrane. c. Let the glue plug dry for 2-3 h before proceeding. 5. Once the glue plug is dry, gently tap/move the membrane down the capillary until the inlet is ~100 μm away from the glue plug. 6. Mix a small amount of 5-minute epoxy and carefully apply a small amount around the entire backside of the membrane. You should see the glue fill the back. Let dry overnight. 
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a. If you apply too much, the glue can wick up the membrane and clog the outlet. If you are careful you can create an even seal around the entire membrane 
 
Figure B-8 Opto-dialysis probe, steps 1 – 6. 7. Slide the 450/670 capillary holder over the back side of the inlet/outlet assembly, followed by sliding the fiber optic into the backside of the capillary holder. a. The fiber optic is rigid cannot handle much angled force.  8. Position the fiber optic so the tip is next to the outlet, keeping the capillary holder is as close as possible to the ferrule. 9. Carefully apply the thin cyanoacrylate glue to the secure the capillary holder to the inlet/outlet assembly and fiber optic together. a. Careful to not apply so much glue that it results in wicking onto the membrane. 10. Take 30G thin walled Teflon tubing and slide over the inlet and outlet cover capillaries until all but ~ 1mm of capillary is covered. 
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a. Use a sharp razor blade and gently score the Teflon closest to the exposed capillary. This scoring will help glue to hold Teflon in place.  
 
Figure B-9 Opto-dialysis probe, steps 7 – 10. 11. Slide the inlet and outlet covers over the respective inlet and outlet and secure with thin cyanoacrylate (applied to the joint side/exposed capillary side of inlet/outlet cover) 12. Use a large plastic pipette tip, and cut a small piece off the pipette tip to use as a junction cover. 13. Use gel glue and apply around the entire joint. 14. Carefully slide the pipette tip over the membrane/fiber optic and up to the joint with glue. 15. Apply some glue accelerator to the joint. a. I find it helpful to let the joint dry, for a few minutes and reinforce with 5-minute epoxy around the inlet/outlet covers and fiber optic. 
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16. Cut excess inlet and outlet capillaries as close to the inlet and outlet covers right before use. 
 
Figure B-10 Opto-dialysis probe, steps 11 – 15.  
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